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Infection	   with	   chronic	   hepatitis	   C	   virus	   (HCV)	   is	   the	   leading	   indication	   for	   liver	  
transplantation.	   Recurrence,	   however	   of	   HCV	   is	   universal	   after	   liver	   transplantation	  
and	   subsequent	   fibrosis	   rates	   after	   transplantation	   are	   accelerated	   leading	   to	  
significant	   morbidity	   and	   mortality.	   In	   addition,	   treatment	   of	   recurrent	   HCV	   after	  
transplantation	   with	   pegylated-­‐interferon	   (PEG)	   and	   ribavirin	   (RBV)	   are	   poorly	  
tolerated	  and	  are	  associated	  with	  inferior	  treatment	  outcomes.	  The	  ability	  to	  therefore	  
understand	  the	  mechanisms	   that	   relate	   to	  disease	   recurrence	  and	  therefore	  develop	  
markers	   of	   fast	   fibrosis	   and	   treatment	   response	   would	   be	   beneficial	   for	   clinicians	  
caring	  for	  these	  patients.	  
	  
The	   role	  of	  donor	  and	   recipient	   rs12979860	   IL-­‐28B	  genotype	  was	  examined	   first.	  My	  
results	   demonstrated	   recipient	   non-­‐CC	   IL-­‐28B	   genotype	  was	   associated	  with	   a	   rapid	  
fibrosis	  (F≥2)	  progression	  at	  12	  months	  and	  increased	  risk	  of	  F≥4	  post	  transplantation.	  
The	   donor/recipient	   CC	   IL-­‐28B	   combination	   was	   associated	   with	   attenuated	   fibrosis	  
progression	  post	  transplantation.	  
	  
Next,	   the	   role	   of	   CXCL10	   in	   predicting	   fibrosis	   rates	   and	   treatment	   response	   was	  
examined.	  My	  results	  that	  CXCL10	  levels	  taken	  6	  months	  following	  liver	  transplantation	  
correlated	   with	   fibrosis	   rates	   at	   12	   months	   and	   were	   predictive	   of	   rapid	   fibrosis	  
progression	   at	   12	  months	   and	   F≥4.	   CXCL10	   levels	   pre-­‐treatment	   with	   PEG	   and	   RBV	  





Finally,	   the	   role	   of	   microRNAs	   (miRNAs)	   were	   examined	   to	   delineate	   their	   role	   in	  
predicting	  HCV	  recurrence.	  	  My	  results	  demonstrated	  intragraft	  expression	  of	  miRNA-­‐
146a,	   miRNA-­‐19a,	   miRNA-­‐20a	   and	   miRNA-­‐let7e	   in	   patients	   with	   slow	   fibrosis	  
progression	   (F<2)	   at	   12	  months.	   These	  miRNAs	   regulated	   the	   expression	   of	   cardinal	  
genes	   implicated	   in	   promoting	   antifibrotic,	   antiangiogenic	   and	   anti-­‐inflammatory	  
pathways.	   miRNA-­‐19a	   and	   miRNA-­‐20a	   may	   also	   be	   possible	   serum	   biomarkers	   of	  
fibrosis	  progression	  in	  patients	  with	  HCV	  post	  transplantation.	  
	  
These	  experiments	  demonstrate	  and	  identify	  further	  predictors	  of	  fibrosis	  progression	  
in	  patients	  with	  HCV	  recurrence	  after	  liver	  transplantation.	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   Antibody	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  presenting	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ALD	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  related	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ALT	   	   Alanine	  aminotransferase	  
ANOVA	   Analysis	  of	  variance	  
APRI	   	   Aspartate	  aminotransferase-­‐to-­‐platelet	  ratio	  index	  
AR	   	   Acute	  rejection	  
AST	   	   Aspartate	  transaminase	  
ATG	   	   Anti-­‐thymocyte	  globulin	  
AUROC	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  under	  the	  receiver	  operating	  characteristic	  curve	  
AVT	   	   Anti-­‐viral	  therapy	  
BMI	   	   Body	  mass	  index	  
CCL	   	   Chemokine	  ligand	  
CD	   	   Cluster	  of	  differentiation	  
cDNA	   	   Complimentary	  DNA	  
CI	   	   Confidence	  interval	  
CIT	   	   Cold	  ischaemia	  time	  
CLD	   	   Chronic	  liver	  disease	  
CMV	   	   Cytomegalovirus	  
CNI	   	   Calcineurin	  inhibitor	  
CPA	   	   Collagen	  proportionate	  area	  
CPS	   	   Child	  Pugh	  score	  
CR	   	   Chronic	  rejection	  
CXCL	   	   C-­‐X-­‐C	  chemokine	  ligand	  
CXCR	   	   C-­‐X-­‐C	  chemokine	  receptor	  
DAAs	   	  	   Directly	  acting	  anti-­‐virals	  
DBD	   	   Donation	  after	  brain	  death	  
DC	   	   Dendritic	  cells	  
DCD	   	   Donation	  after	  cardiac	  death	  
DDP4	   	   Dipeptidyl	  peptidase	  4	  
DM	   	   Diabetes	  mellitus	  
DRI	   	   Donor	  risk	  index	  
ECM	   	   Extracellular	  matrix	  
ELISA	   	   Enzyme-­‐linked	  immunosorbent	  assay	  
EGFR	   	   Epidermal	  growth	  factor	  receptor	  
EOTR	   	   End	  of	  treatment	  response	  
ER	   	   Endoplasmic	  reticulum	  
ESLD	   	   End-­‐stage	  liver	  disease	  
EVR	   	   Early	  virologic	  response	  
F	   	   Fibrosis	  
Fas-­‐L	   	   Fas	  Ligand	  




G	   	   Genotype	  
H&E	   	   Henatoxylin	  and	  eosin	  
HA	   	   Hyaluronic	  acid	  
HAT	   	   Hepatic	  artery	  thrombosis	  
HBV	   	   Hepatitis	  B	  virus	  
HBcAb	  	   Hepatitis	  B	  core	  antibody	  
HCA	   	   Hierarchical	  cluster	  analysis	  
HCC	   	   Hepatocellular	  carcinoma	  
HCV	   	   Hepatitis	  C	  virus	  
HDL	   	   High	  density	  lipoprotein	  
HIV	   	   Human	  immunodeficiency	  virus	  
HLA	   	   Human	  leukocyte	  antigen	  
HOMA	  	   Homeostasis	  model	  assessment	  
HPMT	   	   High	  pure	  filter	  microtube	  
HR	   	   Hazard	  ratio	  
HSC	   	   Hepatic	  stellate	  cells	  
HVPG	   	   Hepatic	  venous	  pressure	  gradient	  
ICAM	   	   Intracellular	  adhesion	  molecule	  
ICU	   	   Intensive	  care	  unit	  
IFN	   	   Interferon	  
Ig	   	   Immunoglobulin	  
IGD	   	   Immune	  mediated	  graft	  dysfunction	  
IGF	   	   Insulin-­‐like	  growth	  factor	  
IL	   	   Interleukin	  
INR	   	   International	  normalised	  ratio	  
IP-­‐10	   	   Interferon	  gamma	  inducible	  protein-­‐10	  
IR	   	   Insulin	  resistance	  
IRF	   	   Interferon	  regulatory	  factor	  7	  
IRS	   	   Insulin	  receptor	  substrate	  
ISG	   	   Interferon	  sensitive	  genes	  
IVDU	   	   Intra-­‐venous	  drug	  users	  
JAK	   	   Janus	  kinase	  
KIRS	   	   Killer	  cell	  immunoglobulin-­‐like	  receptors	  
LADR	   	   Low	  accelerating	  dosing	  regimen	  
LDL	   	   Low	  density	  lipoprotein	  
LPS	   	   Lipopolysacharide	  
LS	   	   Liver	  stiffness	  
LT	   	   Liver	  transplantation	  
LTC	   	   London	  transplant	  centre	  
MHC	   	   Major	  histocompatibility	  complex	  
mRNA	   	   Messenger	  RNA	  
miRNA	  	   MicroRNA	  
MELD	   	   Model	  for	  end	  stage	  liver	  disease	  
MF	   	   Myofibroblasts	  
MIAME	   Minimum	  information	  about	  a	  microarray	  experiment	  
MMF	   	   Mycophenalate	  mofetil	  




MRE	   	   Magnetic	  resonance	  elastrography	  
MSM	   	   Men	  who	  have	  sex	  with	  men	  
NFκB	   	   Nuclear	  factor	  kappa	  B	  
NHANES	   National	  Health	  and	  Nutrition	  Examination	  Surveys	  
NI	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Necro-­‐inflammatory	  
NK	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Natural	  killer	  
NKG2D	  	  	  	  	  	  	  	  	  	  	  	  	  	  Natural	  killer	  group	  2,	  member	  D	  
NO	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Nitric	  oxide	  
NODAT	  	  	  	  	  	  	  	  	  	  	  	  	  New	  onset	  diabetes	  after	  transplantation	  
NPV	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Negative	  predictive	  value	  
NR	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Non	  responder	   	  
NS	   	  	   Non	  structural	  
OAS	   	   Oligoadenylate	  synthetase	  
OR	   	   Odds	  ratio	  
PBMC	   	   Peripheral	  blood	  mononuclear	  cell	  
PCA	   	   Principal	  component	  analysis	  
PCH	   	   Plasma	  cell	  hepatitis	  
PCR	   	   Polymerase	  chain	  reaction	  
pDC	   	   Plasmacytoid	  dendritic	  cells	  
PDGF	   	   Platelet	  derived	  growth	  factor	  
PEG	   	   Pegylated	  interferon	  
PKR	   	   Protein	  kinase	  R	  
PIIINP	   	   Pro-­‐peptide	  of	  type	  III	  pro-­‐collagen	  
PNF	   	   Primary	  non-­‐function	  
PPV	   	   Positive	  predictive	  value	  
qPCR	   	   Quantitative	  PCR	  
rHCV	   	   Recurrent	  HCV	  
RBV	   	   Ribavirin	  
Rh	   	   Rhesus	  
RNA	   	   Ribonucleic	  acid	  
ROC	   	   Receiver	  operator	  characteristic	  	  
ROS	   	   Reactive-­‐oxygen	  species	  
RPM	   	   Revolutions	  per	  minute	  
RR	   	   Responder	  relapser	  
RT	   	   Reverse	  transcription	  
RVR	   	   Rapid	  virologic	  response	  
S	   	   Structural	  
SNP	   	   Single	  nucleotide	  polymorphisms	  
SOF	   	   Sofosbuvir	  
STAT	   	   Signal	  transducers	  and	  activators	  of	  transcription	  
SVR	   	   Sustained	  virologic	  response	  
TE	   	   Transient	  elastography	  
TFLT	   	   Time	  from	  liver	  transplantation	  
TGF-­‐B1	  	   Transforming	  growth	  factor	  –	  beta	  1	  	  
TGFBR	   	   Transforming	  growth	  factor	  receptor	  
TIMMPS	   Tissue	  inhibitors	  of	  matrix	  metalloproteinases	  




TNF	   	   Tumour	  necrosis	  factor	  
TRAIL	   	   Tumour	  necrosis	  factor-­‐related-­‐apoptosis-­‐inducing	  ligand	  
TRAIL-­‐R	   Tumour	  necrosis	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Hepatitis	   C	   virus	   (HCV)	   infection	   is	   a	   global	   epidemic	   and	   a	   leading	   cause	  of	   chronic	  
liver	  disease	  (CLD)	  (Williams,	  2006).	  Currently,	  HCV	  is	  the	  leading	  cause	  of	  death	  from	  
liver	   disease	   and	   the	   leading	   indication	   for	   liver	   transplantation	   in	   the	  United	   States	  
and	   United	   Kingdom	   (Kim,	   2002).	   Data	   from	   the	  World	   Health	   Organisation	   (WHO)	  
estimates	   that	   3-­‐4	   million	   people	   are	   infected	   with	   HCV	   every	   year	   (WHO,	   2012).	  
Globally	  the	  prevalence	  of	  chronic	  HCV	  has	  been	  estimated	  to	  be	  between	  2-­‐3%	  (130-­‐
170	  million	  people)	  (Lavanchy,	  2009,	  Shepard	  et	  al.,	  2005)	  	  
	  
Countries	  with	  high	  prevalence	  rates	  of	  chronic	  infection	  include	  Egypt	  (22%),	  Pakistan	  
(5%)	   and	   China	   (3%)	   (WHO).	   Published	   data	   suggests	   that	   populations	   in	   Western	  
Europe	   have	   a	   prevalence	   rate	   of	   antibody	   to	   HCV	   (anti-­‐HCV)	   to	   be	   under	   2.5%	  
(Lavanchy,	   2011).	   Estimating	   the	   prevalence	   of	   chronic	   HCV	   remains	   difficult	   and	  
published	   figures	   are	   based	   solely	   on	   specific	   patient	   groups,	   not	   necessarily	  
representative	   of	   the	   general	   population.	   These	   specific	   or	   high-­‐risk	   groups	   include	  
blood	   donors,	   intravenous	   drug	   users	   (IVDUs)	   and	   individuals	   with	   high-­‐risk	   sexual	  
behaviours.	   The	   National	   Health	   and	   Nutrition	   Examination	   Surveys	   (NHANES)	   have	  
periodically	   collected	  and	  published	  data	   in	   the	  USA	  on	  HCV	  prevalence	   (Alter	  et	  al.,	  
1999).	   Their	   most	   recent	   estimates	   suggest	   1.6%	   or	   4.1	   million	   persons	   in	   the	   USA	  
were	   anti-­‐HCV	   positive,	   the	   majority	   of	   whom	   were	   born	   between	   1945	   and	   1964	  
(Armstrong	   et	   al.,	   2006).	   Other	   high-­‐risk	   groups	   include	   homeless	   persons	   and	  





In	  the	  Western	  World,	  the	   incidence	  of	  acute	  HCV	   infection	  particularly	  amongst	  HIV	  
(human	   immunodeficiency	  virus)	  positive	   individuals	  has	   shown	  a	   recent	   increase,	   in	  
particular	  amongst	  men	  who	  have	  sex	  with	  men	  (MSM)	  (Bollepalli	  et	  al.,	  2007,	  Fox	  et	  
al.,	  2008,	  Low	  et	  al.,	  2008).	  Transfusion-­‐acquired	   infection	  rates	  however,	  have	  been	  
rare	  since	  the	  introduction	  of	  mandatory	  testing	  for	  all	  blood	  products/donors	  in	  1991.	  
IVDU	  related	  infection	  has	  also	  shown	  a	  decrease	  due	  to	  increased	  awareness	  and	  the	  
combination	   of	   needle	   exchange	   programmes	   and	   safe	   injection	   education.	   Vertical	  
transmission	   remains	   an	   important	   source	   especially	   given	   the	   global	   migration	   of	  
individuals	   from	  countries	  with	  high	  prevalence	   rates	   i.e.	  Africa,	   Eastern	   Europe	   and	  
South	  East	  Asia.	  
	  
One	   patient	   group	   that	   are	   presenting	   increasingly	   with	   evidence	   of	   chronic	   HCV	  
infection	  and	  its	  long-­‐term	  complications	  are	  HIV	  co-­‐infected	  individuals.	  One	  third	  of	  
patients	  with	  HIV	  infection	  in	  Europe	  and	  the	  USA	  are	  co-­‐infected	  with	  HCV,	  and	  up	  to	  
90%	   of	   deaths	   in	   HIV	   positive	   individuals	   with	   end-­‐stage	   liver	   disease	   (ESLD)	   are	  
attributed	   to	  HCV	   infection	   (Rosenthal	   et	   al.,	   2007).	   HIV/HCV	   co-­‐infected	   individuals	  
have	  a	  reduced	  rate	  of	  spontaneous	  HCV	  RNA	  clearance,	  with	  80%	  of	  individuals	  going	  
on	  to	  develop	  evidence	  of	  chronic	  infection	  (Graham	  et	  al.,	  2001).	  	  
2.	  Hepatitis	  C	  virus	  structure	  and	  lifecycle	  
	  
HCV	   is	   a	   small	   (55-­‐65nm),	   enveloped	   RNA	   virus	   (Figure	   1.1a)	   which	   belongs	   to	   the	  
Flaviviridae	   family,	   genus	   Hepacivirus	   and	   encodes	   a	   single	   polyprotein.	   Other	  




Japanese	  encephalitis	  virus	  and	  Tick-­‐borne	  encephalitis	  virus.	  HCV	  is	  closely	  related	  to	  
the	  human	  virus	  GB	  virus	  C	  (Lindenbach	  and	  Rice,	  1999).	  HCV	  has	  at	  least	  6	  genotypes	  
(1-­‐6)	   with	   further	   subtypes	   (a,	   b,	   c,	   etc.).	   There	   is	   a	   high	   intra-­‐genotype	   nucleotide	  
sequence	  variability.	  The	  structure	  of	  the	  HCV	  genome	  is	  integral	  in	  the	  understanding	  
of	  the	  new	  directly	  acting	  anti-­‐viral	  (DAAs)	  agents	  and	  their	  action.	  	  
	  
HCV	  is	  an	  enveloped	  virus	  that	  consists	  of	  a	  single	  positive	  RNA	  strand,	  that	  encodes	  a	  
single,	  9600	  base	  pairs	  (Rosenberg,	  2001).	  It	  posses	  both	  5’	  and	  3’	  untranslated	  regions	  
(UTRs).	   A	   long	   open	   reading	   frame	   encodes	   the	   10	   viral	   proteins	   (Figure	   1.1b).	   HCV	  
virions	  exist	  as	  lipoviroparticles	  (LVP)	  
	  
	  




It	  consists	  of	  3	  structural	  (S)	  proteins	  (Core;	  E1;	  E2)	  in	  the	  N-­‐terminal	  one-­‐third	  and	  7	  
non-­‐structural	   (NS)	   proteins	   (p7,	   NS2,	   NS3,	   NS4A,	   NS4B,	   NS5A	   and	   NS5B)	   in	   the	   C-­‐
terminal	   two-­‐third	  of	   the	  polyprotein.	  The	  core	  protein	   forms	   the	  viral	  nucleocapsid,	  
and	   the	  envelope	   (E1,	  E2)	  proteins	  are	  glycosylated	  membrane	  proteins.	  NS-­‐proteins	  
have	   essential	   functions	   in	   viral	   replication.	   NS-­‐proteins	   are	   released	   from	   the	  
polyprotein	  following	  cleavage	  by	  HCV	  proteases	  (NS2-­‐3	  and	  NS3-­‐4A)	  whilst	  S-­‐proteins	  
are	   released	  by	  host	  endoplasmic	   reticulum	  signal	  peptidases	   (Reed	  and	  Rice,	  2000).	  
The	  HCV	  genome	  consists	  of	  an	  open	  reading	  frame	  of	  approximately	  9600	  base	  pairs	  
which	  is	  translated	  as	  a	  single	  polypeptide	  of	  approximately	  3000	  amino	  acids.	  It	  lacks	  
a	  proof-­‐reading	  function	  for	  the	  RNA-­‐dependent	  RNA	  polymerase	  which	  accounts	  for	  
the	  high	  mutation	  rate	  and	  genetic	  variability	  every	  4-­‐6	  hours	  (quasispecies).	  	  	  
	  
HCV	   replication	   largely	   occurs	   within	   hepatocytes.	   HCV	   can	   directly	   infect	   dendritic	  
cells	  (DC),	  monocytes	  and	  lymphocytes	  (Pachiadakis	  et	  al.,	  2005,	  Muratori	  et	  al.,	  1996,	  
Lerat	  et	  al.,	  1998,	  Bain	  et	  al.,	  2001,	  Sung	  et	  al.,	  2003).	  Infection	  of	  B	  cells	  is	  thought	  to	  
drive	   clonal	   proliferation	   and	   account	   for	   cryoglobulinemia	   and	   related	  
lymphoproliferative	   disorders	   that	   can	   occur	   with	   HCV	   infection	   (Rosa	   et	   al.,	   2005,	  
Carbonari	   et	   al.,	   2005,	   Charles	   et	   al.,	   2008,	   Giordano	   et	   al.,	   2007).	   HCV	   binds	   to	   a	  
receptor	  on	  the	  cell	  surface	  which	   leads	  to	  endocytosis	  of	  the	  viral	  particle.	   	  The	  LDL	  
(low	   density	   lipoprotein)	   receptor	   and	   glycosaminoglycans	   facilitate	   initial	   binding	  
followed	   E1-­‐E2	   interaction	   with	   CD-­‐81	   and	   scavenger	   receptor	   class	   B	   type	   I	   (SR-­‐
BI)(Barth	  et	  al.,	  2003,	  Agnello	  et	  al.,	  1999,	  Pileri	  et	  al.,	  1998).	  Claudin-­‐1	   (CLDN1)	  and	  
occluding	   (OCLN)	   are	   necessary	   for	   entry	   (Ploss	   et	   al.,	   2009).	   The	   HCV	   genome	   is	  




membrane.	   HCV	   positive	   strand	   RNA	   is	   directly	   translated	   with	   production	   of	   HCV	  
proteins.	  Expression	  of	  these	  HCV	  proteins	  induces	  intracellular	  membrane	  alterations	  
(site	   of	   RNA	   replication).	   NS-­‐proteins	   (NS3-­‐NS5B)	   assemble	   and	   form	   a	   replication	  
complex	   which	   is	   also	   responsible	   for	   RNA	   replication.	   A	   nucleocapsid	   is	   formed	  




Figure	  1.2.	  Life	  cycle	  of	  HCV	  replication	  (Scheel	  and	  Rice,	  2013)	  
LVP,	   lipoviroparticles;	   miR,	   micro	   RNA;	   EphA2,	   ephrin	   receptor	   type	   A2;	   GAG,	  
glycosaminoglycans;	  PL,	  phospholipids;	  TG,	  triglycerides;	  	  
	  




2.1	  Functions	  of	  HCV	  structural	  proteins	  
Core	   protein.	   The	   core	   protein	   is	   an	   RNA-­‐binding	   protein	   that	   helps	   form	   the	   viral	  
nucleocapsid.	   It	  also	  plays	  a	   role	   in	  cell	   signalling,	  apoptosis,	  carcinogenesis	  and	   lipid	  
metabolism	  and	  steatosis.	  
	  
E1	  and	  E2	  glycoproteins.	  These	  envelope	  proteins	  help	  create	  the	  viral	  envelope	  and	  
also	   essential	   for	   virus	   entry	   and	   fusion	   as	   well	   as	   contributing	   to	   virus	   assembly	  
(Bartosch	  and	  Cosset,	  2006,	  Cocquerel	  et	  al.,	  2006).	  
	  
2.2	  Functions	  of	  HCV	  non-­‐structural	  proteins	  	  
p7.	  The	  p7	  polypeptide	   is	  a	   transmembrane	  protein	  and	   is	   located	  at	   the	   junction	  of	  
the	  S-­‐	  and	  NS-­‐	  proteins.	  In	  vitro	  data	  suggests	  that	  p7	  belongs	  to	  the	  viroporin	  family	  
and	   acts	   as	   a	   calcium	   ion	   channel	   across	   the	   endoplasmic	   reticulum	  membrane	   (ER)	  
(Gonzalez	  and	  Carrasco,	  2003).	  It	  is	  not	  required	  for	  RNA	  replication	  but	  appears	  to	  be	  
essential	  for	  viral	  assembly	  and	  the	  infectivity	  of	  HCV.	  
	  
NS2.	  NS2	  is	  a	  zinc	  dependent	  cysteine	  protease	  involved	  in	  the	  protease	  activity	  at	  the	  
NS2/NS3	   junction.	   It	   is	   not	   essential	   for	   the	   formation	   of	   the	   replication	   complex	  
(Blight	   et	   al.,	   2000,	   Lohmann	   et	   al.,	   1999).	   The	   role	   of	   NS2	   in	   its	   entirety	   remains	  
unclear.	  
	  
NS3	   and	  NS4A.	  The	  NS3-­‐NS4A	   protease	   is	   essential	   for	   the	  HCV	   lifecycle.	   NS3-­‐NS4A	  




also	   involved	   in	   attenuation	   of	   the	   host	   innate	   anti-­‐viral	   response	   (Lindenbach	   and	  
Rice,	  2005,	  Foy	  et	  al.,	  2003).	  The	  first	  generation	  protease	   inhibitors,	  boceprevir	  acts	  
on	   NS3	   whilst	   Telaprevir	   inhibits	   the	   NS3-­‐NS4A	   protease	   activity.	   The	   second	  
generation	  protease	  inhibitor,	  simeprevir	   inhibits	  the	  NS3/4A	  protease	  activity.	  These	  
drugs	  are	  predominately	  used	  in	  genotype	  1	  patients.	  
	  
NS4B.	  NS4B	  is	  an	  integral	  membrane	  protein	  and	  acts	  as	  a	  membrane	  anchor	  for	  the	  
replication	  complex.	  
	  
NS5A.	   The	   NS5A	   is	   a	   membrane	   protein	   that’s	   acts	   as	   a	   membrane	   anchor	   and	   is	  
essential	   for	   genome	   replication	   (Appel	   et	   al.,	   2006,	   Seeger,	   2005).	   Daclatasvir,	  
ledipasvir	  and	  ombitasvir	  (formerly	  known	  as	  Abbvie,	  ABT-­‐267)	  are	  NS5A	  inhibitors.	  	  
	  
NS5B.	   	  NS5B	   is	   an	  RNA-­‐dependent	  RNA	  polymerase	   that	   catalyses	   the	   replication	  of	  
HCV	  (Behrens	  et	  al.,	  1996).	  It	  also	  interacts	  with	  cyclophilin	  B,	  stimulating	  RNA	  binding	  
activity	  (Ishii	  et	  al.,	  2006).	  Cyclosporin	  A	  is	  known	  to	  inhibit	  cyclophilin	  B	  and	  therefore	  
HCV	   replication	   in	   cell	   line	   culture	   (Watashi	   et	   al.,	   2003).	   Sofosbuvir	   is	   a	   nucleotide	  
inhibitor	  that	  acts	  on	  the	  NS5B.	  The	  catalytic	  site	  of	  NS5B	  protein	  is	  highly	  conserved	  
across	  all	  genotypes,	  making	   the	  nucleos(t)ide	   inhibitors	   that	   target	   this	  protein	  very	  
appealing	   as	   a	   treatment	   option	   (Asselah	   and	   Marcellin,	   2012).	   Dasabuvir	   (formely	  
known	  as	  Abbvie,	  ABT-­‐333)	   is	  also	  a	  NS5B	  RNA	  non-­‐nucleoside	  polyemerase	  inhibitor	  
that	  has	  been	  used	  in	  conjunction	  with	  ABT-­‐450/ritonavir	  and	  ombitasvir	  (Andreone	  et	  





3.	  Pathogenesis	  of	  HCV	  infection	  
	  
HCV	   can	   cause	   direct	   liver	   injury	   or	   indirect	   liver	   injury	   through	   immune	   mediated	  
pathways.	   	   The	   typical	   tissue	   reaction	   in	   this	   setting	   is	   a	   chronic	   wound	   healing	  
reaction	  which	  is	  characterised	  by	  the	  simultaneous	  presence	  of	   inflammation,	  tissue	  
remodelling	   and	   regeneration.	   The	   deposition	   of	   fibrillar	   extracellular	   matrix	   (ECM)	  
represents	   the	   best	   available	   solution	   aimed	   at	   maintaining	   tissue	   continuity	   in	   a	  
context	   of	   extensive	   tissue	   necrosis/apoptosis.	   Fibrogenesis	   is	   a	   dynamic	   process.	  
Indeed,	  newly	  deposited	  fibrillar	  ECM	  is	  rapidly	  degraded	  and	  tissue	  fibrosis	  is	  usually	  
observed	   after	   a	   significant	   amount	   of	   time,	   when	   the	   rate	   of	   synthesis	   of	   fibrillar	  
collagens	  (I,	  III,	  VI	  etc)	  by	  myofibroblasts	  exceeds	  the	  rate	  of	  degradation.	  This	  occurs	  
for	   two	   main	   reasons:	   1)	   the	   number	   of	   activated	   myofibroblasts	   reaches	   a	   peak	  
hyperplasia	  partly	  in	  reason	  of	  a	  progressive	  resistance	  to	  apoptosis	  (activation	  phase),	  
and	   2)	   the	   perpetuation	   of	   the	   activation	   of	   this	   cell	   type	   is	   characterized	   by	   a	  
progressive	  reduction	  of	  its	  ability	  to	  degrade	  and	  remodel	  fibrillar	  ECM	  (perpetuation	  
phase).	  	  
	  
In	   general,	   in	   chronic	   HCV	   infection	   as	   well	   other	   chronic	   liver	   diseases	   evolving	  
towards	   cirrhosis,	   a	   significant	  accumulation	  of	   fibrillar	   ECM	   is	  observed	  only	  after	   a	  
clinical	   course	   lasting	   several	   years	   and	   even	   decades.	   For	   example,	   in	   the	   large	  
majority	   of	   patients	   with	   chronic	   HCV	   there	   is	   a	   long	   latency	   period	   (10-­‐15	   years)	  
between	  HCV	  infection	  and	  the	  detection	  of	  minimal	  stages	  of	  fibrosis,	  in	  the	  presence	  





The	  end-­‐point	   is	  however	   the	  same,	  progressive	  hepatic	   fibrosis,	   leading	  to	  cirrhosis.	  
Liver	   fibrosis	   occurs	   due	   to	   the	   accumulation	   of	   extracellular	   matrix	   (ECM)	  
components,	  a	  down-­‐regulation	  of	  ECM-­‐removing	  matrix	  metalloproteinases	   (MMPs)	  
and	  an	  increase	  of	  tissue	  inhibitors	  of	  MMPs	  (TIMMPS)	  (Schulze-­‐Krebs	  et	  al.,	  2005).	  In	  
essence,	   a	   switch	   to	   a	  matrix	   secretion	   and	   accumulation	   phenotype	   occurs	   from	   a	  
secretion	   and	   degradation	   phenotype	   (Henderson	   and	   Iredale,	   2007).	   Interstitial	  
collagen	  type	  I	  and	  III	  and	  type	  IV	  make	  up	  the	  majority	  of	  ECM	  components	  (Schulze-­‐
Krebs	   et	   al.,	   2005).	  Myofibroblasts	   (MF)	   produce	   these	   collagens,	  MMPs	   and	   TIMPs	  
and	   are	   derived	   from	   either	   activated	   hepatic	   stellate	   cells	   (HSCs)	   or	   activated	  
portal/perivascular	   fibroblasts	   (McCrudden	   and	   Iredale,	   2000,	   Knittel	   et	   al.,	   1999,	  
Friedman,	   2000).	   HSCs	   reside	   in	   the	   space	   of	   Disse	   and	   have	   been	   identified	   as	   the	  
main	  fibrogenic	  cell	  type	  in	  all	  forms	  of	  liver	  injury	  (Schuppan	  et	  al.,	  2003).	  HSCs	  store	  
approximately	   70%	   of	   the	   body’s	   retinoid	   (Vitamin	   A)	   stores.	   Following	   liver	   injury,	  
HSCs	   they	   differentiate	   into	   myofibroblast-­‐like	   cells.	   HSCs	   become	   responsive	   to	  
inflammatory	  cytokines	  and	  stimuli	  (‘activation	  stage’)	  before	  proliferating,	  migrating,	  








Figure	  1.3	  Pathway	  of	  hepatic	  stellate	  cell	  activation	  (Friedman,	  2008a)	  
	  
Although	  cirrhosis	  is	  the	  common	  result	  of	  progressive	  fibrogenesis,	  there	  are	  distinct	  
patterns	   of	   fibrotic	   development,	   related	   to	   the	   underlying	   disorders	   causing	   the	  
fibrosis.	  The	  typical	  pattern	  of	  chronic	  hepatitis	  C	  is	  defined	  “portal-­‐central”	  and	  is	  the	  
result	   of	   bridging	   necrosis	   progressing	   from	   around	   the	   portal	   tract	   towards	   the	  
centrolubular	   vein.	   This	   leads	   to	   the	   preferential	   formation	   of	   portal-­‐central	   fibrotic	  
septa.	  In	  addition,	  this	  form	  of	  fibrogenic	  evolution	  is	  characterized	  by	  the	  presence	  of	  
“interface”	  hepatitis	  and	  development	  of	  portal	  to	  portal	  septa	  and	  septa	  ending	  blind	  
in	   the	   parenchyma,	   and	  by	   the	   rapid	   derangement	   of	   the	   vascular	   connections	  with	  
both chemokines54 and extracellular nucleotides.55 In
contrast, progressive recruitment of bone-marrow–de-
rived cells may occur over time, such that these cells
can represent a substantial fraction of the total fibro-
genic population in more chronic injury. Bone marrow
recruitment of mesenchymal cells remains a somewhat
confusing event because of contradictory findings that
on the one hand, bone marrow may provide fibrogenic
cells, yet on the other hand autologous bone mar-
row56,57 and marr w-derived endothelial progenitor
cells58 can be antifibrotic. It remains unclear which
cells within marrow contribute to fibrogenesis and
which might be antifibrotic, and/or what mediators
regulate these apparently divergent activities of bone-
marrow–derived cells.
Because cellular sources of fibrogenic cells may differ
among different etiologies, the relative value of particular
antifibrotic therapies also may depend on the underlying
disease. For example, the integrin !v"6 is up-regulated
only on biliary epithelium during experimental choles-
tatic liver fibrosis,59 implying that antagonists to this
integrin might be more rational in biliary than in paren-
chymal liver diseases.
Pathways of Stellate Cell Activation:
A Moving Target
Initiating Pathways
Stellate cell activation unfolds progressively in
sequential stages; this paradigm provides a useful frame-
work for defining fibrogenic events after liver injury (Fig-
ure 2). In particular, the initiation phase, which r fers to
early events that render the quiescent stellate cell respon-
sive to a range of growth factors, remains an important
focus. Rapid induction of "-PDGF receptor, development
of a contractile and fibrogenic phenotype, as well as
modulation of growth factor signaling are the cardinal
features of this early response. Initiating stimuli include
paracrine signals such as reactive oxygen species from
Figure 2. Pathways of hepatic stellate cell activation. Features of stellate cell activation can be distinguished between those that stimulate initiation
and those that contribute to perpetuation. Initiation is provoked by soluble stimuli that include oxidant stress signals (reactive oxygen intermediates),
apoptotic bodies, lipopolysaccharide (LPS), and paracrine stimuli from neighboring cell types including hepaticmacrophages (Kupffer cells), sinusoidal
endothelium, and hepatocytes. Perpetuation follows, characterized by a number of specific phenotypic changes including proliferation, contractility,
fibrogenesis, altered matrix degradation, chemotaxis, and inflammatory signaling. FGF, fibroblast growth factor; ET-1, endothelin-1; NK, natural killer;
NO, nitric oxide; MT, membrane type. Modified with permission from Friedman.7




the	  portal	  system.	  This	  early	  derangement	  of	  the	  vascular	  architecture	  of	  the	  liver	  may	  
lead	   to	   a	   significant	   degree	   of	   portal	   hypertension	   in	   the	   presence	   of	   a	   lower	  




Necrosis	  secondary	  to	  oxidant	  stress	  can	  lead	  to	  HSC	  activation	  and	  is	  associated	  with	  
an	  inflammatory	  cell	  infiltrate.	  This	  is	  considered	  to	  be	  a	  classical	  fibrogenic	  pathway.	  	  
	  
3.2	  Apoptosis	  
There	   is	   increasing	   data	   to	   suggest	   that	   HCV	  mediated	   liver	   damage	   is	   through	   the	  
induction	  of	  apoptosis	   (Bantel	  and	  Schulze-­‐Osthoff,	  2003).	  These	  findings	  were	  made	  
following	  the	  observation	  of	  acidophilic	  (Councilman)	  bodies	  in	  the	  liver	  lobule.	  During	  
apoptosis,	  or	  programmed	  cell-­‐death,	  cells	  become	  fragmented	  into	  small	  membrane-­‐
bound	  bodies	  (apoptotic	  bodies)	  and	  are	  then	  removed	  by	  phagocytosis	  (Henson	  et	  al.,	  
2001,	  Savill,	  2000,	  Thornberry,	  1998).	  Apoptosis	  occurs	  through	  intrinsic	  and	  extrinsic	  
pathways.	   Death	   receptors	   work	   via	   the	   extrinsic	   pathway	   and	   include	   Fas	   (CD95),	  
tumour	  necrosis	  factor	  (TNF)-­‐receptor-­‐1	  and	  tumour	  necrosis	  factor-­‐related-­‐apoptosis-­‐
inducing	   ligand	   receptors-­‐1	   and-­‐2	   (TRAIL-­‐R1	   and	   –R2)	   (Canbay	   et	   al.,	   2004).	   Death	  
receptors	   are	   secreted	   in	   response	   to	   foreign	   antigens	   and	   then	   bind	   to	   their	  
respective	  ligands,	  resulting	  in	  the	  production	  of	  caspases	  (Ashkenazi	  and	  Dixit,	  1998).	  
Intrinsic	  pathways	  involve	  disruption	  of	  the	  mitochondrial	  membrane	  resulting	  again	  in	  




the	  induction	  of	  Fas-­‐ligand	  (L)	  on	  T-­‐lymphocytes	  which	  correlates	  with	  the	  severity	  of	  
inflammation	   and	   results	   in	   apoptosis	   (Hayashi	   et	   al.,	   1997,	   Ferenbach	   et	   al.,	   1997,	  
Pianko	  et	  al.,	  2001,	  Iio	  et	  al.,	  1998,	  Nelson	  et	  al.,	  1997,	  Erickson	  et	  al.,	  2001).	  
	  
3.3	  Angiogenesis	  
Angiogenesis	  in	  combination	  with	  inflammation	  contribute	  to	  the	  profibrogenic	  mileu.	  
New	   blood	   vessel	   formation,	   sinusoidal	   modelling	   and	   HSC	   expansion	   have	   been	  
demonstrated	   and	   are	   mediated	   by	   mediators	   such	   as	   VEGF	   (vascular	   endothelial	  
growth	  factor)	  and	  PDGF	  (platelet	  derived	  growth	  factor)	  (Cassiman	  et	  al.,	  2002).	  
	  
3.4	  Transforming	  Growth	  Factor-­‐Beta	  1	  
TGF-­‐B1	   (transforming	   growth	   factor	   –Beta	   1)	   is	   the	  major	   fibrogenic	   cytokine	   in	   the	  
liver	   (Seki	   et	   al.,	   2007).	   It	   activates	   quiescent	   HSCs	   to	   smooth	   muscle	   alpha-­‐actin	  
expressing	   MF	   (Schulze-­‐Krebs	   et	   al.,	   2005).	   TGFB	   expression	   is	   upregulated	   on	  
hepatocytes	   following	  exposure	   to	  HCV	  non-­‐structural	   proteins	   (Schulze-­‐Krebs	   et	   al.,	  
2005).	  TGF-­‐B1	  plasma	   levels	  and	   intrahepatic	   liver	  expression	  are	  elevated	   in	  chronic	  
HCV	  infection,	  with	  higher	  levels	  associated	  with	  unsuccessful	  viral	  clearance	  (Flisiak	  et	  
al.,	  2005).	  HCV	  can	  also	  lead	  to	  the	  production	  of	  reactive-­‐oxygen	  species	  (ROS)	  which	  
in	  turn	  can	  induce	  TGFB-­‐1	  (De	  Bleser	  et	  al.,	  1999,	  Garcia-­‐Trevijano	  et	  al.,	  1999).	  Toll	  like	  
receptor	   (TLR)	   4	   plays	   an	   important	   role	   in	   hepatic	   fibrogenesis	   by	   enhancing	   TGFB	  





Quiescent	  HSCs	  express	  CD81	  and	  LDL-­‐receptor,	  putative	  receptors	  for	  HCV	  suggesting	  
that	   HSCs	   can	   be	   targeted	   directly	   by	   HCV	   (Bataller	   et	   al.,	   2004).	   Recombinant	   HCV	  
proteins	   can	   also	   exert	   a	   direct	   fibrogenic	   effect	   on	  HSCs	   (Bataller	   et	   al.,	   2004).	   The	  
continuous	  expression	  of	  HCV	  proteins	  on	  HSCs	  results	  in	  on-­‐going	  production	  TGFB-­‐1	  
(Bataller	  et	  al.,	  2004).	  	  
	  
4.	  Immune	  response	  to	  HCV	  infection	  
	  
4.1	  Interferon	  pathways	  
Following	   infection	  with	   HCV,	   HCV	   RNA	   triggers	   the	   production	   of	   type-­‐1	   interferon	  
(IFN)	  α/B	  within	  hepatocytes	  leading	  to	  the	  activation	  of	  IFN-­‐sensitive	  genes	  (ISGs)	  via	  
the	  JAK/STAT	  pathway	  (Thimme	  et	  al.,	  2006,	  Gale	  and	  Foy,	  2005).	  Type-­‐1	   interferons	  
are	  also	  produced	  by	  plasmacytoid	  dendritic	  cells	  (pDCs).	  ISGs	  include	  the	  OAS1/RNAse	  
L	   system,	   RNA-­‐specific	   ADAR1,	   P56	   and	   PKR	   and	   are	   involved	   in	   degrading	   and	  
destabilising	  viral	  RNA	  structures	  (Guo	  et	  al.,	  2004,	  Taylor	  et	  al.,	  2005,	  Hui	  et	  al.,	  2003,	  
Pflugheber	  et	  al.,	  2002,	  Polyak	  et	  al.,	  2001a).	  IFN	  can	  also	  up-­‐regulate	  the	  expression	  of	  
HCV	  antigens	  on	  the	  surface	  of	  infected	  hepatocytes.	  	  However,	  HCV	  can	  dampen	  the	  
IFN	   response	   through	   different	   mechanisms:	   increased	   expression	   of	   HCV	   core	  
interferes	  with	  the	  JAK/STAT	  pathway	  of	  ISG	  induction	  by	  inhibiting	  STAT1	  activation;	  
increased	   expression	   HCV	  NS3/4A	   protein	   complex	   decreases	   IFN-­‐β	   production;	   and	  
HCV	  NS5A	  inhibits	  ISG	  expression	  through	  induction	  of	  IL-­‐8	  (Polyak	  et	  al.,	  2001a).	  Non-­‐
responders	   have	   higher	   ISG	   expression	   in	   pre-­‐treatment	   liver	   biopsies	   compared	   to	  




ISGs	  appears	  to	  be	  confined	  to	  the	  liver	  and	  is	  not	  evident	  in	  PBMCs	  (Sarasin-­‐Filipowicz	  
et	  al.,	  2008).	  The	  NS3/4A	  protease	  in	  addition	  to	  processing	  viral	  proteins	  also	  plays	  an	  
important	  role	  in	  the	  inhibition	  of	  type	  I	  IFN	  through	  the	  inactivation	  of	  TRIF	  and	  Cardif	  
as	   well	   as	   interfering	   with	   NFκB	   (nuclear	   factor	   kappa	   B)	   production	   (Meylan	   and	  
Tschopp,	  2006).	  	  	  
	  
The	   addition	   of	   ribavirin	   to	   IFN	   alters	   gene	   expression	   in	   pathways	   affecting	   HSC	  
activation	   and	   maybe	   one	   possible	   explanation	   for	   the	   finding	   of	   reduced	   hepatic	  
fibrosis	   in	   patients	   receiving	   long-­‐term	   ribavirin	   monotherapy	   (Feld	   et	   al.,	   2007,	  
Hoofnagle	   et	   al.,	   2003).	   A	  more	   recent	   study	   demonstrated	   the	   induction	   of	   several	  
antiviral	  genes	  specifically	  by	  ribavirin	  in	  particular	  IRF7	  and	  IRF9	  (Thomas	  et	  al.,	  2011).	  
IRF7	  mRNA	  levels	  from	  PBMCs	  are	  known	  to	  correlate	  with	  the	  response	  to	  anti-­‐viral	  
therapy	   (AVT),	   whilst	   IRF9	   has	   a	   direct	   antiviral	   action	   against	   HCV	   in	   tissue	   culture	  
(Thomas	  et	  al.,	  2011,	  Taylor	  et	  al.,	  2007).	  
	  
4.2	  Natural	  killer	  cells	  
Natural	   killer	   (NK)	   cells	   are	   abundant	   in	   the	   liver	   making	   up	   approximately	   50%	   of	  
lymphocytes	  within	  the	  liver	  (Corado	  et	  al.,	  1997).	  Phenotypically	  NK	  cells	  are	  defined	  
by	  the	  presence	  of	  the	  surface	  marker	  CD56	  and	  the	  absence	  of	  CD3.	  CD56	  dim	  NK	  cells	  
represent	   the	   majority	   of	   NK	   cells	   (>90%)	   and	   express	   higher	   levels	   of	   killer	   cell	  
immunoglobulin-­‐like	  receptors	  (KIRs),	  CD16	  and	  perforin	  and	  are	  therefore	  regarded	  to	  
be	  more	  cytotoxic.	  CD56bright	  NK	  cells	  constitute	  approximately	  10%	  of	  NK	  cells	  and	  are	  




(Chan	   et	   al.,	   2007).They	   also	   possess	   regulatory	   functions	   in	   the	   production	   of	   pro-­‐
inflammatory	  cytokines.	  	  CD56bright	  NK	  cells	  have	  less	  cytotoxic	  ability	  but	  express	  high	  
levels	   of	   inhibitory	   receptors	   CD94:NKG2A.	   CD56bright	   NK	   cells	   exert	   their	   cytotoxic	  
action	  through	  expression	  of	  tumour	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  
(TRAIL)	   (Stegmann	  et	  al.,	  2010).	   In	  the	  absence	  of	   inflammation	  or	   infection,	  NK	  cells	  
receive	   mainly	   inhibitory	   signals.	   NK	   cell	   activating	   receptors	   include	   NKG2D,	  
CD94:NKG2C,	  CD94:NKG2E,	  NKp30,	  NKp44	  and	  NKp46.	  Inhibitory	  cell	  receptors	  include	  
CD94:NKG2A,	  2DL1	  and	  2DL2/3.	  	  
	  
NK	   cells	   do	   not	   require	   priming	   in	   order	   to	   either	   exert	   a	   cytoxic	   action	   or	   release	  
cytokines.	  NK	  cells	  play	  an	  important	  role	  in	  the	  host	  defences	  against	  viral	  infections	  
including	  cytomegalovirus	   (CMV)	  and	   influenza	  virus	   (Kubota	  et	  al.,	  1999,	  Mao	  et	  al.,	  
2010).	   NK	   cells	   are	   activated	   by	   IL-­‐12	   and	   IFN-­‐α/β	   and	   then	   secrete	   IFN-­‐ɣ,	   tumour	  
necrosis	  factor	  (TNF)	  and	  other	  chemokines	  (Biron	  et	  al.,	  1989).	   In	  HCV	  infection,	  the	  
role	  of	  NK	  cells	  has	  been	  studied	  extensively.	  Binding	  of	   the	  HCV-­‐E2	  protein	  to	  CD81	  
results	   in	   the	  attenuation	  of	  NK	  cell	   function	   (Crotta	  et	  al.,	  2002,	  Tseng	  and	  Klimpel,	  
2002).	  NK	  cytotoxicity	  cell	  receptors	  are	  also	  downregulated	  by	  HCV	  via	  the	  HCV	  core	  
protein	  (Herzer	  et	  al.,	  2003,	  Horner	  and	  Gale,	  2009,	  Wen	  et	  al.,	  2008).	  
	  
A	  seminal	  paper	  in	  2004,	  reported	  a	  genetic	  polymorphism	  in	  the	  genes	  encoding	  the	  
inhibitory	  NK	  cell	  receptor,	  KIR2DL3	  and	  the	  human	  leukocyte	  antigen	  C	  group	  1	  (HLA-­‐
C1)	   ligand	   directly	   influenced	   resolution	   of	   HCV	   (Khakoo	   et	   al.,	   2004).	   	   Subsequent	  
studies	  have	  described	  reduced	  number	  of	  NK	  cells	  peripherally	  and	  within	  the	  liver	  in	  




difference	  (Deignan	  et	  al.,	  2002,	  Lin	  et	  al.,	  2004,	  Meier	  et	  al.,	  2005,	  Morishima	  et	  al.,	  
2006,	  Par	  et	  al.,	  2002).	  A	  recent	  study	  demonstrated	  the	  induction	  of	  cytotoxic	  NK	  cell	  
function	   in	   association	   with	   the	   first-­‐phase	   virological	   response	   of	   IFN-­‐alpha	   based	  
therapy;	  NK	   cell	   TRAIL	  production	  peaked	  at	  24	  hour	   (Ahlenstiel	   et	   al.,	   2011).	   In	   the	  
same	   study,	   patients	   that	   achieved	   an	   early	   virological	   response	   demonstrated	   an	  
increased	  expression	  of	  NKG2D,	  NKp30	  and	  CD16	  (activating	  receptors)	  and	  decreased	  
expression	  of	  NKG2C	  resulting	  in	  NK	  cell	  activation	  (Ahlenstiel	  et	  al.,	  2011).	  In	  contrast,	  
another	   study	   demonstrated	   that	   patients	   with	   impaired	   viral	   kinetics	   have	   higher	  
expression	  levels	  of	  inhibitory	  receptors	  (CD158a,	  CD158b	  and	  CD158e	  whilst	  patients	  
who	   have	   an	   early	   viral	   decline	   have	   higher	   pre-­‐treatment	   expression	   levels	   of	   the	  
activating	   receptor	   NKp44	   (Golden-­‐Mason	   et	   al.,	   2011).	   On	   univariate	   analysis,	   pre-­‐
treatment	   levels	  of	  NKRp44,	  TRAIL	  and	  CD161	  were	  associated	  with	  SVR	  whilst	   levels	  
of	  the	  inhibitory	  receptors	  NKG2A,	  CD158e	  and	  CD158b	  negatively	  correlated	  with	  SVR	  
(Golden-­‐Mason	   et	   al.,	   2011).	   Successful	   antiviral	   therapy	   with	   pegylated-­‐interferon	  
(PEG)	  is	  associated	  with	  increased	  NK	  cell	  numbers	  and	  expression	  of	  activating	  NK	  cell	  
receptor	  (NKG2D)	  and	  perforin	  (Dessouki	  et	  al.,	  2010).	  
	  
4.3	  Dendritic	  cells	  
Dendritic	  cells	  (DC)	  function	  as	  antigen	  presenting	  cells	  (APCs)	  and	  help	  link	  the	  innate	  
and	   adaptive	   immune	   response.	   DCs	   can	   be	   divided	   into	  myeloid	   and	   plasmacytoid	  
lineage.	  Myeloid	  DCs	  (mDCs)	  secrete	  IL-­‐12	  and	  TNFα	  and	  differentiate	  naïve	  CD4	  cells	  
towards	   a	   Th1	   phenotype,	   whilst	   plasmacytoid	   DCs	   (pDCs)	   secrete	   IFN-­‐α	   and	   drive	  




proteins	  have	  been	  shown	  to	  impair	  DC	  function	  (Dolganiuc	  et	  al.,	  2003,	  Sarobe	  et	  al.,	  
2002).	  	  DC	  and	  NK	  cells	  are	  also	  involved	  in	  reciprocal	  activation.	  
	  
4.4	  T	  lymphocytes	  
T-­‐cells	   as	   part	   of	   the	   adaptive	   immune	   response	   are	   critical	   in	   the	   clearance	  of	  HCV	  
(Lechner	   et	   al.,	   2000,	   Thimme	   et	   al.,	   2001).	   CD4+	   T	   helper	   cells	   secrete	   antiviral	  
cytokines	  and	  activate	  B	  cells	  and	  CD8+	  T	  cells.	  Studies	  have	  shown	  that	  patients	  that	  
develop	  HCV	  specific	  CD4+	  T	   cells	  with	   subsequent	   IL-­‐2	  and	   IFN-­‐ɣ	   production	  will	   go	  
onto	  clear	  HCV	  compared	  to	  patients	  that	  generate	  a	  poor	  or	  weak	  CD4	  T	  cell	  response	  
(Kaplan	   et	   al.,	   2007,	   Urbani	   et	   al.,	   2006).	   CD8+	   T	   cells	   become	   stunned	   and	   fail	   to	  
proliferate	   in	   the	   setting	   of	   acute	   HCV	   function(Kasprowicz	   et	   al.,	   2008).	   However,	  
CD8+	   T	   cells	   dysfunction	   resolves	   once	   a	   CD4+	   T	   cell	   response	   has	   been	   mounted	  
(Lechner	  et	  al.,	  2000,	  Thimme	  et	  al.,	  2001,	  Urbani	  et	  al.,	  2006).	  Chronic	  HCV	  is	  related	  
to	  loss	  of	  T	  cell	  function,	  with	  reduced	  HCV-­‐specific	  CD4+	  and	  CD8+	  T	  cell	  responses.	  
	  
Pre-­‐	  liver	  transplantation,	  the	  development	  of	  chronic	  HCV	  infection	  appears	  to	  occur	  
due	  to	  a	  combination	  of	  factors	  and	  in	  particular,	  exhaustion	  of	  the	  adaptive	  immune	  
response	  (Spangenberg	  et	  al.,	  2005).	  In	  addition,	  the	  lack	  of	  proof	  reading	  capacity	  of	  
the	  HCV	  RNA	  polymerase	  leads	  to	  HCV	  escape	  mutations	  and	  allows	  the	  virus	  further	  
opportunities	   to	   escape	   from	   the	   individual’s	   immune	   response.	   High	   levels	   of	   IL-­‐10	  
are	   observed	   in	   chronic	   HCV	   infection	   and	   lead	   to	   inhibition	   of	   IFN-­‐α,	   increased	  
apoptosis	   of	   DCs	   and	   further	   dampens	   the	   T-­‐cell	   response	   (Dolganiuc	   et	   al.,	   2006,	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1.	  Natural	  history	  of	  HCV	  infection	  pre-­‐liver	  transplantation	  
	  
Acute	   HCV	   infection	   is	   invariably	   asymptomatic	   or	   characterised	   by	   non-­‐specific	  
symptoms	  i.e.	  lethargy,	  malaise,	  pyrexia.	  HCV	  RNA	  becomes	  initially	  detectable	  within	  
1-­‐2	  weeks	   of	   exposure	   before	   an	   increase	   in	   viral	   titres,	   peaking	   at	   approximately	   8	  
weeks.	  The	  development	  of	  jaundice	  at	  the	  time	  of	  acute	  infection	  is	  associated	  with	  a	  
decreased	   risk	   of	   chronic	   infection	   (Wiese	   et	   al.,	   2000).	   HCV	   anti-­‐body	   (Ab)	   usually	  
becomes	   detectable	   at	   the	   time	   of	   onset	   of	   symptoms	   but	   can	   remain	   negative	   in	  
approximately	  30%	  of	  patients	  (Farci	  et	  al.,	  1991).	  
	  
Chronic	  HCV	   infection	   is	   defined	  by	   the	   presence	   of	  HCV	  RNA	   for	   at	   least	   6	  months	  
after	  the	  onset	  of	  acute	  infection.	  Up	  to	  85%	  of	  patients	  will	  go	  onto	  develop	  chronic	  
HCV	   infection.	   Our	   understanding	   of	   the	   natural	   history	   of	   HCV	   infection	   has	   come	  
from	   retrospective	   studies	   of	   iatrogenic	   induced	   HCV	   infection	   or	   population	   based	  
cross	  sectional	  studies	  (Bellentani	  and	  Tiribelli,	  2001,	  Kenny-­‐Walsh,	  1999,	  McMahon	  et	  
al.,	   2010,	   Poynard	   et	   al.,	   1997,	   Vogt	   et	   al.,	   1999).	   Studies	   based	   upon	  women	  who	  
received	   HCV	   contaminated	   anti-­‐D	   immune	   globulin,	   used	   to	   prevent	   Rh	   (rhesus)	  
immunisation	   during	   pregnancy,	   demonstrated	   that	   chronic	   infection	   occurred	   in	  
approximately	   55%	  over	   an	  extended	  period	  of	   time,	   usually	   decades	   (Kenny-­‐Walsh,	  
1999).	  Individuals	  that	  are	  more	  likely	  to	  develop	  chronic	  HCV	  infection	  include	  those	  
co-­‐infected	  with	  HIV,	  of	  African	  descent	  and	   IVDUs	  (Alter	  et	  al.,	  1999,	  Graham	  et	  al.,	  
2001,	  Thomas	  et	  al.,	   2000).	  No	  differences	   in	   rates	  of	   chronicity	  were	  demonstrated	  
between	   men	   and	   women	   by	   two	   large	   studies	   (Alter	   et	   al.,	   1999,	   Bellentani	   and	  




The	  natural	  history	  of	  chronic	  HCV	   infection	   is	  highly	  variable	  but	   is	  characterised	  by	  
progressive	   fibrosis	   and	   in	   some	   the	   development	   of	   cirrhosis,	   liver	   failure	   and	  
hepatocellular	   carcinoma	   (HCC).	   A	   recent	   meta-­‐analysis	   using	   111	   studies,	   involving	  
33,121	   individuals	   demonstrated	   that	   liver	   fibrosis	   progression	   was	   non-­‐linear	   and	  
disease	   progression	   was	   strongly	   influenced	   by	   duration	   of	   infection	   (Thein	   et	   al.,	  
2008).	   The	  estimated	  prevalence	  of	   cirrhosis	  at	  20	  years	  and	  30	  years	  post	   infection	  
was	   16%	   and	   41%	   respectively.	   The	   rate	   of	   fibrosis	   varies	   dramatically	   between	  
different	  patients	  cohorts.	  Recognised	  risk	  factors	  that	  are	  associated	  with	  a	  more	  pro-­‐
fibrotic	  phenotype	  include	  male	  gender,	  race,	  age	  at	  infection,	  iron	  over	  load,	  cigarette	  
smoking,	  cannabis	  use,	  duration	  of	  infection,	  alcohol	  consumption	  >	  50g/day,	  hepatic	  
steatosis	   in	   particular	   patients	   with	   genotype	   3	   HCV,	   increased	   BMI,	   diabetes	   and	  
uncontrolled	   infections	   (HIV,	   HBV	   and	   shistosomiasis)	   co-­‐infection	   (Adinolfi	   et	   al.,	  
2001,	   Caronia	   et	   al.,	   1999,	   Freeman	   et	   al.,	   2001,	   Haydon	   et	   al.,	   1998,	  Mason	   et	   al.,	  
1999,	  Poynard	  et	  al.,	  2001,	  Sachithanandan	  et	  al.,	  1997,	  Thein	  et	  al.,	  2008).	  HIV/HCV	  
co-­‐infected	   individuals	   have	   accelerated	   fibrosis	   rates	   compared	   to	   immuno-­‐
competent	   HCV	   mono-­‐infected	   individuals,	   cirrhosis	   developing	   on	   average	   12-­‐16	  
years	   earlier	   (Bonnard	   et	   al.,	   2007,	   Soto	   et	   al.,	   1997,	   Joshi	   et	   al.,	   2011).	   Active	   HIV	  
replication,	   low	  baseline	  CD4+	  cell	  count	  and	  age	  >	  25	  years	  when	  HCV	  was	  acquired	  
are	  specific	  risk	  factors	  for	  HIV/HCV	  co-­‐infected	  individuals	  (Benhamou	  et	  al.,	  1999).	  
	  




2.	  Natural	  history	  of	  HCV	  infection	  post-­‐liver	  transplantation	  
	  
Re-­‐infection	  of	  the	  liver	  allograft	   is	  universal	   in	   individuals	  with	  HCV	  viraemia.	  During	  
the	  anhepatic	  phase	  of	  transplantation,	  HCV	  RNA	  concentrations	  decrease	  (Fukumoto	  
et	  al.,	  1996,	  Garcia-­‐Retortillo	  et	  al.,	  2002).	  The	  rate	  of	  viral	  load	  decay	  does	  not	  appear	  
to	  be	  related	  to	  the	  pre-­‐transplant	  viral	  load	  or	  duration	  of	  the	  anhepatic	  phase	  but	  an	  
association	   with	   the	   amount	   of	   blood	   loss	   during	   the	   anhepatic	   phase	   (r=0.78,	  
p<0.001),	  the	  number	  of	  red	  blood	  cell	  concentrates	  transfused	  during	  the	  anhepatic	  
phase	  (r=0.71,	  p=0.001)	  and	  during	  the	  entire	  surgical	  procedure	  (r=0.76,p<0.001)	  has	  
been	  demonstrated	   (Garcia-­‐Retortillo	  et	  al.,	   2002).	   The	   sharp	   fall	   in	  HCV-­‐RNA	  occurs	  
due	  to	  lack	  of	  virion	  production	  (Fukumoto	  et	  al.,	  1996).	  Following	  reperfusion	  of	  the	  
graft,	  HCV-­‐RNA	  titres	  continue	  to	  decrease	  secondary	  to	   large	  volume	  uptake	  of	  HCV	  
by	   hepatocytes	   and	   the	   reticulo-­‐endothelial	   system	   (Garcia-­‐Retortillo	   et	   al.,	   2002).	  
Within	  12	  hours	  of	  transplantation,	  HCV-­‐RNA	  titres	  start	  to	  increase	  returning	  to	  pre-­‐
transplant	   levels	  within	  4	  days	   (Garcia-­‐Retortillo	  et	   al.,	   2002).	   In	   some	  patients,	  HCV	  
RNA	  titres	  can	  exceed	  pre-­‐transplant	   levels	  (Feliu	  et	  al.,	  2004,	  Garcia-­‐Retortillo	  et	  al.,	  
2002).	   The	   development	   of	   more	   homogenous	   quasispecies	   population	   is	   one	  
hypothesis	  postulated	  for	  this	  occurrence	  (Feliu	  et	  al.,	  2004).	  HCV-­‐RNA	  titres	  increase	  
thereafter	  and	  peak	  at	  the	  time	  of	  acute	  graft	  dysfunction	  which	  occurs	  between	  the	  
first	  and	  6th	  month	  post-­‐transplant	  (Gane	  et	  al.,	  1996a).	  
	  
The	   clinical	   course	   of	   HCV	   post	   liver	   transplantation	   (LT)	   is	   that	   of	   progressive	   and	  
accelerated	  fibrosis	  resulting	  in	  cirrhosis,	  graft	  loss	  and	  possible	  re-­‐consideration	  for	  LT	  




HCV	   has	   been	   demonstrated	   as	   early	   as	   the	   second	   week	   following	   LT	   (Garcia-­‐
Retortillo	   et	   al.,	   2002,	   Saraf	   et	   al.,	   2007).	   Activation	   of	   HSCs	   is	   clearly	   an	   important	  
event.	   Studies	   using	   α-­‐SMA	   (alpha	   smooth	   muscle	   actin)	   staining	   have	   shown	   that	  
HSCs	   are	   activated	   as	   early	   as	   4	  months	   post	   transplant	   resulting	   in	   severe	   fibrosis	  
(Cisneros	  et	  al.,	  2007,	  Gawrieh	  et	  al.,	  2005).	  This	  early	   involvement	  of	  HSC	  reflects	  a	  
common	  feature	  of	  post-­‐LT	  HCV-­‐induced	  liver	  fibrosis	  often	  characterised	  by	  a	  pattern	  
of	   evolution,	   i.e.	   periportal	   fibrosis	   associated	   with	   significant	   capillarisation	   of	  
sinusoids,	   different	   from	   what	   normally	   observed	   in	   pre-­‐transplant	   chronic	   HCV	  
infection.	  This	  potentially	  leads	  to	  misclassification	  when	  staging	  fibrosis	  with	  METAVIR	  
in	   the	   post-­‐LT	   setting	   since	   this	   semi-­‐quantitative	   scoring	   system	   does	   not	   consider	  
sinusoidal	  fibrosis.	  Accordingly,	  a	  more	  appropriate	  assessment	  in	  this	  setting	  could	  be	  
obtained	   by	   employing	   quantitative	  measures	   of	   fibrosis	   such	   as	   the	  morphometric	  
evaluation	   of	   the	   collagen	   proportionate	   area	   (Bedossa	   et	   al.,	   2003,	   Standish	   et	   al.,	  
2006).	  
	  
Approximately	   5%	   of	   patients	   will	   develop	   a	   severe	   cholestatic	   recurrence	   of	   HCV,	  
which	   is	   characterised	   by	   rapid	   portal	   fibrosis,	   hyperbilirubinaemia,	   cholestasis	   and	  
liver	   failure(Davies	   et	   al.,	   1991,	   Zylberberg	   et	   al.,	   1997).	   Histological	   features	   of	  
recurrent	  HCV	  post	   liver-­‐transplantation	  demonstrate	  many	  features	  seen	   in	  patients	  
with	   HCV	   pre-­‐transplantation.	   They	   include	   hepatocyte	   ballooning,	   intrahepatic	  
cholestasis	   and	   biliary	   ductular	   proliferation	   without	   lobular	   inflammation.	   Early	  
changes	  (0-­‐2	  weeks)	  include	  mild	  lobular	  inflammation	  and	  cell	  swelling	  with	  scattered	  





Figure	   2.1	   Early	   histopathological	   changes	   of	   HCV	   recurrence	   post	   liver	  
transplantation.	  
H&E	   400x.	   Mild	   lobular	   inflammation	   (arrow	   heads)	   and	   two	   acidophilic	   bodies	  












Figure	  2.2	  Fibrosing	  cholestatic	  hepatitis.	  H&E.	  Image	  demonstrates	  a	  portal	  lymphoid	  
aggregate	   and	   ductular	   reaction	   at	   the	   limiting	   plate	   in	   a	   cholangiolitic	   pattern.	  
Provided	  by	  Dr	  Alberto	  Quaglia.	  
	  
 80 
Figure 1.5: Histological findings of acute HCV recurrence 
Liver biopsy findings in a patient 62 days after transplantation. Mild lobular 
inflammation in the form of mononuclear inflammatory cell infiltrates (arrow heads). 







At	   one	   year,	   nearly	   50%	   of	   individuals	   will	   demonstrate	   significant	   histological	  
evidence	  of	  HCV	  recurrence	  (Figure	  2.3),	  44%	  being	  cirrhotic	  within	  5-­‐10	  years	  (Feray	  
et	   al.,	   1992,	  Gane	  et	   al.,	   1996b,	   Prieto	   et	   al.,	   1999,	   Rosen	  et	   al.,	   1996,	   Rosen	  et	   al.,	  
1998).	  Studies	  that	  have	  used	  serial	  protocol	  liver	  biopsies	  have	  demonstrated	  a	  more	  
rapid	   fibrosis	   progression	   rate/year	   compared	   to	   immunocompetent	   patients	   pre-­‐LT	  
(Baiocchi	  et	  al.,	  2008,	  Berenguer	  et	  al.,	  2000,	  Belli	  et	  al.,	  2007,	  Firpi	  et	  al.,	  2004,	  Gane	  
et	  al.,	  1996a,	  Neumann	  et	  al.,	  2004a,	  Pelletier	  et	  al.,	  2000,	  Sebagh	  et	  al.,	  2003,	  Wali	  et	  
al.,	   2002,	  Yilmaz	  et	  al.,	   2007).	   Fibrosis	   stage	  ≥	   2	  and	   severity	  of	  necro-­‐inflammatory	  
activity	  at	  12	  months	  appear	  to	  be	  important	  predictors	  of	  cirrhosis	  at	  5	  years	  (Firpi	  et	  
al.,	   2004,	   Neumann	   et	   al.,	   2004b,	   Prieto	   et	   al.,	   1999).	   The	   clinical	   impact	   of	   this	  
accelerated	  disease	  course	  is	  that	  greater	  than	  70%	  of	  patients	  will	  have	  an	  episode	  of	  
hepatic	   decompensation	   by	   3	   years	   therefore	   necessitating	   consideration	   for	   re-­‐
transplantation	  (Berenguer	  et	  al.,	  2000,	  Pruthi	  et	  al.,	  2001).	  Recurrent	  HCV	  remains	  a	  

















Figure	   2.3	   Liver	   biopsy	   12	   months	   post	   transplantation	   demonstrating	   HCV	  
recurrence	   (F<2).	   H&E	   stain	   inset	   demonstrating	   a	   lymphocytic	   portal	   infiltrate.	  
Reticulin	  stain	  (larger	  image)	  demonstrating	  portal	  expansion.	  Provided	  by	  Dr	  Alberto	  






Figure	   2.4,	   Natural	   history	   of	   HCV	   infection	   post	   liver	   transplantation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




3.	  Patient	  and	  graft	  survival	  
	  
Initial	  single	  centre	  studies	  reported	  similar	  outcomes	  between	  HCV	  positive	  and	  HCV	  
negative	  patients	  (Boker	  et	  al.,	  1997,	  Ghobrial	  et	  al.,	  2001,	  Sanchez-­‐Fueyo	  et	  al.,	  2002).	  
One	   of	   the	   first	   reports	   intimating	   inferior	   long-­‐term	   outcomes	   of	   HCV	   infection	  
following	   liver-­‐transplantation	   was	   a	   single	   centre,	   UK	   study	   (Gane	   et	   al.,	   1996b).	  
Although	  the	  data	  demonstrated	  comparable	  patient	  and	  graft	  survival	  at	  both	  1	  and	  5	  
years	   between	   HCV-­‐positive	   and	   HCV-­‐negative	   patients	   (79%	   and	   70%	   vs.	   75%	   and	  
69%,	  p=NS),	  there	  was	  a	  suggestion	  that	  with	  longer	  follow-­‐up,	  HCV-­‐positive	  patients	  
may	  have	  poorer	  outcomes	  (Gane	  et	  al.,	  1996b).	  
	  
Since	   then,	   large	   transplant	  database	   studies	  have	  confirmed	   this	   initial	  observation,	  
reporting	   significantly	   inferior	   graft	   and	   patient	   survival	   rates	   in	   patients	   with	   HCV	  
(Forman	  et	  al.,	  2002,	  Mutimer	  et	  al.,	  2006,	  Thuluvath	  et	  al.,	  2007,	  Zekry	  et	  al.,	  2003).	  A	  
European	  based	  study	  also	  demonstrated	  that	  whilst	  1-­‐year	  graft	  survival	  rates	  in	  HCV-­‐
negative	   patients	   had	   improved	   slowly	   over	   a	   10-­‐year	   period	   (1991-­‐2000),	   the	  
opposite	  was	  evident	  in	  HCV-­‐positive	  patients	  (Berenguer	  et	  al.,	  2002,	  Ghobrial	  et	  al.,	  
2001).	  One	  subsequent	  single	  centre	  study,	  reported	  long-­‐term	  outcomes	  post-­‐LT	  over	  
a	  period	  of	  20	  years	  and	  clearly	  demonstrated	   inferior	  survival	   rates	   in	  patients	  with	  
HCV	   (81%	  at	  1-­‐year,	  68%	  at	  5-­‐years,	  62%	  at	  10-­‐years)	  compared	  to	  other	  aetiologies	  







Author	   N	  
(HCV/non-­‐HCV)	  
Outcomes	  
(Gane	  EJ	  et	  al.,	  
1996b)	  
149/623	   Inferior	  outcomes	  in	  HCV:	  
	  
1	  &	  5-­‐year	  patient	  survival	  HCV:	  79%	  &	  70%	  
1	  &	  5-­‐year	  patient	  survival	  non-­‐HCV:	  75%	  &	  
69%	  
	  
(Berenguer	  M	  et	  al.,	  
2002)	  
283/239	   Inferior	  outcomes	  in	  HCV:	  
	  
1	  and	  5-­‐year	  patient	  survival	  HCV:77%	  &	  61%	  
1	  and	  5-­‐year	  patient	  survival	  non-­‐HCV:87%	  &	  
76%	  
	  
(Thuluvath	  et	  al	  
PJ.,2007)	  
7,459/20,734	   Inferior	  outcomes	  in	  HCV:	  
	  
3-­‐year	  patient	  survival	  rate	  HCV:	  79%	  
3-­‐year	  patient	  survival	  rate	  non-­‐HCV:	  81%	  
	  
Improved	  graft	  and	  patient	  survival	  rates	  in	  
non-­‐HCV	  patients.	  No	  change	  in	  HCV	  patients	  
	  
(Mutimer	  DJ	  et	  al.,	  
2006)	  
4,736/5,406	   Inferior	  outcomes	  in	  HCV:	  
	  
Improved	  10-­‐year	  graft	  and	  patient	  survival	  in	  
non-­‐HCV	  patients	  compared	  to	  HCV	  (p<0.001)	  
	  
(Sanchez-­‐Fueyo	  A	  et	  
al.,	  2002)	  
122/215	   No	  difference	  in	  outcomes	  between	  HCV	  and	  
non-­‐HCV:	  
	  
3,5,&	  7-­‐year	  graft	  survival	  HCV:	  86%,	  78%	  
&71%	  
3,5,&	  7-­‐year	  graft	  survival	  non-­‐HCV:85%,79%	  &	  
74%	  
	  
3,5,&	  7-­‐year	  patient	  survival	  HCV:	  89%,82%&	  
74%	  
3,5,&7-­‐year	  patient	  survival	  non-­‐HCV:	  89%,84%	  
and	  79%	  
	  
(Boker	  KH	  et	  al.,	  
1997)	  
61/474	   No	  difference	  in	  outcomes	  between	  HCV	  and	  
non-­‐HCV:	  
	  
2,5&	  10-­‐year	  survival	  HCV:	  67%,62%	  and	  62%	  




Table	   2.1	  Outcomes	   for	   transplantation	   in	   HCV-­‐positive	   patients	   in	   comparison	   to	  




4.	  Re-­‐transplantation	  for	  HCV	  
	  
Indications	   for	   re-­‐transplantation	   include	   primary	   non-­‐function	   (PNF),	   hepatic	   artery	  
thrombosis	   (HAT),	   chronic	   rejection	   and	   disease	   recurrence.	   In	   general,	   reported	  
outcomes	  for	  re-­‐transplantation	  irrespective	  of	  the	  underlying	  aetiology	  are	  associated	  
with	  a	  poorer	  clinical	  outcome	  (Ghabril	  et	  al.,	  2007).	  Re-­‐transplantation	  for	  recurrent	  
HCV	  post-­‐LT	  however,	  remains	  a	  controversial	   issue.	  Re-­‐transplantation	  outcomes	  for	  
emergency	   indications	   i.e.	  PNF	  or	  HAT	   in	  HCV-­‐positive	   individuals	  are	   comparable	   to	  
HCV-­‐negative	   individuals.	  The	  occurrence	  of	  a	  severe	  fibrosing	  cholestatic	  recurrence	  
of	   HCV	   	   pre	   the	   DAA	   era	   was	   regarded	   as	   an	   absolute	   contraindication	   to	   re-­‐
transplantation.	  
	  	  	  	  
Initial	   reports	   suggested	   poorer	   outcomes	   after	   re-­‐transplantation	   in	   HCV-­‐positive	  
individuals	   but	  more	   recent	   studies	   have	   demonstrated	   no	   differences	   in	   patient	   or	  
graft	  outcomes	   in	  HCV	  –	  positive	   individuals	   (Ghabril	  et	  al.,	  2008,	  McCashland	  et	  al.,	  
2007).	  Analysis	  of	  the	  UNOS	  database	  has	  demonstrated	  improved	  graft	  survival	  rates	  
following	  re-­‐transplantation	  post	  2002	  in	  all	  patients	  irrespective	  of	  aetiology	  including	  
HCV	  positive	  individuals	  (Ghabril	  et	  al.,	  2008).	  This	  observation	  would	  certainly	  support	  
the	   hypothesis	   of	   ‘a	   learning	   curve’	   by	   transplant	   centres	   in	   the	   identification	   and	  
management	   of	   HCV	   re-­‐transplant	   recipients.	   Predictors	   of	   an	   increased	   risk	   of	  
mortality	  post	  re-­‐transplantation	   in	  HCV-­‐positive	   individuals	   include	  MELD	  score	  >25,	  
increased	  donor	  and	  recipient	  age,	  elevated	  serum	  bilirubin,	  elevated	  INR	  and	  elevated	  
creatinine.	   Careful	   evaluation	   and	   selection	   is	   therefore	   advocated	   of	   patients	   with	  




Author	   N	   Outcomes	   Predictors	  








(Watt	  et	  al.,	  2003)	   899	   1-­‐year	  patient	  survival:	  61%	  
3-­‐year	  patient	  survival:	  50%	  
5-­‐year	  patient	  survival:	  45%	  
MELD	  >	  25	  
(Ghabril	  M	  et	  al.,	  
2008)	  
1034	   1-­‐year	  patient	  survival:	  70%	  
1-­‐year	  graft	  survival:	  63%	  
3-­‐year	  patient	  survival:	  59%	  






interval	  <	  1	  year	  
(McCashland	  T	  et	  
al.,	  2007)	  
43	   1-­‐year	  patient	  survival:	  69%	  
3-­‐year	  patient	  survival:	  49%	  
-­‐	  
(Roayaie	  et	  al.,	  
2003)	  
42	   -­‐	   -­‐Prothrombin	  time	  
-­‐Donor	  age	  
(Pelletier	  et	  al.,	  
2005)	  
464	   Mortality	  risk	  for	  HCV:	  




-­‐Admission	  to	  ICU	  
(Rowe	  et	  al.,	  2010)	   34	   5-­‐year	  graft	  survival	  45%	   -­‐	  
	  
(Andres	  et	  al.,	  
2012)	  	  








*	  at	  second	  
transplant	  
	  
Table	  2.2	  Studies	  evaluating	  the	  role	  of	  re-­‐transplantation	  in	  patients	  with	  recurrent	  








5.	  Factors	  influencing	  HCV	  recurrence	  post	  liver	  transplantation	  
	  
HCV	   recurrence	   is	   influenced	   by	   a	   complex	   combination	   of	   recipient,	   donor,	  
immunosuppresive,	   viral,	   infectious	   and	   surgical	   factors	   (Figure	   2.5),	   some	   of	   which	  




Figure	  2.5	  Factors	  influencing	  HCV	  recurrence	  post	  liver	  transplantation.	  
CIT,	  cold	  ischaemia	  time;	  WIT,	  warm	  ischaemia	  time;	  HLA,	  human	  leukocyte	  antigen;	  IL28B,	  interleukin	  
28B;	  DM,	  diabetes	  mellitus;	  CMV,	  cytomegalovirus;	  HIV,	  human	  immunodeficiency	  virus;	  HBV,	  hepatitis	  
















5.1	  Surgical	  factors	  
A	  prolonged	  cold-­‐ischaemia	  time	  (CIT)	  and	  warm-­‐ischaemia	  (WIT)	  time	  have	  both	  been	  
associated	  with	  severe	  recurrence	  of	  HCV	  post	  transplant	  (Baron	  et	  al.,	  2000,	  Briceno	  
et	   al.,	   2007,	   Cameron	   et	   al.,	   2006).	   Experimental	   data	   has	   suggested	   that	   sinusoidal	  
endothelial	  cells	  are	  affected	  more	  by	  a	  prolonged	  CIT	  whereas	  hepatocytes	  appear	  to	  
be	  more	  susceptible	  to	  the	  effects	  of	  a	  prolonged	  WIT	  (Baron	  et	  al.,	  2000,	  Clavien	  et	  
al.,	   1992).	   Subsequent	   hepatocyte	   proliferation	   would	   therefore	   enhance	   HCV	  
incorporation	  into	  new	  hepatocytes	  within	  the	  new	  allograft	  (Baron	  et	  al.,	  2000).	  One	  
study	  demonstrated	  that	  the	  risk	  of	  severe	  HCV	  recurrence	  within	  1-­‐year	  increased	  as	  
the	  WIT	   increased;	  19%,	  40%	  and	  65%	  after	  30,	  60	  and	  90	  minutes	  WIT	   respectively	  
(p=0.04)	  (Baron	  et	  al.,	  2000).	  A	  CIT	  >	  12	  hours	  was	  also	  associated	  with	  reduced	  graft	  
survival	  at	  12	  months	  (51%	  versus	  75%,	  p<0.0001).	  In	  the	  same	  study,	  on	  multivariate	  
analysis	  a	  CIT	  >	  12	  hours	  was	  associated	  with	  an	  increased	  risk	  of	  graft	  failure	  (OR	  7.0,	  
p=0.034)	  (Baron	  et	  al.,	  2000).	  
	  
5.1.1	  Preservation	  injury	  
Preservation	   injury	   is	   also	   known	  as	   harvesting	  or	   reperfusion	   injury.	   Abnormal	   liver	  
enzymes	  in	  the	  immediate	  post-­‐transplant	  period	  is	  the	  manifestation	  of	  preservation	  
injury	   but	   the	   diagnosis	   is	   usually	   made	   histologically	   (Figure	   1.5).	   Features	   include	  
neutrophil	  infiltration,	  microvesicular	  steatosis,	  hepatatocytes	  cytoplasmic	  aggregation	  
which	   progresses	   to	   centrilobular	   necrosis,	   hepatocyte	   swelling	   and	   cholestasis.	  
Preservation	  injury	  is	  associated	  with	  hepatocyte	  loss	  followed	  by	  proliferation	  which	  




study	   studied	   the	   impact	   of	   preservation	   injury	   in	   both	   HCV	   and	   non-­‐HCV	   infected	  
patients	  (Watt	  et	  al.,	  2006).	  Preservation	  injury	  has	  been	  identified	  as	  a	  risk	  factor	  for	  
the	  development	  of	  a	   stage	  F3/4	  and	  was	  associated	  with	   inferior	   survival	   rates	  at	  1	  
and	  3	  years	  post-­‐LT	  (Watt	  et	  al.,	  2006).	  
	  
	  
Figure	   2.6	   Preservation	   injury	   (A)	   mild	   (no	   steatosis,	   no	   necrosis,	   no	   neutrophilic	  
infiltration)	   and	   (B)	   severe	   (moderate	   steatosis,	   hepatocyte	   loss).	   H&E	   stain.	  
Provided	  by	  Dr	  Alberto	  Quaglia.	  
	  
5.2	  Donor	  factors	  
Donor	   factors	  are	  a	  potential	  area	  where	  modifications	  are	  possible.	  However,	  given	  
the	  limited	  donor	  pool	  and	  availability	  of	  suitable	  grafts,	  the	  use	  of	  marginal	  grafts	   is	  
increasing.	   The	   umbrella	   term	   of	   ‘marginal	   donor	   grafts’	   or	   extended	   criteria	   donor	  
grafts	   include	  donors	  after	   cardiac	  death	   (DCD),	  donors	   infected	  hepatatotropic	   viral	  






5.2.1	  Donor	  age	  
One	   of	   the	   most	   significant	   risk	   factors	   associated	   with	   a	   more	   rapid	   and	   severe	  
histological	  progression	  of	  HCV	  is	  increasing	  donor	  age	  (Berenguer	  et	  al.,	  2002,	  Khapra	  
et	  al.,	  2006,	  Lake	  et	  al.,	  2005,	  Machicao	  et	  al.,	  2004,	  Neumann	  et	  al.,	  2004b,	  Rayhill	  et	  
al.,	   2007).	   The	   underlying	   mechanism	   is	   due	   to	   a	   combination	   of	   a	   greater	  
susceptibility	   to	   cold	   ischaemia	   and	   preservation	   injury,	   in	   addition	   to	   the	   increased	  
likelihood	  of	  pre-­‐existing	  steatosis.	  A	  donor	  age	  of	  greater	  than	  50	  years	  compared	  to	  a	  
donor	  age	  of	   less	   than	  31	  years	  was	  associated	  with	  an	   increased	   likelihood	  (OR	  7.8,	  
p=0.001)	   of	   developing	   severe	   HCV	   recurrence	   within	   the	   first	   2	   years	   after	  
transplantation(Berenguer	  et	  al.,	  2003).	  A	  large	  US	  retrospective	  study	  demonstrated	  a	  
linear	  increase	  in	  the	  risk	  of	  graft	  loss	  with	  increasing	  donor	  age:	  41-­‐50	  years,	  HR	  1.67;	  
51-­‐60	  years,	  HR	  1.86;	  >	  60	  years,	  HR	  2.21	  p<0.001)(Lake	  et	  al.,	  2005).	  
	  
5.2.2	  Steatosis	  
Steatosis	   accumulates	   within	   the	   liver	   as	   age	   increases	   and	   is	   therefore	   one	  
mechanism	   by	   which	   older	   donor	   grafts	   are	   associated	   with	   a	   worse	   outcome	   post	  
transplantation.	  An	  increased	  likelihood	  of	  initial	  poor	  graft	  function	  in	  donor	  allografts	  
with	   severe	   donor	   macro-­‐vesicular	   steatosis	   was	   demonstrated	   compared	   to	   donor	  
allografts	  with	  moderate	  steatosis	  (35%	  vs	  17%,	  p<0.03)(Verran	  et	  al.,	  2003).	  A	  study	  of	  
51	   patients	   however	   failed	   to	   identify	   any	   accelerated	   fibrosis	   rates	   in	  HCV	  patients	  





5.2.3	  Donor	  risk	  index	  (DRI)	  
The	  donor-­‐risk	   index	  (DRI)	  comprises	  of	  eight	  donor	  and	  graft	  characteristics	  that	  are	  
significantly	   and	   independently	   associated	  with	   increased	   failure	   of	   deceased	   donor	  
liver	   transplants	   (Feng	  et	  al.,	  2006).	  The	  DRI	  allows	   for	  an	  objective	  and	  quantitative	  
assessment	  of	  relative	  risk	  of	  graft	  failure	  relative	  to	  a	  ‘standard’	  donor.	  A	  DRI	  value	  of	  
greater	  than	  or	  equal	  to	  1.7	  was	  defined	  as	  an	  extended	  criteria	  donor	  graft	  (Maluf	  et	  
al.,	   2009).	   The	   DRI	   has	   been	   shown	   to	   be	   a	   sensitive	   predictor	   of	   graft	   and	   patient	  
survival	  in	  HCV	  patients	  (Maluf	  et	  al.,	  2009).	  
	  
5.2.4	  Donation	  after	  cardiac	  death	  (DCD)	  vs.	  donation	  after	  brain	  death	  (DBD)	  
In	  donation	  after	  cardiac	  death	  (DCD)	   livers,	  death	   is	  declared	  on	  the	  basis	  of	  cardio-­‐
vascular	  criteria	  as	  opposed	  to	  brain	  function.	  Given	  the	   increasing	  experience	   in	  the	  
use	  of	  DCD	  livers,	  attention	  has	  focused	  on	  the	  use	  in	  HCV	  patients	  but	  data	  appears	  to	  
be	  conflicting.	  Initial	  single	  centre	  studies	  reported	  poorer	  outcomes	  using	  DCD	  livers	  
compared	   to	   the	   use	   of	   DBD	   livers	   (Nguyen	   et	   al.,	   2009,	   Yagci	   et	   al.,	   2008).	   Recent	  
studies	  however	  have	  been	  more	  encouraging	  with	  no	  long-­‐term	  differences	  in	  patient	  
or	  graft	  survival	  or	   time	  to	   the	  development	  of	   fibrosis	  stage	  ≥	  2	   (Taner	  et	  al.,	  2011,	  
Tao	  et	  al.,	  2010).	  Although	  the	  largest	  study,	  using	  the	  UNOS	  database	  demonstrated	  
inferior	  graft	  survival	  amongst	  DCD	  HCV	  patients	  in	  comparison	  to	  DBD	  HCV	  patients,	  
graft	   survival	   between	   DCD	   HCV	   positive	   and	   DCD	   HCV	   negative	   patients	   were	  





5.3	  Viral	  factors	  
5.3.1	  HCV	  genotype	  
It	  remains	  unclear	  as	  to	  whether	  HCV	  genotype	  affects	  the	  fibrosis	  recurrence	  post-­‐LT.	  
Available	  data	  suggests	  an	  aggressive	  pattern	  of	  disease	  recurrence	  amongst	  patients	  
with	  genotype	  1	  disease,	   in	  particular	  1b	   (Di	  Martino	  et	  al.,	  1997,	  Feray	  et	  al.,	  1995,	  
Feray	   et	   al.,	   1999,	   Ghobrial	   et	   al.,	   1999,	   Prieto	   et	   al.,	   1999).	  Mechanisms	   suggested	  
include	  increased	  DNA	  fragmentation,	  Fas-­‐mediated	  liver	  cell	  apoptosis	  and	  increased	  
antigen	   expression	   (Di	   Martino	   et	   al.,	   1997).	   Data	   however	   from	   the	   US	   does	   not	  
support	  the	  notion	  of	  a	  more	  aggressive	  recurrence	  in	  genotype	  1b	  patients	  but	  maybe	  
due	   the	   decreased	   prevalence	   of	   genotype	   1b	   disease	   compared	   to	   European	  
populations	  (Gayowski	  et	  al.,	  1997,	  Silini	  et	  al.,	  1996).	  A	  more	  rapid	  fibrosis	  progression	  
rate	  amongst	  patients	  with	  genotype	  4	  disease	  (1.51	  versus	  0.95)	  with	  a	  reduced	  time	  
to	  cirrhosis	  has	  also	  been	  reported	  (Wali	  et	  al.,	  2003).	  At	  present,	  no	  clear	  conclusions	  
of	  the	  effect	  of	  HCV	  genotype	  on	  HCV	  recurrence	  rates	  post-­‐transplant	  can	  be	  made.	  	  
	  
5.3.2	  HCV	  viral	  load	  
Individuals	  entering	  transplantation	  with	  active	  HCV	  replication	  will	  develop	  recurrent	  
HCV	  viraemia	  post	   transplantation.	  During	   the	  anhepatic	  phase,	  HCV	  RNA	  viral	   titres	  
decrease	  but	  re-­‐infection	  occurs	  during	  reperfusion	  of	  the	  liver	  allograft.	  Initially,	  viral	  
titres	  continue	  to	  decline	  due	  to	  uptake	  of	  HCV	   into	  hepatocytes	  within	  the	  allograft	  
before	   viral	   titres	   return	   to	   pre-­‐transplant	   levels	   at	   approximately	   72	   hours.	   In	   the	  
majority	   of	   patients	   viral	   titres	   exceed	   the	   pre-­‐transplant	   levels	   (Fukumoto	   et	   al.,	  




more	   likely	   to	   have	   higher	   viral	   loads	   in	   the	   post-­‐transplant	   period	   with	   good	  
correlation	   between	   liver	   tissue	   and	   serum	   (Sreekumar	   et	   al.,	   2000,	   Terrault	   et	   al.,	  
1997).	  HCV	  viral	  loads	  at	  4	  months	  post-­‐transplant	  was	  identified	  as	  sensitive	  predictor	  
of	   histological	   fibrosis	   at	   3	   years	   post-­‐transplant	   whilst	   another	   demonstrated	   the	  
higher	   HCV	   viral	   loads	   at	   1	   year	   in	   patients	   with	   more	   advanced	   fibrosis	  	  
(Papatheodoridis	  et	  al.,	  1999,	  Sreekumar	  et	  al.,	  2000).	  
	  	  
5.3.3	  Quasispecies	  
The	   HCV	   genome	   has	   significant	   genetic	   heterogenieity	   due	   to	   the	   accumulation	   of	  
mutations	   during	   viral	   replication	   which	   arises	   due	   to	   the	   inability	   of	   the	   RNA	  
polymerase	  to	  proof-­‐read.	  The	  E2	  protein	  region	  is	  particularly	  susceptible	  to	  this.	  This	  
tendency	   to	  mutation	   has	   therefore	   led	   to	   a	   survival	   advantage	   in	   evading	   the	   host	  
immune	  response.	  The	  role	  of	  viral	  quasispecies	  in	  recurrent	  HCV	  post-­‐transplant	  has	  
also	   been	   studied	   and	   are	   thought	   to	   occur	   due	   to	   pressure	   exerted	   on	   the	   host	  
immune	  system	  in	  part	  by	  the	  iatrogenic	  introduction	  of	  immunosuppression	  (Doughty	  
et	   al.,	   2000b,	  Doughty	  et	   al.,	   2000a).	   Following	   transplantation,	   there	   is	   a	   significant	  
decrease	  in	  genetic	  diversity	  resulting	  in	  a	  more	  homogenous	  viral	  population	  up	  until	  
the	   fourth	   week	   post-­‐transplant	   (Feliu	   et	   al.,	   2004).	   These	   very	   early	   changes	   in	  
quasispecies	   composition	   suggest	   entry	   of	   HCV	   into	   hepatocytes	   generate	   a	  
‘bottleneck’	  effect	  by	  selecting	  certain	  variants	  from	  the	  viral	  population	  (Feliu	  et	  al.,	  
2004).	  Two	  further	  studies	  demonstrated	  that	   immediately	  post-­‐transplantation,	  viral	  
quasispecies	   complexity	   also	   decreases	   and	   remains	   low	   in	   patients	   that	   develop	   an	  




Lyra	   et	   al.,	   2002).	   In	   a	   study	   of	   11	   patients,	   those	   that	   developed	  mild	   fibrosis	   had	  
greater	  heterogeneity	  compared	  to	  patients	  with	  severe	  fibrosis	  (Lyra	  et	  al.,	  2002).	  	  
	  
5.4	  Infections	  
5.4.1	  Cytomegalovirus	  (CMV)	  
Cytomegalovirus	   (CMV)	   has	   been	   associated	  with	   reduced	   graft	   survival	   and	   a	  more	  
aggressive	   fibrosis	  progression	   rate	   in	  patients	  with	  HCV	  post	   LT	   (Bosch	  et	   al.,	   2012,	  
Neumann	   et	   al.,	   2004b,	   Razonable	   et	   al.,	   2002,	   Rosen	   et	   al.,	   1997).	   Different	  
mechanisms	  of	  how	  CMV	  propagates	  HCV	  disease	  have	  been	  postulated	  and	   include	  
increase	   tumour	   necrosis	   factor	   levels,	   increased	   ICAM-­‐1	   expression	   and	   increased	  
immunological	   stimulation	   through	   MHC	   Class	   II	   molecules	   (Ballardini	   et	   al.,	   1994,	  
Granot	  et	  al.,	  2001,	  Smith	  et	  al.,	  1992,	  Tilg	  et	  al.,	  1991).	  CMV	  viraemia	  may	  also	  be	  a	  
surrogate	  marker	   of	   over-­‐immunosuppression.	   CMV	   prophylaxis	   is	   recommended	   in	  
high-­‐risk	  cases	  (recipient	  IgG	  negative,	  donor	  IgG	  positive).	  	  
5.4.2	  HIV	  co-­‐infection	  
HIV	  co-­‐infection	  is	  a	  recognised	  risk-­‐factor	  for	  a	  rapid	  HCV	  recurrence	  and	  FCH	  (Safadi	  
et	   al.,	   2004,	   Joshi	   et	   al.,	   2011,	  Antonini	   et	   al.,	   2011).	  HCV	   recurrence	   in	  HIV	  positive	  
patients	   is	   more	   aggressive	   post	   transplant	   translating	   into	   inferior	   outcomes	  
compared	   to	   HCV	   mono-­‐infected	   patients	   (Terrault	   et	   al.,	   2012,	   Miro	   et	   al.,	   2012,	  
Duclos-­‐Vallee	   et	   al.,	   2008)	   Mechanisms	   for	   this	   accelerated	   fibrosis	   rate	   amongst	  
HIV/HCV	   co-­‐infected	   patients	   remain	   undelineated	   but	   extrapolation	   from	   data	   in	  




weakened	  adaptive	  immune	  response,	  reduced	  ratio	  of	  CD4+	  to	  CD8+	  cells,	  reduced	  IL-­‐
10	  production,	   increased	  microbial	   translocation,	  and	   insulin	  resistance	   (Garba	  et	  al.,	  
2002,	   Safadi	   et	   al.,	   2004,	   Balagopal	   et	   al.,	   2008).	   Along	   these	   lines,	   recent	   evidence	  
suggests	   that	   Impaired	   CD4⁺	   T	   cell	   stimulation	   of	   NK	   cell	   anti-­‐fibrotic	   activity	   may	  
contribute	  to	  accelerated	  liver	  fibrosis	  progression	  in	  HIV/HCV	  patients	  (Glassner	  et	  al.,	  
2013).	  In	  addition,	  HIV	  gp120	  protein	  has	  been	  shown	  to	  modulate	  different	  aspects	  of	  
HSC	  biology,	   including	  directional	  cell	  movement	  and	  expression	  of	  pro-­‐inflammatory	  
cytokines	  (Bruno	  et	  al.,	  2010).	  
	  
5.4.3	  HBV	  co-­‐infection	  
3-­‐11%	  of	  patients	  undergoing	  LT	  are	  co-­‐infected	  with	  HBV	  and	  HCV	  (Feray	  et	  al.,	  1998,	  
Huang	  et	  al.,	  1996).	   In	  post-­‐LT	  setting,	  the	  effect	  of	  HBV/HCV	  co-­‐infection	  appears	  to	  
be	  conflicting.	  Improved	  survival	  rates	  were	  associated	  with	  viral	  co-­‐infection	  but	  only	  
9	  patients	  with	  HBV/HCV	  were	  included	  in	  the	  study	  (Rifai	  et	  al.,	  2007).	  A	  larger	  study	  
of	  652	  patients	  however,	  demonstrated	  a	  milder	  course	  of	  HCV	  recurrence	  in	  patients	  
with	  HBV	   co-­‐infection	   (Feray	   et	   al.,	   1999).	  A	   recent	   study	  using	   the	  UNOS	  database,	  
demonstrated	  superior	  graft	  survival	   in	   the	  HBV/HCV	  co-­‐infected	  group	  compared	  to	  
the	   HCV	   mono-­‐infected	   group	   (84%	   at	   1	   year	   and	   54%	   at	   10	   years	   vs	   83%	   1-­‐year	  
survival	   and	   46%	   10-­‐year	   survival	   (Waki	   et	   al.,	   2011).	   Improved	   survival	   amongst	  
HBV/HCV	  co-­‐infected	  patients	  is	  likely	  to	  be	  due	  to	  a	  combination	  of	  HBV	  prophylaxis	  
and	  antiviral	  therapy,	  and	  the	  observation	  of	  lower	  immediate	  HCV	  viral	  loads	  (Waki	  et	  





Hepatitis	  B	  core	  antibody	  (HBcAb)	  positive	  grafts	  have	  been	  used	  successfully	   in	  HCV	  
positive	  patients	  (Jain	  et	  al.,	  2005,	  Rayhill	  et	  al.,	  2010).	  Data	  is	  conflicting	  with	  regards	  
to	   graft	   survival	   outcomes.	   Recent	   data	   has	   suggested	   inferior	   graft	   survival	   rates	  
amongst	   HCV-­‐RNA	   positive	   recipients	   who	   received	   HBcAb	   positive	   donor	   grafts	  
(Tandoi	  et	  al.,	  2012).	  Prophylaxis	  with	  anti-­‐HBV	  therapy	  is	  recommended	  in	  this	  group.	  
	  
	  5.5	  Recipient	  factors	  
5.5.1	  Human	  leukocyte	  antigen	  (HLA)	  
Given	   the	   integral	   role	   of	  HLA	   class	   I	   and	   class	   II	   antigens	   in	   the	   recognition	  of	  HCV	  
peptides,	   studies	   have	   evaluated	   the	   role	   of	   donor	   recipient	   HLA	   mismatch	   on	  
recurrence	  rates	  of	  HCV	  post-­‐transplant.	  One	  study	  failed	  to	   identify	  any	  relationship	  
between	   histological	   outcome	   and	   the	   extent	   of	   matching	   of	   either	   HLA-­‐DR	   or	   DQ	  
(Gane	  et	  al.,	  1996a).	  A	  more	  recent	  German	  study	  demonstrated	  a	  reduced	  number	  of	  
cases	  of	  rejection	  associated	  with	  a	  decreasing	  numbers	  of	  HLA	  mismatches	  (p	  <0.05)	  
but	   no	   effect	   of	   HLA-­‐A,	   -­‐B	   or	   -­‐DR	   matching	   on	   the	   number	   of	   recurrent	   or	   steroid	  
resistant	  rejection	  episodes	  (Langrehr	  et	  al.,	  2006).	  In	  the	  same	  study,	  HLA-­‐A	  and	  –DR	  
matching	   had	   no	   effect	   on	   fibrosis	   progression	   post	   transplant	   but	   HLA-­‐B	  matching	  
correlated	  significantly	  with	  an	  accelerated	   rate	  of	   fibrosis	  at	  1-­‐year	   (Langrehr	  et	  al.,	  
2006).	   Subsequent	   studies	   have	   however	   demonstrated	   that	   HLA-­‐DRB1	  
donor/recipient	  mismatch,	  in	  particular	  fully	  mismatched	  donor-­‐recipients,	  was	  related	  
to	  histological	   recurrence	  (Belli	  et	  al.,	  2000).	  HCV	  fibrosis	  progression	  was	  associated	  
with	  the	  frequency	  HLA-­‐DRB*11	  and	  HLA-­‐B14	  alleles	  (Belli	  et	  al.,	  2000).	  Patients	  with	  




alleles	   but	   a	   reduced	   frequency	   of	  HLA-­‐B12	   and	  DRB1*11	   in	   comparison	   to	   patients	  
with	  mild	  fibrosis	  (F1-­‐3).	  Full	  DRB1	  mismatch	  remained	  a	  significant	  predictor	  of	  severe	  
recurrence	  on	  multivariate	  analysis	  (HR	  2.9,	  p=0.002)(Belli	  et	  al.,	  2000).	  
	  
5.5.2	  Genetic	  polymorphisms	  
The	  recent	  discovery	  of	  single	  nucleotide	  polymorphisms	  (rs12979860	  and	  rs8099917)	  
near	   the	   IL-­‐28B	   gene,	   which	   encodes	   IFN-­‐λ3,	   are	   associated	   with	   the	   prediction	   of	  
treatment	  success	  with	  PEG-­‐IFN	  and	  ribavirin	  irrespective	  of	  race	  (Ge	  et	  al.,	  2009).	  	  The	  
CC	  genotype	  is	  associated	  with	  the	  greatest	  chance	  of	  SVR,	  followed	  by	  the	  CT	  and	  TT	  
genotypes	  (Ge	  et	  al.,	  2009).	  IL-­‐28B	  polymorphisms	  are	  now	  regarded	  as	  the	  strongest	  
pre-­‐treatment	   predictor	   of	   SVR	   in	   genotype	   1	   infected	   patients	   (Ge	   et	   al.,	   2009,	  
Stattermayer	  et	  al.,	  2011).	  
	  
There	  are	  3	  members	  of	   the	   type	   III	   IFN-­‐	  λ	   family:	   IL-­‐29,	   IL-­‐28A	  and	   IL-­‐28B.	  They	  are	  
functionally	  IFNs,	  structurally	  are	  very	  similar	  to	  IL-­‐10	  and	  located	  on	  chromosome	  19	  
(Gad	  et	  al.,	  2009,	  Kotenko	  et	  al.,	  2003,	  Sheppard	  et	  al.,	  2003).	  The	  most	  studied	  single-­‐
nucleotide	   polymorphisms	   (SNPs)	   in	   response	   to	   IFN-­‐	   therapy,	   rs12979860	   and	  
rs8099917	   are	   upstream	   of	   IL28B	   and	   IL28A.	   These	   IFN-­‐λs	   are	   triggered	   by	   viral	  
infections	   and	   then	   induce	   antiviral	   as	  well	   as	   antitumor	   activity	   through	   the	   innate	  
and	  adaptive	  immune	  system	  pathway	  	  (Yoshimoto	  et	  al.,	  2011,	  Morrow	  et	  al.,	  2010).	  
Both	   IFN-­‐α	   and	   IFN-­‐λ	   induce	   signalling	   through	   the	   Jak-­‐STAT	   (Janus	   kinase	   signal	  
transducer	  and	  activator	  of	  transcription)	  pathway	  which	  then	  activate	  IFN-­‐stimulated	  
genes	   (ISGs)	   (Kotenko	   et	   al.,	   2003,	   Zhou	   et	   al.,	   2007).	   IFN-­‐α	   binds	   to	   type	   I	   IFN	  




et	   al.,	   2006).	   	   In	   contrast,	   IFN-­‐	   λ	   binds	   to	   IL-­‐10	   and	   IL28	   receptors	   expressed	   on	  
hepatocytes,	   epithelial	   cells	   and	   plasmacytoid	   dendritic	   cells	   (Kotenko	   et	   al.,	   2003,	  
Sommereyns	  et	  al.,	  2008).	   	  The	  result	  this	  time	  is	   ISG	  expression	  albeit	  a	  weaker	  one	  
but	   one	   which	   increases	   steadily	   over	   time	   (Zhou	   et	   al.,	   2007).	   The	   NF-­‐κB	   pathway	  
appears	  to	  be	  integral	  in	  the	  IFN-­‐	  λ	  mediated	  activation	  of	  STAT	  (Iversen	  et	  al.,	  2010).	  	  
	  
Genome	   wide	   associated	   studies	   (GWAS)	   permit	   screening	   for	   representative	   SNPs	  
which	  may	  be	  associated	  with	  specific	  disease	  phenotypes	  or	  response	  to	  treatments.	  
However,	   GWAS	   require	   large	   study	   sample	   sizes	   in	   order	   to	   detect	   these	   changes	  
which	  are	  often	  cumulative.	  The	  first	  publication	  was	  performed	  in	  1671	  patients	  who	  
were	  part	  of	  the	  IDEAL	  study	  (McHutchison	  et	  al.,	  2009)	  (Ge	  et	  al.,	  2009).	  The	  cohort	  
consisted	  patients	  of	  European	  ancestry,	  African-­‐Americans	  and	  Hispanics.	  The	  authors	  
identified	  the	  rs	  12979860	  SNP	  which	  was	  located	  in	  a	  noncoding	  region	  3kb	  upstream	  
of	   IL-­‐18B	  to	  be	  strong	  predictor	  of	  SVR	  to	  PEG-­‐IFN	  –α	  and	  ribavirin	   (Ge	  et	  al.,	  2009).	  
Patients	   homozygous	   for	   the	   major	   allele,	   the	   favourable	   genotype	   rs12979860	   CC	  
were	  more	  twice	  as	  likely	  to	  achieve	  an	  SVR	  compared	  to	  patients	  with	  less	  favourable	  
genotypes	  (CT	  >	  TT)	  (p=1.37	  x	  10-­‐28)	  (Ge	  et	  al.,	  2009).	  The	  positive	  predictive	  value	  of	  
the	   CC	   genotype	   was	   evident	   across	   all	   patient	   groups	   (Europeans,	   p=1.06	   x10-­‐25;	  
African-­‐Americans	   p=2.06	   x10-­‐3;	   Hispanics	   p=4.39	   x10-­‐3).	   	   The	   response	   to	   anti-­‐viral	  
therapy	   across	   the	   different	   patient	   cohorts	   helped	   explain	   the	   inferior	   SVR	   rates	   in	  
African-­‐Americans	  observed	  in	  this	  study.	  Subsequent	  studies,	  performed	  in	  Japan	  and	  
Australia	   identified	   the	   rs8099917	   genotype	   (TT	   >	   GT	   >	   GG)	   (Tanaka	   et	   al.,	   2009,	  
Suppiah	  et	  al.,	  2009).	  The	  rs8099917	  SNP	  is	  located	  in	  the	  downstream	  flanking	  region,	  




in	  peripheral	  blood	  mononuclear	  cells	  also	  demonstrated	  significantly	   lower	   levels	  of	  
IL28B	  mRNA	  expression	  in	  patients	  with	  the	  minor	  alleles	  (GT	  and	  GG)	  (Tanaka	  et	  al.,	  
2009).	  
	  
As	  well	  as	  being	  the	  strongest	  pretretament	  predictor	  of	  SVR,	  the	  IL28B	  SNP	  has	  also	  
been	  evaluated	   in	  patients	   that	  are	  able	   to	   resolve	  acute	  HCV	  and	   thereby	  clear	   the	  
infection.	   Two	   studies	  which	   evaluated	   the	   rs8099917	   SNP	   and	   the	   rs12978860	   SNP	  
respectively	   and	   identified	   the	   favourable	   genotypes	   (rs8099917	   TT	   and	   rs12978869	  
CC	  were	  strongly	  associated	  with	  spontaneous	  clearance	  (Thomas	  et	  al.,	  2009,	  Rauch	  
et	   al.,	   2010).	   The	   favourable	   rs12979860	   CC	   genotype	   is	   also	   associated	   with	  
spontaneous	   clearance	   in	   children	   that	   have	   been	   infected	   via	   vertical	   transmission	  
(Ruiz-­‐Extremera	  et	  al.,	  2011).	  	  
	  
	  
The	  SNPs	   in	   IL-­‐28B	   (IFN-­‐	  λ3)	  have	  been	  studied	   in	   the	  post-­‐LT	  both	   in	   the	  donor	  and	  
recipients	   in	   order	   to	   predict	   HCV	   graft	   recurrence(Lange	   et	   al.,	   2011,	   Eurich	   et	   al.,	  
2011,	  Charlton	  et	  al.,	  2011,	  Eurich	  et	  al.,	  2012,	  Duarte-­‐Rojo	  et	  al.,	  2012,	  Veldt	  et	  al.,	  
2012).	  IFN-­‐λ	  plays	  an	  integral	  role	  in	  the	  modulation	  of	  the	  adaptive	  immune	  system	  as	  
well	   increasing	   production	   of	   IP-­‐10	   (interferon-­‐gamma	   inducible	   protein	   –	   10).	  
Unsurprisingly	   patients	   that	   required	   liver-­‐transplantation	   were	  more	   likely	   to	   carry	  
the	  less	  favourable	  rs12979860	  CT	  or	  TT	  genotype	  compared	  to	  the	  non-­‐transplanted	  
patients	  (Lange	  et	  al.,	  2011).	  There	  is	  however	  conflicting	  evidence	  with	  regards	  to	  the	  
predictive	  value	  of	  the	  IL-­‐28B	  SNPs	  on	  HCV	  fibrosis	  rates	  post-­‐	  transplant	  which	  may	  be	  




delayed	  time	  to	  recurrence	  of	  HCV	  with	  the	  rs12979860	  CC	  IL-­‐28B	  genotype	  compared	  
to	   those	   with	   CT	   and	   TT	   genotypes	   at	   5	   years	   (78%	   vs.	   87%	   vs.	   100%,	   p=0.02)	   and	  
another	  study	  demonstrated	  a	  delayed	  time	  to	  the	  development	  of	  advanced	  fibrosis	  
(CC	   =	   64.9	   months,	   CT	   45.8	   months,	   TT	   30.0	   months,	   p=0.02)	   (Eurich	   et	   al.,	   2012).	  
Multivariate	   Cox	   regression	   analysis	   demonstrated	   that	   the	   recipient	   IL-­‐28B	  
rs12979860	   CC	   allele	   was	   an	   independent	   predictor	   of	   delayed	   recurrence	   of	   HCV	  
(defined	   as	   detectable	   HCV	   RNA	   in	   serum	   and	   allograft	   histology	   demonstrating	   a	  
lymphocytic	  infiltrate	  in	  the	  absence	  of	  ACR)	  at	  2	  years	  (HR	  0.62	  p=0.008)	  and	  5	  years	  
(HR	  0.63,	  p=0.003)(Charlton	  et	   al.,	   2011).	   	   The	   relationship	  between	   recipient	   IL-­‐28B	  
genotype	  and	   time	   to	   recurrence	  of	  HCV	  at	   2	   and	  5	   years	   remained	   independent	  of	  
donor	   IL-­‐28B	   genotype	   (p=0.03	   and	   p=0.015	   respectively)	   (Charlton	   et	   al.,	   2011).	  
Another	   study,	   however,	   demonstrated	   no	   correlation	   between	   the	   stage	   of	   fibrosis	  
and	   rs8099917	   IL-­‐28B	   genotype	   although	   a	   higher	   median	   histological	   grade	   of	  
inflammation	   was	   demonstrated	   (3.0	   for	   GG,	   2.5	   for	   GT	   and	   2.0	   for	   TT,	   p<0.001)	  
(Eurich	   et	   al.,	   2011).	   Donor	   rs12979860	   IL-­‐28B	   genotype	   does	   not	   appear	   to	   be	  
predictive	  of	  time	  to	  recurrence	  of	  HCV	  and	  possession	  of	  the	  IL-­‐28B	  CC	  genoytype	  in	  
the	   liver	   donor	   did	   not	   protect	   from	   severe	   HCV	   recurrence	   (Charlton	   et	   al.,	   2011,	  
Cisneros	  et	  al.,	  2012).	  
	  
5.5.3	  Diabetes	  mellitus	  and	  insulin	  resistance	  
Diabetes	   alone	   or	   the	   combination	   of	   diabetes	   and	   donor	   age	   >	   55	   years	   are	  
independent	  predictors	  of	  progression	  to	  bridging	  fibrosis/cirrhosis	  post-­‐LT	  (Foxton	  et	  




advanced	  fibrosis	  between	  patients	  with	  pre-­‐transplant	  diabetes	  and	  those	  with	  new	  
onset	  diabetes	  after	   transplantation	   (NODAT)	   (Veldt	  et	  al.,	  2009).	  HCV	  patients	  post-­‐
transplant	  with	  IR	  (HOMA-­‐IR>2.5)	  were	  found	  to	  have	  a	  higher	  fibrosis	  rates	  at	  1,	  3	  and	  
5	  years	  compared	  to	  patients	  with	  normal	  insulin	  sensitivity	  and	  IR	  was	  identified	  as	  an	  




OKT3,	  an	  anti-­‐CD3	  monoclonal	  antibody,	  and	  ATG	  (rabbit	  anti-­‐thymocyte	  globulin)	  are	  
strong	   risk	   factors	   for	   HCV	   recurrence,	   cirrhosis	   and	   graft	   failure(Neumann	   et	   al.,	  
2004b).	   Use	   of	   corticosteroids	   for	   acute	   cellular	   rejection	   (ACR)	   results	   in	   increased	  
HCV	  RNA	  levels(Gane	  et	  al.,	  1996a,	  Garcia-­‐Retortillo	  et	  al.,	  2002,	  Charlton	  and	  Seaberg,	  
1999).	  Two	  randomised	  trials	  of	  steroid-­‐free	  induction	  using	  daclizumab	  (IL-­‐2	  blocker)	  
failed	   to	   demonstrate	   any	   benefit	   in	   the	   reduction	   of	  mean	   fibrosis	   stage	   at	   1-­‐year	  
post-­‐transplant	  (Kato	  et	  al.,	  2007,	  Klintmalm	  et	  al.,	  2007).	  
	  
The	   rate	   of	   withdrawal	   of	   corticosteroids	   appears	   to	   be	   a	   contentious	   issue.	   Initial	  
reports	   suggested	   that	   early	   withdrawal	   was	   associated	   with	   improved	   outcomes	  
(Everson,	  2002).	  However	  other	  earlier	  studies	  demonstrated	  a	  more	  rapid	  recurrence	  
of	  HCV	  in	  patients	  who	  had	  a	  rapid	  withdrawal	  of	  corticosteroids	  (Belli	  LS	  et	  al.	  2003;	  
Brillanti	  S	  et	  al.	  2002).	  A	  more	  recent	  prospective	  study,	  confirmed	  the	  beneficial	  effect	  
of	  a	  slow	  tapering	  of	  corticosteroids	  (>	  3	  months)(Vivarelli	  et	  al.,	  2007).	  A	  balance	  with	  




immunosuppression	  and	  episodes	  of	  ACR,	  both	  of	  which	  promote	  HCV-­‐related	  disease	  
progression.	  
	  
5.6.2	  Calcineurin	  inhibitors	  
Ciclosporin	   in-­‐vitro	   has	   been	   shown	   to	   demonstrate	   a	   suppressive	   effect	   on	   HCV	  
replicon	  RNA	  levels	  and	  HCV	  protein	  expression	  as	  well	  as	  inhibiting	  the	  multiplication	  
of	   the	   HCV	   genome	   in	   a	   human	   hepatocyte	   HCV	   infected	   cell-­‐lines	   (Watashi	   et	   al.,	  
2003).	   In	   vivo	   data	   has	   also	   demonstrated	   a	   modest	   decline	   in	   HCV	   RNA	   titres	   in	  
switching	  patients	  to	  ciclopsorin	  from	  tacrolimus	  (Firpi	  et	  al.,	  2010).	  These	  data,	  along	  
with	   ciclosporin’s	   inhibition	  of	  NS5B	  binding	   to	   cyclophilin	  B,	   an	   integral	  part	   in	  HCV	  
viral	   assembly,	   might	   suggest	   ciclopsorin	   be	   the	   immunosuppressant	   of	   choice.	  
(Watashi	  et	  al.,	  2003,	  Watashi	  et	  al.,	  2005,	  Hirano	  et	  al.,	  2008,	  Nakagawa	  et	  al.,	  2005).	  
However	   this	   is	  not	   confirmed	  by	  clinical	   studies	   (Berenguer	  et	  al.,	  2007,	   Levy	  et	  al.,	  
2006,	  Berenguer	  et	  al.,	  2010).	  A	  meta-­‐analysis	  also	  highlighted	  the	  use	  of	  tacrolimus	  to	  
be	   associated	   with	   improved	   patient	   survival	   (Berenguer	   et	   al.,	   2007).	   At	   present,	  
available	   data	   would	   not	   suggest	   any	   benefit	   of	   the	   use	   ciclopsorin-­‐based	  




In	   vitro	   studies	   and	   animal	   studies	   have	   shown	   that	   sirolimus	   inhibits	   collagen	  
production	  by	  HSCs	  (Akselband	  et	  al.,	  1991,	  Neef	  et	  al.,	  2006).	  Although	  sirolimus	  has	  




side	  effects	  are	  described	  leading	  to	  early	  discontinuation	  (McKenna	  et	  al.,	  2011).	  No	  
overall	   patient	   survival	   however,	   was	   conferred	   with	   the	   use	   of	   sirolimus.	   Another	  
important	   finding	   from	   this	   study	   is	   that	  nearly	  half	  of	   the	  patients	   that	   received	  de	  
novo	  sirolimus	  had	  to	  stop	  due	  to	  impending	  surgery	  or	  side	  effects	  (i.e.	  mouth	  ulcers,	  
cytopenias).	   At	   present,	   further	   prospective	   studies	   are	   required	   to	   validate	   the	  
benefits	   of	   sirolimus	   in	   attenuating	   fibrosis	   progression	   in	   HCV	   patients	   post-­‐
transplant.	  
	  
5.6.4	  Other	  agents	  
Initial	  data	   identified	  MMF	  (mycophenalate	  mofetil)	  use	  as	  a	  potential	   risk	   factor	   for	  
recurrent	  HCV	  disease,	  but	  no	  clear	  association	  has	  been	  demonstrated	  in	  more	  recent	  
studies	   (Berenguer	  et	  al.,	  2003,	  Wiesner	  et	  al.,	  2005).	   Interleukin-­‐2	  receptor	  blockers	  
do	  not	  appear	  to	  impact	  negatively	  on	  HCV	  recurrence	  (Klintmalm	  et	  al.,	  2007).	  Recent	  
data	   suggests	   that	   azathioprine	   in	   combination	   with	   tacrolimus	   delays	   fibrosis	  
progression	   although	   the	   mechanism	   of	   action	   appears	   unclear	   (Manousou	   et	   al.,	  










6.	  Assessment	  of	  liver	  fibrosis	  and	  progression	  post-­‐transplant	  
	  
6.1	  Liver	  biopsy	  
Liver	   biopsy	   remains	   the	   ‘gold	   standard’	   to	   assess	   fibrosis	   in	   patients	  with	   recurrent	  
HCV	  post	  LT	  (Bain	  et	  al.,	  2004).	  The	  Ishak	  scoring	  system	  is	  the	  most	  widely	  used	  but	  
other	   commonly	  used	   criteria	   include	   the	  Metavir	   and	   Sheuer	   (Ishak	   et	   al.,	   1995).	  A	  
one-­‐year	   protocol	   liver	   biopsy	   can	   stratify	   fibrosis	   progression.	   In	   one	   study,	   13%	  of	  
patients	   with	   moderate	   fibrosis	   (F2-­‐3,	   Ishak)	   at	   12	   months	   progressed	   to	   cirrhosis	  
within	  3	  years	  compared	  to	  no	  patients	  with	  minimal	   fibrosis	   (p<0.0001)	   (Firpi	  et	  al.,	  
2004).	   In	   the	   same	   study,	   14%	   of	   patients	   with	  minimal	   fibrosis	   on	   their	   12	  month	  
biopsy	  developed	  advanced	   fibrosis	   (F>4,	   Ishak)	   compared	   to	  34	   	  %	  of	   patients	  with	  
moderate	  fibrosis	  on	  the	  12	  month	  biopsy	  (p=0.02)(Firpi	  et	  al.,	  2004).	  Other	  benefits	  of	  
liver	  biopsy	  include	  the	  ability	  to	  identify	  and	  exclude	  other	  causes	  of	  liver	  dysfunction	  
in	   the	  post-­‐transplant	  period.	   Limitations	  of	   the	  use	  of	   liver	  biopsy	   include	   sampling	  
variability	  and	  both	  inter-­‐	  and	  intra-­‐observer	  variability	  (Bedossa	  et	  al.,	  2003,	  Westin	  et	  
al.,	  1999).	  Measurement	  of	  the	  hepatic	  venous	  pressure	  gradient	  (HVPG)	  has	  also	  been	  
used	  in	  the	  post-­‐transplant	  setting	  (Samonakis	  et	  al.,	  2007).	  One	  study	  deemed	  it	  to	  be	  
more	   accurate	   than	   liver	   biopsy	   in	   identifying	   patients	   at	   risk	   of	   clinical	  
decompensation	   (Blasco	   et	   al.,	   2006).	   A	   HVPG	   >	   6	   mmHG	   1	   year	   post	   transplant	  
appears	   to	   identify	   patients	   with	   HCV	   recurrence	   that	   are	   likely	   to	   decompensate	  
(Samonakis	  et	  al.,	  2007,	  Blasco	  et	  al.,	  2006).	  
	  
Histological	   scores	   listed	  above	  are	   categorical	   systems	   that	  provide	  a	  description	  of	  




(CPA)	   is	   a	   quantitative	   assessment	   of	   collagen	   deposition	   using	   computer-­‐assisted	  
digital	  image	  analysis.	  It	  utilizes	  picro	  Sirius	  red	  stained	  histological	  sections	  to	  quantify	  
liver	  collagen	  and	   therefore	   fibrosis	   (Standish	  et	  al.,	  2006,	  Bedossa	  et	  al.,	  2003).	  The	  
quantity	  of	   bound	   stain	   correlates	  with	   the	   chemically	   determined	   collagen	   content.	  
CPA	   does	   not	   interfere	   with	   other	   evaluations	   and	   excludes	   collagenous	   structures	  
irrelevant	   to	   the	   disease	   process	   (Standish	   et	   al.,	   2006).	   CPA	   correlates	   with	   Ishak	  
stage,	   HVPG	   and	   the	   CPA	   at	   12	   months	   post-­‐LT	   is	   predictive	   of	   clinical	   outcome	  
(Calvaruso	  et	  al.,	  2009,	  Manousou	  et	  al.,	  2011).	  The	  rate	  of	  CPA	  increase	  (CPA	  fibrosis	  
progression	  rate)	  also	  appears	  to	  be	  predictive	  of	  clinical	  outcome	  post	  –LT	  (Manousou	  
et	  al.,	  2013).	  
	  
6.2	  Laboratory	  based	  tests	  
6.2.1	  Indirect	  markers	  
The	  inherent	  risks	  of	  liver	  biopsy	  have	  led	  to	  the	  development	  of	  non-­‐invasive	  markers	  
of	   fibrosis.	   The	   ‘aspartate	   aminotransferase	   (AST)-­‐to-­‐platelet’	   ratio	   index	   (APRI)	   has	  
been	  studied	  extensively	  pre-­‐transplant(Shaheen	  and	  Myers,	  2007,	  Lin	  et	  al.,	  2011).	  In	  
a	   study	   of	   51	   patients,	   using	   AUROC	   (area	   under	   receiver	   operating	   characteristic)	  
curves,	  the	  APRI	  was	  able	  to	  predict	  fibrosis	  (0.8,	  p<0.0001)	  with	  an	  optimal	  cut-­‐off	  of	  
>1.4	  to	  predict	  fibrosis	  stage	  >	  F2	  (sensitivity	  76%,	  specificity	  77%,	  positive	  predictive	  
value	   46%	   and	   negative	   predictive	   value	   93%)(Toniutto	   et	   al.,	   2007).	   Another	   study	  
identified	   4	   variables	   on	   multivariate	   analysis	   (prothrombin	   time,	   albumin/total	  
protein	   ratio,	   AST	   and	   time	   from	   liver	   transplantation	   that	   were	   associated	   with	  




construct	  a	  formula	  (Benlloch	  score)	  that	  was	  predictive	  of	  fibrosis	  progression	  in	  both	  
a	  training	  and	  validation	  set	  (AUROC	  0.8	  and	  0.85	  respectively)	  (Benlloch	  et	  al.,	  2005).	  	  
	  
6.2.2	  Direct	  markers	  
One	   study	   evaluated	   the	   combination	   pro-­‐peptide	   of	   type	   III	   pro-­‐collagen	   (PIIINP),	  
hyaluronic	   acid	   (HA)	   and	   tissue	   inhibitors	   of	   matrix	   metalloproteinases	   (TIMP-­‐1)	   to	  
develop	   the	  3-­‐M-­‐ALG	  algorithm	  {discriminant	   score	  =	   -­‐7.412	  +	   [ln	   (HA)	  x	  0.681]	  +	   [ln	  
(PIIINP)	  x	  0.775]	  +	  [in(TIMP-­‐1]	  x	  0.494}	  (Carrion	  et	  al.,	  2010a).	  Recordings	  were	  taken	  at	  
3,	  6	  and	  12	  months	  post-­‐transplant	  and	  compared	  to	  HVPG	  and	  histological	  scoring	  on	  
liver	  biopsy	  at	  12	  months.	  AUROC	  analysis	  for	  identifying	  F	  ≥2	  for	  3-­‐M-­‐ALG	  at	  3,	  6	  and	  
12	   months	   were	   0.67,	   0.77	   and	   0.78	   in	   comparison	   to	   0.75,	   0.87	   and	   0.90	   for	  
HVPG(Carrion	   et	   al.,	   2010a).	   The	   3-­‐M-­‐ALG	   score	   demonstrated	   a	   greater	   diagnostic	  
ability	   than	  the	  APRI,	  AST/ALT	  ratio	  and	  the	  Benlloch	  score.	  Patients	  with	  a	  3-­‐M-­‐ALG	  
score	   ≥	   2	   also	   had	   an	   increased	   risk	   of	   developing	   an	   episode	   of	   clinical	  
decompensation	  (Carrion	  et	  al.,	  2010a).	  The	  London	  Transplant	  Centre	   (LTC),	  derived	  
from	   the	   King’s	   Score	   incorporates	   time	   from	   liver	   transplantation,	   AST,	   INR	   and	  
platelet	  count	  (Cross	  et	  al.,	  2010,	  Cross	  et	  al.,	  2009).	  The	  LTC	  AUROC	  (0.8)	  for	  advanced	  
fibrosis	   (Ishak	   F>4)	   appeared	   better	   than	   the	   King’s	   score	   (0.73)	   and	   the	   APRI	  
(0.73)(Cross	   et	   al.,	   2010).	   The	   FibroTransplant	   score,	   another	   derived	  model	   for	   the	  
prediction	   of	   advanced	   fibrosis	   post-­‐transplant,	   performed	   as	   well	   as	   the	   Benlloch	  





6.3	  Transient	  elastography	  
The	  most	  studied	  non-­‐invasive	  measurement	  of	  fibrosis	   is	  transient	  elastography	  (TE)	  
and	  allows	  a	  longitudinal	  assessment.	  It	  is	  important	  to	  emphasize	  that	  cut-­‐off	  values	  
are	  different	  to	  non-­‐transplant	  patients.	   In	  a	  study	  of	  95	  patients	  with	  recurrent	  HCV	  
post	  LT,	  a	  LS	  value	  of	  5.6kPa	  was	  representative	  of	  F	  0-­‐1	  (Ishak),	  7.6kPa	  representative	  
of	   F2-­‐3	   and	   16.7kPa	   representative	   of	   F4-­‐6(Rigamonti	   et	   al.,	   2008).	   AUROC	   analysis	  
demonstrated	   a	   cut-­‐off	   of	   7.9kPa	   to	   be	   representative	   of	   F≥3	   (0.85,	   95%	   CI	   0.76-­‐
0.92)(Rigamonti	   et	   al.,	   2008).	   In	   another	   study	   TE	   was	   evaluated	   at	   3,	   6,	   9	   and	   12	  
months	   post-­‐transplant	   in	   comparison	   to	   a	   12month	   post-­‐transplant	   liver	   biopsy	  
(Carrion	  et	  al.,	  2010b).	  Their	  results	  demonstrated	  statistically	  different	  TE	  readings	  at	  
3,	  6,	  9	  and	  12	  months	  between	  patients	  with	  slow	  fibrosis	  progression	   (6.9,	  6.9,	  7.5,	  
6.6	  kPa)	  compared	  to	  patients	  with	  rapid	  fibrosis	  progression	  (7.5,	  9.9,	  9.5,	  12.1	  kPa,	  p	  
<0.01).	  LS	  measurements	  of	  between	  8.7-­‐9.9	  kPa	  appear	  to	  be	  representative	  F	  >	  2	  in	  
patients	  post	   transplantation	  with	  recurrent	  HCV(Carrion	  et	  al.,	  2010b,	  Harada	  et	  al.,	  
2008).	  A	  LS	  value	  of	  ≥	  8.7kPa	  at	  12	  months	  was	  associated	  with	  an	   increased	   risk	  of	  
hepatic	  decompensation	  5	  years	  post	  LT	  (47%	  vs.	  8%,	  p<0.001)	  and	  an	  increased	  risk	  of	  
graft	   loss	   (Crespo	  et	  al.,	  2014).	   	  Comparative	  studies	  have	  been	  performed	  to	  assess	  
the	  utility	  of	  TE	  and	  laboratory	  based	  markers(Harada	  et	  al.,	  2008,	  Beckebaum	  et	  al.,	  
2010).	   	  One	  study	  of	  56	  patients	  found	  that	  serum	  HA	  (AUROC	  0.52),	  type-­‐4	  collagen	  
(AUROC	   0.62),	   ALT	   (AUROC	   0.64)	   and	   APRI	   (AUROC	   0.70)	   were	   all	   inferior	   to	   TE	   in	  




6.4	  Magnetic	  resonance	  elastography	  (MRE)	  
MRE	   utilises	   acoustic	   shear	   waves	   that	   pass	   through	   the	   liver	   and	   generates	  
propagation	   patterns	   which	   provide	   quantitative	   stiffness	   values	   of	   the	   entire	  
liver(Manduca	   et	   al.,	   2001).	   MRE	   has	   been	   evaluated	   in	   the	   pre-­‐LT	   setting	  
demonstrating	   a	   good	   ability	   to	   distinguish	   between	   normal	   and	   fibrotic	  
livers(Rouviere	  et	  al.,	  2006,	  Talwalkar	  et	  al.,	  2008).	  MRE	  appeared	  to	  be	  a	  sensitive	  tool	  
to	  detect	  fibrosis	  post-­‐LT	  in	  one	  small	  study(Lee	  et	  al.,	  2011).	  In	  the	  same	  study,	  falsely	  
elevated	  values	  were	  noted	  in	  cases	  with	  alterations	   in	  regional	  blood	  flow,	  oedema,	  
inflammation,	  portal	   vein	   thrombosis	   and	   rejection	   (Lee	  et	   al.,	   2011).	  At	  present,	  no	  
standardized	  cut-­‐off	  values	  for	  MRE	  exist	  for	  the	  different	  stages	  of	  fibrosis.	  
	  
6.5	  CXCL10	  
Given	  the	  integral	  role	  of	  the	  innate	  and	  adaptive	  immune	  system	  in	  the	  pathogenesis	  
of	   HCV	   infection,	   both	   chemokines	   and	   cytokines	   have	   been	   suggested	   as	   possible	  
markers	  of	   treatment	  outcome.	   Interferon-­‐gamma	   inducible	  protein	  10kDa	  (IP-­‐10)	  or	  
CXCL10	   is	   a	  potent	   chemokine	  which	  plays	   an	   important	   role	   in	   the	  pathogenesis	   of	  
HCV	  infection	  (Qin	  et	  al.,	  1998,	  Zeremski	  et	  al.,	  2007).	  CXC	  chemokines	  can	  be	  divided	  
into	   two	   subgroups	  according	   to	   the	  presence	  of	   the	  ELR	  motif	   or	  Glu-­‐Leu-­‐Arg:	   ELR+	  
CXC	   chemokines	   are	   pro-­‐angiogenic	   compared	   to	   ELR-­‐	   chemokines	   such	   as	   CXCL10	  
which	   demonstrates	   angiostatic	   properties	   (Belperio	   et	   al.,	   2000).	   CXCL10	   binds	   the	  
chemokine	   (C-­‐X-­‐C	   motif)	   receptor	   3	   (CXCR3)	   which	   is	   a	   seven	   trans-­‐membrane	  
receptor	   coupled	   to	   G	   proteins.	   CXCL10	   is	   secreted	   by	   CD4+,	   NK,	   NK-­‐T	   cells,	  




preadipocytes	  and	   is	  dependent	  on	   IFN-­‐γ,	  which	   in	  turn	   is	  dependent	  on	   IL-­‐12	  (Engel	  
and	   Neurath,	   2010).	   CXCL10	   levels	   are	   a	   marker	   of	   the	   host	   immune	   response	   in	  
particular	  the	  T	  helper	  (Th)	  1	  response.	  The	  activated	  and	  recruited	  Th1	  lymphocytes	  
are	   responsible	   for	   the	   increased	   IFN-­‐γ	   and	   TNF-­‐α	   production	   which	   results	   in	  
increased	   CXCL10	   secretion	   through	   an	   amplification	   feedback	   loop	   (Antonelli	   et	   al.,	  
2008).	  
	  
CXCL10	   is	   induced	   in	   hepatocytes	   in	   chronic	   infection	   through	   the	   recognition	   of	  
conserved	   PAMPS	   (pathogen	   associated	   molecular	   patterns)	   by	   innate	   pattern	  
recognition	   receptors	   including	   TLR3	   and	   retinoic	   acid	   inducible	   gene	   1	   (RIG-­‐1)	  
(Beinhardt	  et	  al.,	  2012,	  Sumpter	  et	  al.,	  2005).	  TLR3	  and	  RIG1	  both	  sense	  HCV	  infection,	  
TLR3	  in	  particular	  recognises	  double	  stranded	  RNAs	  generated	  during	  viral	  replication	  
(Wang	  et	  al.,	  2009,	  Li	  et	  al.,	  2012,	  Saito	  et	  al.,	  2008).	  The	  resultant	  activated	  TLR3	  binds	  
TRIF	   (TIR-­‐domain	   containing	   adapter	   inducing	   IFN-­‐β	   which	   activates	   a	   variety	   of	  
transcriptional	   factors	   (IRF3,	   IRF7,	   NF-­‐κB)	   which	   induce	   pro-­‐inflammatory	  	  
cytokines/chemokines	  and	  type	  I	  and	  type	  III	  IFNs(Takeuchi	  and	  Akira,	  2010,	  Osterlund	  
et	   al.,	   2007).	   Type	   I	   IFNs	   bind	   to	   IFNAR1/IFNAR2	   receptors	   which	   activates	   Janus	  
kinases	  and	  STAT	  proteins	  which	   in	   turn	   induce	   ISGs	   (Ank	  et	  al.,	  2006,	  Aaronson	  and	  






Concentrations	  of	  CXCL10	  are	  elevated	  in	  HCV	  infection	  compared	  to	  healthy	  controls	  
and	  it	  is	  an	  important	  chemo-­‐attractant	  for	  CD4+	  lymphocytes,	  monocytes	  and	  natural	  
killer	  (NK)	  cells	  but	  not	  for	  CD8+	  lymphocytes	  or	  neutrophils	  (Taub	  et	  al.,	  1993,	  Taub	  et	  
al.,	   1995).	   Serum	   levels	   of	   CXCL10	   are	   reflective	   of	   hepatic	   IP-­‐10	  mRNA	   and	   predict	  
HCV	   RNA	   first	   phase	   decline	   during	   anti-­‐viral	   treatment	   (Askarieh	   et	   al.,	   2010).	  
Decreased	  pre-­‐treatment	  levels	  of	  CXCL10	  have	  been	  previously	  associated	  with	  SVR	  in	  
HCV	  mono-­‐infected,	   ‘difficult	   to	   treat’	   HCV	  mono-­‐infected	   and	   HIV/HCV	   co-­‐infected	  
cohorts	  (Lagging	  et	  al.,	  2006,	  Reiberger	  et	  al.,	  2008,	  Romero	  et	  al.,	  2006).	  	  High	  CXCL10	  
levels	   are	   associated	   with	   failure	   of	   spontaneous	   HCV	   clearance	   in	   acute	   infection	  
(Grebely	   et	   al.,	   2013).	   Data	   in	   patients	   with	   acute	   and	   early	   chronic	   HCV	   infection	  
suggests	   that	   CXCL10	   levels	   were	   predictive	   of	   early	   viral	   kinetics	   but	   not	   of	   the	  
ultimate	  treatment	  outcome	  (Feld	  et	  al.,	  2013).	  
	  
The	  role	  of	  hepatic	  gene	  expression,	  in	  particular	  interferon-­‐stimulated	  genes	  (ISG)	  has	  
been	  studied	  pre-­‐	  and	  post-­‐	  anti-­‐viral	  therapy	  in	  order	  to	  establish	  host	  factors	  which	  
may	  be	  associated	  with	  treatment	  response	  (Feld	  et	  al.,	  2007,	  Sarasin-­‐Filipowicz	  et	  al.,	  
2008).	   Animal	   models	   have	   also	   demonstrated	   that	   interferon	   non-­‐response	   is	  
associated	   with	   pre-­‐activated,	   either	   maximally	   or	   inappropriately	   stimulated	  
intrahepatic	   ISG	   expression	   (Asselah	   et	   al.,	   2008,	   Chen	   et	   al.,	   2005).	   Induction,	   of	  
already	   high	   baseline	   ISGs,	   by	   exogenous	   administration	   of	   interferon	   is	   therefore	  





CXCL10	  is	  a	  valid	  marker	  of	  ISG	  activation,	  lower	  levels	  associated	  with	  a	  lower	  level	  of	  
activation	   of	   the	   innate,	   interferon	   associated	   immune	   response	   (Chen	   et	   al.,	   2005,	  
Sarasin-­‐Filipowicz	  et	  al.,	  2008).	  CXCL10	  is	  also	  produced	  by	  liver	  sinusoidal	  endothelial	  
cells	   and	   hepatic	   stellate	   cells	   (Harvey	   et	   al.,	   2003,	   Holt	   et	   al.,	   2009,	   Shields	   et	   al.,	  
1999).	  CXCR3	  is	  highly	  expressed	  in	  IL-­‐2	  activated	  T	  lymphocytes	  but	  is	  undetectable	  in	  
resting	   T	   lymphocytes,	   B	   lymphocytes,	   monocytes	   or	   granulocytes	   (Jinquan	   et	   al.,	  
2000).	  CXCR3	  is	  highly	  expressed	  on	  activated	  effector	  cells	  and	  is	  closely	  linked	  to	  the	  
Th1-­‐type	   immune	  response	   indicating	   its	   integral	  role	   in	  the	  recruitment	  of	  activated	  
lymphocytes	  to	  the	  inflamed	  liver	  (Qin	  et	  al.,	  1998).	  Given	  that	  CXCL10	  is	  produced	  by	  
endothelial	  cells,	  monocytes	  and	  by	  HSCs	  attention	  has	  therefore	  turned	  to	  assessing	  
the	   role	   of	   CXCL10	   in	   predicting	   fibrosis	   progression.	   It	   remains	   unclear	   as	   to	   why	  
lower	  CXCL10	  levels	  are	  associated	  with	  a	  successful	  treatment	  response.	  CXCL10	  gene	  
expression	  is	  increased	  after	  exposure	  to	  interferon,	  and	  therefore	  one	  mechanism	  of	  
action	  postulated	  is	  that	  CXCL10	  and	  hence	  ISGs	  are	  up-­‐regulated	  and	  demonstrate	  a	  
more	  robust	  response	  to	  the	  administration	  of	  exogenous	  interferon	  which	  results	  in	  a	  
higher	  SVR	  rate.	  Another	  suggested	  hypothesis	  is	  that	  the	  elevated	  CXCL10	  levels	  are	  in	  
an	   antagonist	   or	   truncated	   form	   in	   non-­‐responders	   (Casrouge	   et	   al.,	   2011).	   The	  
antagonist	  form	  of	  CXCL10	  is	  generated	  due	  to	  in	  situ	  amino-­‐terminal	  truncation	  of	  the	  
protein	  and	  via	  dipeptidyl	  peptidase	   IV	   (DDP4	  or	  CD26)	  possibly	   in	  combination	  with	  
other	   proteases	   (Casrouge	   et	   al.,	   2011).	   DPP4	   is	   itself	   expressed	   and	   regulated	   by	   T	  
lymphocyte	   function	   with	   high	   serum	   DPP4	   levels	   associated	   with	   poor	   treatment	  





	  The	   truncated	   form	  of	  CXCL10	   retains	  CXCR3	  binding	  but	  does	  not	   induce	   signalling	  
(Casrouge	  et	  al.,	  2011,	  Proost	  et	  al.,	  2001).	  Studies	  have	  also	  shown	  that	  differences	  in	  
the	   expression	   of	   hepatic	   ISGs	   before	   treatment	   are	   associated	   with	   the	   IL-­‐28B	  
polymorphism	   (Honda	  et	   al.,	   2010,	  Urban	  et	   al.,	   2010).	   The	  non	  CC	   IL-­‐28B	   genotype	  
exhibited	  higher	  ISG	  levels	  compared	  to	  the	  CC	  IL-­‐28B	  genotype.	  
	  	  
6.6	  MicroRNAs	  
MicroRNAs	   (miRNA)	   were	   discovered	   in	   1993	   and	   are	   small	   (approximately	   22	  
nucleotides)	  non-­‐coding	  RNAs	  that	  regulate	  gene	  expression	  at	  the	  post-­‐transcriptional	  
level	   by	   specifically	   binding	   to	   target	   messenger	   RNA	   (mRNA),	   leading	   to	   their	  
degradation	  or	  translational	  repression	  (van	  Rooij	  and	  Olson,	  2007).	  miRNAs	  have	  been	  
shown	  to	  regulate	  more	  than	  one-­‐third	  of	  all	  human	  genes	  (Krek	  et	  al.,	  2005).	  Genes	  
that	   encode	  miRNA	   are	   transcribed	   from	  miRNA	   genes	   via	   RNA	   polymerase	   II	   or	   III	  
(primary	   transcript	   (pri-­‐miRNA)),	   and	   then	   cleaved	   by	   DROSHA-­‐DGCR8	   complex	   	   to	  
make	   a	   short	   precursor	   (pre-­‐miRNA)	   (Bartel,	   2009).	   This	   occurs	   in	   the	   nucleus.	   	   The	  
pre-­‐miRNA	  is	  then	  exported	  into	  the	  cytoplasm	  through	  the	  exportin-­‐5	  complex.	  	  Next,	  
the	   pre-­‐miRNA	   is	   cleaved	   by	   DICER	   and	   TRBP	   to	   create	   a	   miRNA	   duplex	   (mature	  
miRNA).	  The	  most	  stable	  aspect	  of	   the	  strand	   is	   then	  selected	  and	   loaded	  with	  Ago2	  
and	  GW182	   into	   the	  RNA-­‐induced	   silencing	   complex.	  Mature	  miRNA	   complentary	   to	  
the	  3’	  UTR	  of	  the	  target	  miRNA	  gene	  either	  undergo	  cleavage,	  translational	  repression	  






miRNAs	   repress	   their	   target	   	   through	   the	   interaction	  with	   the	  3’	  untranslated	   region	  
(UTR)	   and	   this	   change	   is	   detectable	   at	   the	   RNA	   level	   	   (Ambros,	   2004,	   Bartel,	   2009).	  
Conversely,	  miRNAs	  that	  engage	  their	  targets	  in	  a	  non-­‐3	  UTR	  dependent	  fashion	  cause	  
upregulation	  of	   their	   targets.	   	  Multiple	  miRNAs	   are	   able	   to	   regulate	  messenger	  RNA	  
(mRNA),	   therefore	   creating	   a	   complex	   situation	   with	   regards	   to	   their	   capacity	   to	  
modulate	   various	   biological	   processes	   (Szabo	   and	   Bala,	   2013).	   By	   simultaneously	  
regulating	  the	  expression	  of	  large	  numbers	  of	  genes,	  miRNAs	  have	  been	  implicated	  in	  
controlling	   diverse	   biological	   processes,	   including	   apoptosis,	   proliferation,	  
inflammation	  and	  differentiation.	  They	  have	  highly	  conserved	  cross	  species	  sequence	  
homology	  (Cummins	  and	  Velculescu,	  2006).	  	  
	  
6.6.1	  miRNAs	  and	  liver	  disease	  
miRNAs	   have	   been	   implicated	   in	   a	   variety	   of	   mechanisms	   which	   are	   relevant	   to	  
progression	   of	   liver	   disease.	   Liver	   inflammation	   is	   an	   important	   mechanism	   a	   key	  
mechanism	  and	  miRNA-­‐155	  induction	  has	  been	  highlighted	  in	  mouse	  models	  of	  NASH	  
and	  alcohol	  related	  steato-­‐hepatitis	  (Cheung	  et	  al.,	  2008,	  Bala	  et	  al.,	  2011).	  Increased	  
miR-­‐155	   can	   lead	   to	   increased	   TNF	   expression	   which	   promotes	   liver	   inflammation	  	  
(Bala	  et	  al.,	  2011).	  Conversely,	  miRNA-­‐146a	  acts	  as	  a	  molecular	  break	  for	  inflammation	  
and	  therefore	  mice	  deficient	  in	  miRNA-­‐146a	  develop	  hyper-­‐inflammation	  through	  NF-­‐
κB	  (Zhao	  et	  al.,	  2011).	  
	  
Other	   relevant	   mechanisms	   include	   apoptosis,	   necrosis	   and	   cell	   cycle	   proliferation.	  
Inhibition	  of	  miRNA	  –	  15b	  and	  miRNA-­‐16	  in	  a	  mouse	  model	  resulted	  in	  a	  reduction	  of	  




been	   shown	   to	   inhibit	   hepatocyte	   DNA	   synthesis	   (Song	   et	   al.,	   2010).	   Other	   miRNA	  
implicated	   in	   cell	   profileration	   include	   miRNA-­‐26a	   (down	   regulated	   	   after	  
hepatectomy),	  miRNA-­‐217	  (down	  regulated	  during	  liver	  regeneration)	  and	  miRNA-­‐221	  	  
(Pan	  et	  al.,	  2012,	  Yuan	  et	  al.,	  2013).	  
	  
miRNA-­‐122	   is	   specifically	   and	  abundantly	  expressed	   in	  hepatocytes	  and	  accounts	   for	  
approximately	  70%	  of	   the	   total	  miRNA	  within	   the	   liver	   (Jopling	  et	  al.,	   2005).	  miRNA-­‐
122	  is	   involved	  in	  key	  hepatic	  homeostatic	  mechanisms	  affecting	  genes	  involved	  with	  
cholesterol	   and	   lipid	   metabolism.	   Mice	   deficient	   in	   miRNA-­‐122	   had	   increased	  
intrahepatic	   recruitment	   of	   inflammatory	   cells	   and	   pro-­‐inflammatory	   cytokines,	  
thereby	  also	  implicating	  an	  integral	  role	  in	  hepatic	  inflammation	  (Tsai	  et	  al.,	  2012,	  Hsu	  
et	  al.,	  2012).	  Mice	  that	  are	  deficient	  in	  miRNA-­‐122	  develop	  steatohepatitis	  and	  fibrosis,	  
with	  the	  miRNA-­‐122a-­‐KLF6	  axis	  playing	  an	  integral	  role	  (Tsai	  et	  al.,	  2012)(13).	  Further	  
data	   from	   a	   CCl4-­‐	   induced	   liver	   fibrosis	   mouse	   model	   demonstrated	   a	   reduction	   in	  
miRNA-­‐122	  in	  activated	  HSCs	  (Li	  et	  al.,	  2013).	  	  miRNA-­‐21	  has	  been	  shown	  to	  correlate	  
positively	   with	   HCV	   mediated	   fibrosis	   by	   targeting	   SMAD7	   which	   enhances	   TGF-­‐β	  
mediated	  fibrosis	  (Marquez	  et	  al.,	  2010).	  A	  study	  performed	  in	  HCV	  infected	  patients	  
with	   fibrosis	   and	  healthy	   volunteers	   	   demonstrated	   	  upregulation	  of	  miRNA-­‐20a	  and	  
miRNA-­‐92a	  	  in	  patients	  HCV	  related	  fibrosis	  (Shrivastava	  et	  al.,	  2013).	  	  
	  
miRNA-­‐122	  has	  been	  shown	  to	  facilitate	  the	  replication	  of	  HCV	  RNA	  by	  interacting	  with	  
the	   5’	   non-­‐coding	   region	   of	   the	   viral	   genome.	   Serum	   levels	   have	   been	   shown	   to	  




activity	   in	   patients	   with	   HCV	   (Jopling	   et	   al.,	   2005,	   Bihrer	   et	   al.,	   2011).	   The	   role	   of	  
miRNAs	   in	   hepatic	   fibrosis	   has	   been	   evaluated	   previously	   in	   a	  mouse	  model	   and	   in	  
human	  liver	  biopsies	  from	  patients	  with	  HCV	  pre	  liver	  transplantation	  (Murakami	  et	  al.,	  
2011).	   	  miRNAs	  have	  been	  shown	  to	  play	  an	  essential	  role	  in	  HSC	  function,	  activation	  
and	  therefore	  hepatic	  fibrosis	  (Moreira,	  2007,	  Atzori	  et	  al.,	  2009).	  A	  number	  of	  miRNAs	  
have	  been	   identified	  which	  play	  an	   important	   role	   in	   the	   regulation	  of	  hepatic	   fibrosis.	  Both	  
profibrotic	   (miRNA-­‐119a/b,	  miRNA-­‐34)	  and	  antifibrotic	   (miRNA-­‐29,	  miRNA-­‐150)	  miRNAs	  have	  
been	   identified	   (Roderburg	   et	   al.,	   2011,	   Kwiecinski	   et	   al.,	   2012,	   Mannaerts	   et	   al.,	   2013,	  
Venugopal	  et	  al.,	  2010).	  	  
	  
6.6.2	  miRNAs	  as	  biomarkers	  
miRNAs	  are	  viewed	  as	  attractive,	  potential	  biomarkers	  because	  of	  their	  stable,	  cell-­‐free	  
form	   in	   blood.	  miRNAs	  have	  been	  demonstrated	   in	   different	   body	   fluids	   and	   can	  be	  
released	   in	  microvesicles,	  exosomes	  apopotic	  bodies	  or	  bound	   to	  HDL	   (Weber	  et	  al.,	  
2010,	  Mitchell	  et	  al.,	  2008,	  Vickers	  et	  al.,	  2011).	  These	  circulating	  miRNAs	  are	  resistant	  
to	  endogenoud	  RNases	   in	   the	  blood.	  Critically,	  what	   remains	  unclear	   is	  how	  miRNAs	  
make	   their	   way	   into	   the	   blood-­‐stream	   or	   into	   other	   bodily	   fluids;	   whether	   it	   is	   the	  
result	   of	   cell	   death	   or	   secondary	   to	   active	   secretion	   from	   tissue	   cells.	   There	   is	  
increasing	   evidence	   that	   serum/plasma	   concentrations	   of	   miRNAs	   are	   altered	   in	  
multiple	  disease	  pathologies,	  including	  HCC	  (Fan	  et	  al.,	  2008,	  Kosaka	  et	  al.,	  2010a,	  Xu	  
et	   al.,	   2011).	   Studies	   specific	   to	   HCV	   demonstrate	   that	   miRNA-­‐122	   expression	  
correlates	  with	  serum	  transaminases	  and	  necro-­‐inflammatory	  activity	  on	  liver	  biopsy,	  
but	  not	  with	  fibrosis	  stage	  or	  parameters	  of	  liver	  function	  in	  patients	  with	  chronic	  HCV	  




patients	  who	  do	  not	  respond	  to	  anti-­‐viral	  therapy	  compared	  to	  responders	  in	  the	  non-­‐
transplant	  setting	  (Sarasin-­‐Filipowicz	  et	  al.,	  2008).	  Elevated	  circulating	  levels	  of	  miRNA-­‐
122	  have	  been	  demonstrated	   in	  variety	  of	  aetiologies	   	   including	  HCV,	  HBV,	  ALD,	  HCC	  
and	  NAFLD	  (Bala	  et	  al.,	  2012,	  Bihrer	  et	  al.,	  2011,	  Roderburg	  et	  al.,	  2012,	  Ji	  et	  al.,	  2011,	  
Tryndyak	  et	  al.,	  2012).	  It	  however,	  remains	  unclear	  as	  to	  whether	  the	  raised	  levels	  of	  
miRNA-­‐122	  is	  due	  to	  hepatocyte	  injury	  alone.	  	  
	  
As	   well	   as	   providing	   diagnostic	   information,	   miRNAs	   provide	   the	   possibility	   of	  
therapeutic	   intervention.	  Novel	   targeted	  anti-­‐miRNA	   therapies,	   so-­‐called	   antagamirs,	  
have	  been	  postulated	  as	   future	   therapeutic	   targets.	   In	   two	   separate	  murine	  models,	  
the	  introduction	  of	  an	  anti-­‐sense	  oligonucleotide/antagamir	  resulted	  in	  a	  reduction	  of	  
hepatic	   steatosis	   and	   tumorgenesis	   repression,	   respectively	   (Kota	   et	   al.,	   2009).	  
Although	  the	  use	  of	  antagamirs	  remains	  in	  its	  infancy,	  recently	  published	  data	  using	  a	  
potent	   inhibitor	   of	   miRNA-­‐122	   function,	   has	   demonstrated	   a	   dose-­‐dependent	  
reduction	   in	   HCV	   RNA	   titres	   (Janssen	   et	   al.,	   2013).	   A	   phase	   2a	   study	   evaluated	  
miravirsen,	   a	   locked	   nucleic	   acid	   modified	   DNA	   phosphorothioate	   antitense	  
oligonucleotide	   that	   sequesters	   mature	  miRNA-­‐122	   in	   a	   highly	   stable	   hetero-­‐duplex	  
and	   therefore	   inhibits	   its	   function.	   	   In	   total,	   36	   patients	  with	   genotype	   1	   HCV	  were	  
enrolled	   in	   a	   randomised,	   double-­‐blind,	   placebo-­‐controlled	   sequential	   series,	  
ascending	   multiple	   dose-­‐ranging	   study.	   Patients	   received	   3mg,	   5mg,	   or	   7mg	   of	  
miravirsen	   or	   placebo.	   The	   results	   demonstrated	   that	   there	  was	   a	   reduction	   in	   HCV	  
RNA	  in	  a	  dose-­‐dependent	  manner	  and	  was	  sustained	  beyond	  the	  administrative	  period	  
for	  miravirsen	  	  (Janssen	  et	  al.,	  2013).	  Some	  patients	  were	  able	  to	  achieve	  undetectable	  




transaminases	   were	   also	   observed	   in	   addition	   to	   a	   reduction	   in	   serum	   cholesterol	  
levels.	   Side-­‐effects	   were	   minimal.	   These	   data	   are	   an	   example	   of	   the	   therapeutic	  
options	  offered	  by	  miRNAs.	  
	  
7.	  Treatment	  of	  recurrent	  HCV	  post-­‐transplantation	  
	  
At	  present,	  AVT	   remains	   the	  only	  viable	   therapeutic	   strategy	  which	  can	  alter	   fibrosis	  
progression	  (Bahra	  et	  al.,	  2007,	  Berenguer,	  2002).	  The	  benefits	  of	  achieving	  a	  SVR	  are	  
clear;	  improvement	  in	  liver	  fibrosis,	  lower	  probability	  of	  decompensation	  and	  a	  lower	  
cumulative	   mortality	   post-­‐transplantation	   (Berenguer	   et	   al.,	   2008,	   Picciotto	   et	   al.,	  
2007).	  It	  should	  be	  emphasized	  that	  the	  role	  of	  AVT	  begins	  in	  the	  pre-­‐transplant	  period	  
with	  potential	  transplant	  candidates	  being	  treated	  on	  the	  waiting	  list.	  	  
	  
7.1	  Pre-­‐transplant	  
AVT	   should	   be	   considered	   in	   all	   patients	   with	   Child	   Pugh	   (CP)	   -­‐	   A	   (compensated)	  
disease	   and	   on	   an	   individual	   case	   basis	   in	   patients	  with	   CP-­‐B.	  Overall,	   AVT	   is	   poorly	  
tolerated	   by	   cirrhotic	   patients,	   although	   achieving	   HCV	   RNA	   negativity	   at	   transplant	  
decreases	   re-­‐infection	   and	   thus	   recurrence	   and	   so	   is	   still	   utilized	   by	   some	   groups.	  
Given	  the	  risk	  of	  decompensation	  and	  side	  effects	  (particularly	  sepsis),	  the	  concept	  of	  
a	  low	  accelerating	  dosing	  regimen	  (LADR)	  was	  introduced(Everson	  et	  al.,	  2005).	  A	  LADR	  
involves	  starting	  patients	  on	  reduced	  doses	  of	  PEG/RBV	  and	  then	  increasing	  the	  doses	  




centre	  US	  study	  using	  PEG/RBV	  only	  has	  suggested	  that	  patients	  need	  to	  be	  treated	  for	  
greater	  than	  16	  weeks	  pre-­‐LT	  in	  order	  to	  remain	  HCV	  RNA	  negative	  post-­‐LT	  (Everson	  et	  
al.,	  2013).	  
	  
Boceprevir	  and	  telaprevir	  (NS3	  protease	  inhibitors)	  in	  combination	  with	  PEG/RBV	  were	  
licensed	   in	   2011	   for	   patients	   with	   genotype	   1	   disease.	   Registration	   trial	   data	  
demonstrated	   improved	   SVR	   rates	   in	   treatment	   naïve	   (68-­‐75%)	   and	   treatment-­‐
experienced	   groups	   (59-­‐88%)	   although	   this	  was	   predominately	   in	   patients	  with	  mild	  
fibrosis	  (Poordad	  et	  al.,	  2011,	  Jacobson	  et	  al.,	  2011,	  Bacon	  et	  al.,	  2011,	  Zeuzem	  et	  al.,	  
2011).	   Interim,	   week	   16	   data	   from	   the	   CUPIC	   (Compassionate	   Use	   of	   Protease	  
Inhibitors	   in	   viral	   C	   Cirrhosis)	   study	   suggests	   triple	   therapy	   (boceprevir	   or	   telaprevir	  
plus	  PEG/RBV)	   in	   treatment-­‐experienced	   cirrhotic	  patients,	   some	  of	  whom	  would	  be	  
potential	  transplant	  candidates,	  is	  associated	  with	  a	  high	  incidence	  of	  serious	  adverse	  
events	   (40%)(Hezode	   et	   al.,	   2013).	   This	   ‘real-­‐life’	   experience	   in	   predominately	   Child-­‐
Pugh-­‐A	  cirrhotic	  patients	  showed	  that	  triple	  therapy	  was	  poorly	  tolerated;	  58	  patients	  
(12%)	  required	  early	  treatment	  discontinuation,	  12	  patients	  (2.4%)	  developed	  hepatic	  
decompensation	   and	   6	   patients	   died.	   Risk	   factors	   for	   severe	   complications	   or	   death	  
were	   delineated	   by	   serum	   albumin	   <	   35g/L	   and	   a	   platelet	   count	   ≤	   100,000/mm3	  
(Hezode	  et	  al.,	  2013).	  
	  
New	   data	   on	   the	   use	   of	   the	   DAAs	   in	   cirrhotic	   patients	   is	   emerging.	   The	   NEUTRINO	  




weeks	   in	  327	  patients	   (17%	  cirrhotic)	  with	  predominantly	  genotype	  1	  disease	  (Lawitz	  
et	   al.,	   2013).	   SOF,	   a	   NS5B	   polymerase	   inhibitor,	   has	   demonstrated	   a	   high	   barrier	   to	  
resistance,	  a	  favourable	  safety	  profile	  and	  pan-­‐genotypic	  action.	  Reported	  SVR	  12	  rates	  
were	   80%	   amongst	   cirrhotic	   patients.	   	   The	   FISSION	   study	   was	   a	   randomized,	   open	  
label,	  active	  control	  study	  of	  SOF	  and	  RBV	  in	  genotype	  2	  or	  3	  patients	  which	  reported	  
SVR12	   rates	   of	   47%	   in	   cirrhotic	   patients	   compared	   to	   72%	   in	   non-­‐cirrhotic	   patients	  
(Lawitz	  et	  al.,	  2013).	  	  
	  
7.2	  Post	  transplant	  
Two	   principal	   strategies	   have	   been	   adopted;	   pre-­‐emptive	   treatment	   and	   treatment	  
following	   evidence	   of	   histological	   recurrence.	   The	   current	   ‘standard	   of	   care’	   in	   the	  
post-­‐transplant	  period	  is	  PEG/RBV	  for	  48	  weeks	  irrespective	  of	  viral	  genotype.	  	  
	  
7.2.1	  Pre-­‐emptive	  treatment	  
Pre-­‐emptive	   treatment	   of	   HCV	   recurrence	   post-­‐LT	   is	   commenced	   immediately	   post-­‐
transplantation	  and	  is	  based	  on	  the	  hypothesis	  that	  virologic	  recurrence	  is	  universal	  in	  
all	  patients.	  The	  obvious	  advantages	  with	  this	  strategy	  are	  that	  HCV	  RNA	  levels	  will	  be	  
at	  their	  lowest	  and	  liver	  fibrosis	  will	  be	  minimal.	  	  
	  
Studies	   to	   date	   that	   have	   adopted	   this	   treatment	   strategy	   are	   both	   limited	   and	  
heterogeneous	   (genotype	   1	   and	   non-­‐genotype	   1	   patients),	   some	   using	   interferon-­‐




(Mazzaferro	  et	  al.,	  2001,	  Sheiner	  et	  al.,	  1998,	  Shergill	  et	  al.,	  2005,	  Singh	  et	  al.,	  1998,	  
Sugawara	   et	   al.,	   2004).	   Two	   randomised,	   prospective	   studies	   that	   used	   interferon-­‐
alpha	  mono-­‐therapy,	   beginning	   2	   weeks	   after	   transplantation,	   clearly	   demonstrated	  
that	  those	  treated	  were	  less	  likely	  to	  develop	  a	  recurrent	  hepatitis	  than	  patients	  who	  
were	  not	  treated	  (Sheiner	  et	  al.,	  1998,	  Singh	  et	  al.,	  1998).	  Neither	  study	  however,	  was	  
able	   to	   demonstrate	   any	   survival	   benefit	   in	   patients	   that	   received	   interferon	  
treatment.	  In	  a	  study	  of	  36	  patients,	  using	  both	  interferon-­‐alpha	  and	  oral	  ribavirin	  for	  
12	  months,	   the	  authors	  were	  able	  to	  demonstrate	  HCV-­‐RNA	  clearance	   in	  12	  patients	  
(33%)	  (Mazzaferro	  et	  al.,	  2001).	  An	  important	  observation	  made	  by	  this	  study	  was	  that	  
HCV-­‐RNA	  clearance	  was	  more	  likely	  to	  be	  achieved	  by	  those	  with	  lower	  baseline	  HCV	  
RNA	  levels.	  	  
	  
More	  recent	  studies	  have	  used	  PR	  and	  demonstrated	  SVRs	  between	  8-­‐18%	  (Chalasani	  
et	  al.,	  2005,	  Shergill	  et	  al.,	  2005).	  Although	  the	  SVR	  rates	  were	  considerably	  lower	  than	  
those	  previously	   reported,	   the	  key	  message	   from	  one	  of	   these	   studies	  was	   that	  pre-­‐
emptive	  AVT	  was	  only	  applicable	  in	  51%	  of	  patients	  and	  the	  desirable	  >	  80%	  treatment	  
dose	  and	  >	  80%	  treatment	  duration	  was	  only	  achieved	  by	  a	  small	  number	  of	  patients	  
(14%)	   (Shergill	   et	   al.,	   2005).	   Cytopenias,	   especially	   anaemia,	   post-­‐operative	  
complications	   and	   severe	   debilitation	   relating	   to	   the	   severity	   of	   illness	   pre-­‐





7.2.2	  Treatment	  of	  established	  HCV	  recurrence	  
Studies	   assessing	   the	   efficacy	   of	   AVT	   once	   histological	   evidence	   of	   hepatitis	   C	  
recurrence	  has	  been	  established	  are	  more	  numerous	  and	  reflect	  the	  preferred	  setting	  
to	   commence	   anti-­‐HCV	   therapy.	   The	   reasons	   for	   this	   seem	   to	   be	   multifactorial:	   a	  
recuperated	   patient	   with	   less	   co-­‐morbid	   or	   post-­‐surgical	   concerns,	   reduced	   risk	   of	  
acute	  cellular	  rejection,	  better	  graft	  function	  and	  lower	  doses	  of	  immunosuppression.	  
Earlier	  studies	  that	  evaluated	  this	  strategy	  reported	  SVR	  rates	  of	  between	  12-­‐24%	  with	  
PEG	  mono-­‐therapy	  and	  PEG/RBV	  (Angelico	  et	  al.,	  2007,	  Chalasani	  et	  al.,	  2005).	  In	  both	  
studies,	  however,	   there	  was	  a	  wide	  variation	   in	  median	  time	  from	  transplantation	  to	  
treatment	   (6-­‐96	   months)	   and	   grade	   of	   baseline	   fibrosis	   demonstrating	   the	  
heterogeneity	  of	  the	  patients	  groups.	  	  	  
	  
Most	   centres	   institute	   AVT	   once	   histological	   evidence	   of	   HCV	   is	   established,	   usually	  
more	  than	  12	  months	  post	  transplantation.	  	  In	  order	  to	  establish	  the	  optimal	  timing	  of	  
when	   to	   begin	   treatment,	   one	   study	   attempted	   to	   extrapolate	   the	   experience	   and	  
success	  of	  treating	  acute	  HCV	  in	  pre-­‐transplant	  cohorts	  and	  treat	  patients	  in	  the	  post-­‐	  
transplant	  period	  as	  soon	  as	  acute	  HCV	  was	  detected	  (Castells	  et	  al.,	  2005,	  Jaeckel	  et	  
al.,	   2001).	   Inclusion	   criteria	   included	   persistent	   ALT	   elevation,	   HCV-­‐RNA	   positivity,	  
histological	   evidence	   of	   lobular	   hepatitis	   consistent	   with	   recurrent	   HCV	   and	   no	  
evidence	   of	   acute	   or	   chronic	   rejection,	   biliary	   obstruction	   or	   ischaemic	   changes.	   24	  
patients	  eventually	  underwent	  treatment	  with	  the	  interval	  between	  LT	  and	  histological	  




EOTR	  and	  8	  (35%)	  had	  a	  SVR.	  Although	  side	  effects	  were	  common,	  asthenia	  and	  muscle	  
pain	  the	  most	  frequent,	  no	  patient	  discontinued	  their	  interferon	  treatment.	  	  
	  
More	  recent	  studies	  have	  used	  PEG-­‐IFN	  alpha-­‐2b	  (1.5mcg/kg)	  or	  alpha-­‐2a	  (180ug)	  and	  
RBV	   800-­‐1200mg	   (Angelico	   et	   al.,	   2007,	   Castells	   et	   al.,	   2005,	   Carrion	   et	   al.,	   2007,	  
Dumortier	  et	  al.,	  2004,	  Oton	  et	  al.,	  2006,	  Picciotto	  et	  al.,	  2007)	   (Table	  2.3).	  Reported	  
SVR	  rates	  for	  all	  genotypes	  range	  between	  8-­‐45%	  (Berenguer,	  2008,	  Wang	  et	  al.,	  2006,	  
Xirouchakis	  et	  al.,	  2008).	  SVR	  rates	  for	  genotype	  1	  patients	  however,	  are	  considerably	  
lower	  ranging	  between	  13-­‐33%	  only	  (Berenguer,	  2008).	  Once	  again	  the	  study	  cohorts	  
were	  heterogeneous	  with	  wide	  variation	  in	  the	  time	  from	  LT	  to	  the	  start	  of	  treatment	  
and	  the	  percentage	  of	  patients	  with	  advanced	  fibrosis	  (Angelico	  et	  al.,	  2007,	  Carrion	  et	  
al.,	  2007,	  Dumortier	  et	  al.,	  2004,	  Oton	  et	  al.,	  2006,	  Picciotto	  et	  al.,	  2007,	  Hanouneh	  et	  
al.,	  2008).	  Treatment	  appears	  to	  be	  more	  efficacious	  when	  the	  histological	  recurrence	  
of	   HCV	   is	   mild;	   48%	   SVR	   in	   patients	   with	   mild	   HCV	   recurrence	   versus	   19%	   SVR	   in	  
patients	   with	   severe	   HCV	   recurrence	   (Carrion	   et	   al.,	   2007).	   One	   consistent	   finding	  
however,	   amongst	   these	   studies	   were	   the	   numbers	   of	   patients	   that	   discontinued	  
treatment	  early	  and	  the	  poor	  tolerability.	  	  Two	  studies	  addressed	  the	  potential	  benefit	  
of	  long-­‐term	  maintenance	  antiviral	  therapy	  but	  failed	  to	  demonstrate	  any	  clear	  benefit	  














SVR	   Duration	  of	  Rx	  
(weeks)	  
Time	   to	  
treatment	  post	  
LT	  (months)	  










et	   al.,	  
2004)	  
97	   20	   16(80%)	   45%(9/20)	   48	   28	  (median)	  	   -­‐	   14	  (20%)	  
(Castells	   et	  
al.,	  2005)	  
83	   24	   24	  (100%)	   -­‐	   24	   3.8	  +/-­‐2.2	   -­‐	   -­‐	  
(Oton	   et	  
al.,	  2006)	  
171	   55	   50	  (91%)	   G1	  –	  40%	  
Overall	  –	  44%	  
48	  weeks	  –	  G1	  
24	   weeks	   –	  
G2/3	  
63	  (mean)	  	   18	  (33%)	   13	  (24%)	  
(Angelico	  
et	   al.,	  
2007)	  
-­‐	   42**	   35(83%)	   36%	   48	   44	  (median)	  
range	  12-­‐96	  
-­‐	   12	  (29%)	  
(Carrion	   et	  
al.,	  2007)	  
140	   81	   73(90%)	   33%	  (18/54)	   24	   15	   27(33%)	   21	   /54	  
(40%)	  
(Picciotto	  
et	   al.,	  
2007)	  
123	   61	   53(87%)	   28%	  (17/61)	   48	  weeks	  –	  G1	  
24	  weeks	  –	  G2	  
25	  (median)	  
Range	  	  	  	  	  	  3-­‐131	  
28	  (46%)	   8	  (15%)	  
(Hanouneh	  
et	   al.,	  
2008)	  
-­‐	   53	   42	  (79%)	   35%	  (19/53)	   48	   15	  (median)	   10	  (19%)	   14	  (26%	  
	  
Table	   2.3.	   Studies	   evaluating	   treatment	   outcomes	   with	   pegylated	   interferon	   and	  
ribavirin	  for	  established	  recurrent	  HCV	  post	  liver	  transplantation.	  	  
*	  Total	  number	  of	  patients	  transplanted	  during	  study	  period	  
**	  Compared	  pegylated	  interferon	  and	  ribavirin	  versus	  pegylated	  interferon	  role	  
SVR,	  sustained	  virologic	  response;	  Rx,	  treatment;	  LT,	  liver	  transplant;	  G1,	  genotype	  1	  
	  
There	   is	   only	   one	   prospective,	   multi-­‐center	   randomised	   study	   published	   that	   has	  
attempted	  to	  determine	  which	  treatment	  strategy	   is	  better	  and	  safest	  (Bzowej	  et	  al.,	  
2011).	   The	   PHOENIX	   (Pegasys	   and	  Copegus	  Administered	  After	   Liver	   Transplantation	  
for	  Hepatitis	  C)	   study	   conducted	   in	  North	  America	   reported	  SVR	   rates	  of	  22%	   in	   the	  
pre-­‐emptive	  group	  but	  with	  discontinuation	  rates	  of	  greater	  than	  40%	  predominately	  
due	   to	   haematological	   side	   effects	   (Bzowej	   et	   al.,	   2011).	   In	   the	   same	   study,	   those	  
treated	   for	   established	   recurrence	   had	   SVR	   rates	   of	   21%.	   This	   study	   was	   unable	   to	  
delineate	   which	   strategy	   was	   optimal	   for	   the	   treatment	   of	   recurrent	   HCV	   infection	  




study	  with	   the	  addition	  of	   the	  DAAs	  may	  be	  able	   to	  establish	   the	  optimal	   treatment	  
strategy	  but	  may	  also	  reveal	  significant	  tolerability	  issues.	  
	  
The	  overall	  poorer	  SVR	  rates	  reported	  in	  patients	  post-­‐transplant	  for	  HCV	  are	  likely	  due	  
to	   a	   combination	   of	   factors;	   1)	   the	   high	   percentage	   of	   patients	   with	   genotype	   1	  
disease,	   (2)	   high	   percentage	   of	   patients	   with	   a	   previous	   poor	   response	   to	   AVT,	   (3)	  
higher	   baseline	   HCV	   viral	   loads,	   (4)	   increased	   incidence	   of	   side	   effects	   leading	   to	  
significant	   dose	   reductions	   or	   discontinuation,	   (5)	   the	   interaction	   with	  
immunosuppression	  and	  (6)	  the	  lack	  of	  use	  of	  growth	  factors	  to	  support	  bone	  marrow	  
function.	  	  
	  
7.2.3	  Predictors	  of	  sustained	  virologic	  response	  with	  pegylated	  interferon	  and	  
ribavirin	  
Predictors	   of	   SVR	   can	   be	   divided	   into	   pre-­‐treatment	   variables	   and	   on-­‐treatment	  
variables.	  Pre-­‐treatment	  factors	  associated	  with	  a	  SVR	  include	  a	  low	  baseline	  HCV	  viral-­‐
load,	   HCV	   RNA	   <	   800,000	   IU/ml,	   younger	   recipient	   age,	   non-­‐genotype	   1	   disease,	  
shorter	   length	   between	   LT	   and	   commencing	   treatment,	   donor	   age	   <	   50	   years,	   low	  
baseline	   bilirubin	   levels	   and	   mild	   fibrosis(Berenguer,	   2008,	   Wang	   et	   al.,	   2006,	  
Xirouchakis	   et	   al.,	   2008,	   Hanouneh	   et	   al.,	   2008,	   Oton	   et	   al.,	   2006,	   Berenguer	   et	   al.,	  













Low	  baseline	  HCV	  viral	  load	  (<	  800,000	  IU/ml)	  
Younger	  recipient	  age	  
Younger	  donor	  age	  
Non	  genotype-­‐1	  disease	  
Shorter	  duration	  between	  liver	  transplantation	  and	  anti-­‐viral	  treatment	  
Mild	  fibrosis	  (F<2)	  




Rapid	  virologic	  response	  (RVR)	  
Early	  virologic	  response	  (EVR)	  
	  
Table	  2.4.	  Pre-­‐treatment	  and	  on-­‐treatment	  predictors	  of	  sustained	  virologic	  response	  
with	  pegylated	  interferon	  and	  ribavirin	  post-­‐liver.	  
	  
The	   IL-­‐28B	  genotype	  has	  also	  been	  evaluated	   in	  the	  post-­‐transplant	  setting	  (Charlton	  
et	  al.,	  2011,	  Eurich	  et	  al.,	  2011,	  Eurich	  et	  al.,	  2012,	  Lange	  et	  al.,	  2011).	  The	  favourable	  
CC	  (rs12979860)	  and	  TT	  (rs8099917)	  genotypes	  are	  both	  associated	  with	  SVR	  (p<0.005)	  
(Lange	  et	  al.,	  2011,	  Eurich	  et	  al.,	  2011,	  Charlton	  et	  al.,	  2011).	  Both	  recipient	  and	  donor	  
IL-­‐28B	  genotype	  have	  been	  evaluated	  with	  one	  study	  suggesting	  a	  more	  dominant	  role	  






Available	  data	  suggests	  that	  the	  use	  of	  ciclosporin	  over	  tacrolimus	  is	  associated	  with	  an	  
increased	   chance	   of	   SVR	   (RR	   2.0,	   CI	   1.2-­‐3.5,	   p=	   0.02)	   and	   a	   reduced	   risk	   of	   relapse	  
(Relative	  risk	  0.4,	  CI	  0.2-­‐0.9,	  p=0.02)	  (Firpi	  et	  al.,	  2006,	  Firpi	  et	  al.,	  2010,	  Campos-­‐Varela	  
et	   al.,	   2012).	   Suggested	  mechanisms	   include	   the	   direct	   antiviral	   effect	   of	   ciclosporin	  
demonstrated	  in-­‐vitro	  and	  the	  inhibition	  of	  NS5B	  binding	  to	  cyclophilin	  B	  (Hirano	  et	  al.,	  
2008,	   Watashi,	   2010).	   Results	   from	   ReViS-­‐TC	   study	   demonstrated	   that	   the	   use	   of	  
ciclosporin	   (Relative	   risk	   1.972,	   p=0.02)	   and	   a	   longer	   treatment	   duration	   of	   AVT	  
(Relative	  risk	  1.2,	  p<0.001)	  were	  predictive	  of	  a	  SVR	  (Campos-­‐Varela	  et	  al.,	  2012).	  
	  
7.2.4	  Side-­‐effects	  and	  tolerance	  	  
Reduced	   tolerability	   due	   to	   fatigue,	   asthenia,	   pyrexia	   and	   the	   development	   of	  
cytopenias,	   in	   particular	   anaemia	   is	   well	   described.	   Side	   effects	   appear	   to	   be	  more	  
prominent	   in	   patients	  with	   a	   severe	   hepatitis	   (Carrion	   et	   al.,	   2007).	   On	  multivariate	  
analysis,	  factors	  associated	  with	  the	  development	  of	  significant	  anaemia	  (>	  5g/dL)	  with	  
the	  use	  of	  PEG/RBV	  only	  included	  estimated	  creatinine	  clearance	  (Relative	  risk=0.951,	  
0.925-­‐0.978,	  p<0.001),	  the	  use	  of	  mycophenolate	  mofetil	  (Relative	  risk	  =	  5.3,	  1.4-­‐20.0,	  
p=0.01),	   ciclosporin	   (Relative	   risk	   =	   3.5,	   1.4-­‐8.7,	   p=0.008),	   baseline	   HCV	   viral	   load	   >	  
600,000	  IU/ml	  (Relative	  risk	  =	  4.8,	  1.7-­‐13.5,	  p=0.003)	  and	  baseline	  haemoglobin	  values	  





The	  use	  of	   interferon	   can	  be	  associated	  with	   the	  development	  of	   immune	  mediated	  
graft	  dysfunction	  (IGD)	  –	  an	  umbrella	  term	  for	  acute	  rejection	  (AR),	  chronic	  rejection	  
(CR)	  and	  plasma	  cell	  hepatitis	  (PCH)	  (Selzner	  et	  al.,	  2011,	  Stanca	  et	  al.,	  2007,	  Wang	  et	  
al.,	   2006,	   Ward	   et	   al.,	   2009).	   Certainly,	   in	   the	   pre-­‐emptive	   treatment	   approach,	  
concerns	  following	  the	  introduction	  of	  interferon	  so	  soon	  after	  transplantation	  are	  due	  
to	  the	  risk	  of	  precipitating	  ACR	  or	  an	  episode	  of	  sepsis.	  The	  development	  of	  a	  PCH	  is	  
associated	  with	  poor	  outcomes	  (Fiel	  et	  al.,	  2008,	  Ward	  et	  al.,	  2009).	  In	  a	  recent	  study,	  
evidence	  of	  a	  PCH	  on	  a	  pre-­‐treatment	  biopsy	  was	  the	  commonest	  finding	   in	  patients	  
that	  developed	  IGD	  and	  appears	  to	  be	  an	  important	  risk	  factor	  for	  the	  development	  of	  
IGD	   (Levitsky	  et	  al.,	  2012)	   (Levitsky	   J	  et	  al.	  2012).	  Other	   risk	   factors	   for	   IGD	   included	  
previously	  treatment	  naïve	  to	  IFN	  based	  therapy,	  use	  of	  PEG-­‐IFN	  alpha	  -­‐	  2a,	  a	  high	  pre-­‐
treatment	   alkaline	   phosphatase	   and	   a	   reduction	   in	   immunosuppression	   prior	   to	  
commencing	   AVT	   (Levitsky	   et	   al.,	   2012).	   The	   risk	   of	   ACR	   precipitated	   by	   treatment	  
overall,	  appears	  to	  be	  low	  (0-­‐5%)(Castells	  et	  al.,	  2005,	  Oton	  et	  al.,	  2006).	  
	  
7.2.5	  New	  DAAs	  post	  liver-­‐transplantation	  
Due	   to	   the	   recurrence	   of	   HCV	   and	   difficulty	   in	   offering	   re-­‐transplantation	   in	   the	  
context	   of	   finite	   donor	   resource	   and	   increasing	   demand	   for	   transplantation,	   several	  
teams	  have	  utilized	  PI	  based	  triple	  therapy	  in	  the	  post	  transplant	  population.	  This	  has	  
been	  primarily	  driven	  by	  clinical	  need	  with	  several	  authors	  reporting	  results.	  However,	  
given	   the	   first	   DAAs	   significant	   drug-­‐drug	   interactions	   (DDI)	   it	   further	   increases	   the	  
complexity	  of	  triple	  based	  therapy.	  Both	  boceprevir	  and	  telaprevir	  inhibit	  the	  P450	  3A	  




(Garg	   et	   al.,	   2011,	   Coilly	   et	   al.,	   2012).	   Initial	   opinion	   was	   cautious	   given	   a	   76	   fold	  
increase	  in	  tacrolimus	  exposure	  with	  concomitant	  usage	  of	  telaprevir	  (Charlton,	  2011)	  
but	   proactive	   clinicians	   faced	   with	   little	   other	   option	   have	   reported	   firstly	   single	  
centre,	  on-­‐response	  treatment	  data	  but	  more	  recently	  SVR	  12	  data.	  Clinical	  series	  have	  
encompassed	  a	  wide	  heterogeneity	  of	  patients	  with	  one	  study	  enrolling	  approximately	  
one	   quarter	   of	   patients	   with	   recurrent	   cirrhosis	   and/or	   re-­‐transplant	   and/or	   co-­‐
infection	  with	  HIV	  (Coilly	  A,	  2013).	  	  To	  increase	  tolerability	  many	  centres	  have	  utilized	  a	  
PEG/RIB	   lead	   in	   prior	   to	   commencement	   of	   PI.	   Several	   themes	   emerge:	   firstly,	   that	  
dose	  reduction	  of	  immunosuppression	  (CNIs)	  is	  feasible	  with	  boceprevir	  and	  telaprevir;	  
secondly,	  that	  discontinuations	  rates	  and	  tolerability	  are	  a	  significant	  issue	  with	  deaths	  
related	  to	  antiviral	  therapy	  (sepsis),	  anaemia,	  requiring	  blood	  transfusion	  and	  growth	  
factor	   support,	   and	   other	   side	   effects	   such	   as	   renal	   failure	   apparent	   with	   >25%	  
discontinuation	   rate;	   thirdly,	   that	  encouraging	  on	   treatment	   response	   rates	   translate	  
into	  only	  moderately	  acceptable	  SVR12	  rates	  of	  between	  48-­‐58%	  for	  G1	  patients	  (Coilly	  
A,	  2013,	   Stravitz,	   2013,	  Pungpapong	  et	  al.,	   2013).	  Whilst	   this	   is	   an	   improvement	   the	  
amount	   of	   resource	   and	   time	   required	   to	   deliver	   PI	   based	   triple	   therapy	   in	   post-­‐LT	  







Table	  2.5	  Experience	  of	  use	  of	  triple	  therapy	  for	  HCV	  recurrence	  post	  transplantation.	  
AVT,	  anti-­‐viral	  therapy;	  BOC,	  boceprevir;	  EVR,	  early	  virologica	  response;	  EOTR,	  end	  of	  treatment	  of	  
response;	  SVR,	  sustained	  virologic	  response;	  NA,	  not	  available.	  
Case	  reports	  have	  emerged	  on	  the	  use	  of	  daclatasvir	  (a	  NS5A	  complex	  inhibitor)	  with	  
PEG/RBV	   and	   sofusbuvir	   (SOF)	   in	   patients	   with	   FCH	   and	   severe	   HCV	   recurrence	  
respectively	  resulting	  in	  a	  SVR(Fontana	  et	  al.,	  2012).	  Furthermore,	  a	  further	  case	  report	  
demonstrated	   PEG-­‐free	   therapy	   pre-­‐LT	   abrogated	   HCV	   viral	   recurrence	   (Kwo	   and	  
Tector,	  2013).	  In	  a	  phase	  2	  open	  label	  study,	  patients	  with	  HCV	  received	  SOF	  and	  RBV	  
prior	  to	  LT	  (Curry	  MP,	  2013).	  Of	  39	  evaluable	  patients,	  25	  (64%)	  achieved	  SVR12.	  The	  
only	   factor	   independently	   associated	   with	   likelihood	   of	   HCV	   recurrence	   was	  
continuous	  number	  of	  days	   that	  HCV	  RNA	  was	  not	  detected	  using	  a	  highly	   stringent	  
assay	  (<10	  IU/ml)	  before	  LT	  (OR	  1.042,	  1.012-­‐1.083,	  p=0.0007).	  SOF	  and	  RBV	  were	  well	  
tolerated	  with	  no	  drug-­‐drug	  interactions	  post-­‐LT.	  This	  early	  data	  would	  suggest	  a	  role	  
for	  SOF	  and	  RBV	  to	  help	  reduce	  recurrence	  of	  HCV	  post-­‐LT.	  
	  
A	   prospective,	   multi-­‐center	   study	   (n=40)	   assessing	   SOF	   +	   RBV	   for	   24	   weeks	   for	   the	  
treatment	   of	   established	   HCV	   recurrence	   post-­‐LT	   demonstrated	   no	   drug-­‐drug	  










































interactions	  and	  very	  few	  significant	  side-­‐effects	  (Charlton	  MR,	  2013).	  100%	  of	  patients	  
had	   a	   rapid	   virologic	   response	   (RVR)	   and	   end	   of	   treatment	   response	   (EOTR)	  
respectively,	  although	  final	  SVR4	  rates	  were	  only	  77%.	  Potentially,	  a	  longer	  duration	  of	  
AVT	  may	  result	  in	  improved	  SVR	  rates.	  	  
	  
Post	   transplant,	  SOF+RBV	  with	  or	  without	  PEG	  has	  been	  available	   for	  compassionate	  
use	  on	  an	  individual	  case	  basis	  for	  patients	  with	  severe	  HCV	  recurrence	  post-­‐LT	  (Forns	  
X,	  2013).	  In	  total	  115	  patients	  have	  been	  approved,	  with	  44	  patients	  having	  received	  a	  
SOF	  containing	  regimen	  (32	  x	  SOF	  +RBV;	  12	  x	  SOF	  +	  PEG/RBV	  SVR	  4	  and	  12	  rates	  for	  
the	  SOF	  +	  RBV	  group	  were	  74%	  and	  60%	  respectively	  compared	  to	  56%	  and	  50%	  in	  the	  
SOF	   +	   PEG/RBV	   group.	   71%	   of	   patients	   demonstrated	   evidence	   of	   re-­‐compensation	  
with	  resolution	  of	  ascites,	   improvement	   in	  encephalopathy,	   improvement	   in	  bilirubin	  
and	  MELD.	  	  Overall,	  SOF-­‐based	  therapy	  was	  well	  tolerated	  in	  this	  very	  sick	  population	  
with	   minimal	   side	   effects,	   although	   25%	   patient	   died	   due	   to	   disease	   progression,	  
reflecting	  the	  true	  compassionate	  nature	  of	  this	  patient	  group.	  It	  maybe	  that	  AVT	  with	  
the	  new	  DAAs	  will	  allow	  for	  rescue/salvage	  therapy	  in	  patients	  whom	  otherwise	  would	  
need	  reconsideration	  for	  re-­‐LT.	  In	  a	  study	  using	  SOF	  and	  low	  ascending	  dose	  RBV	  for	  24	  
weeks,	  all	  patients	  achieved	  a	  RVR	  and	  EOT	  virologic	  response	  whilst	  70%	  achieved	  a	  
SVR	  (Charlton	  et	  al.,	  2015b).	  The	  SVR	  in	  patients	  without	  cirrhosis	  was	  75%	  compared	  
to	  62.5%	   in	  patients	  with	   cirrhosis.	   	   The	  SOLAR-­‐1	   study	  assessed	   ledipasvir,	   SOF	  and	  
RBV	  for	  12	  or	  24	  weeks	  in	  patients	  with	  genotype	  1	  or	  4	  HCV	  with	  and	  without	  cirrhosis	  
post	  transplantation	  (Charlton	  et	  al.,	  2015a).	  Overall	  reported	  SVR12	  rates	  were	  75%.	  




the	  degree	  of	  severity	  of	  cirrhosis	  (Child-­‐Pugh	  A	  88%,	  Child-­‐Pugh	  B	  85%,	  Child-­‐Pugh	  C	  
60%).	  The	  data	  demonstrated	  that	  12	  weeks	  was	  as	  effective	  as	  24	  weeks	  (Charlton	  et	  
al.,	  2015a).	  The	  ALLY-­‐1	  study	  was	  performed	  in	  53	  patients	  with	  the	  use	  of	  daclatasvir	  
and	   SOF	   for	   12	  weeks	   (Poordad	  et	   al.,	   2016).	   The	  overall	   SVR	  12	   rate	  was	  94%.	   Sub	  
analysis	  of	  viral	  genotype	  demonstrated	  a	  higher	  SVR12	  rate	  in	  patients	  with	  genotype	  
1	   infection	   (94%)	  compared	   to	  patients	  with	  genotype	  3	   infection	   (91%).	  The	  French	  
prospective	  CUPILT	   study	   included	  130	   transplant	   patients,	   one	   third	  of	  whom	  were	  
cirrhotic	  treated	  with	  daclatasvir,	  SOF	  with	  or	  without	  RBV	  for	  12	  or	  24	  weeks	  (Coilly	  A,	  
2015).	  SVR12	  rates	  were	  67%	  and	  100%	  in	  patients	  with	  or	  without	  RBV	  for	  12	  weeks	  
compared	  to	  96%	  and	  97%	  in	  patients	  with	  or	  without	  RBV	  in	  the	  24	  week	  arm.	  These	  
data	  would	   suggest	   RBV	   is	   not	   essential	   especially	   renal	   dysfunction	  was	   a	   common	  
observation	  (Coilly	  A,	  2015).	  The	  use	  of	  the	  Abbvie	  3D	  regimen	  (paritaprevir/ritonavir,	  
dasabuvir,	   ombitasvir)	   with	   RBV	   requires	   adjustments	   in	   the	   CNI	   dose	   due	   to	   the	  






The	  aims	  of	  this	  thesis	  were	  to	  investigate	  possible	  non-­‐invasive	  markers	  of	  fibrosis	  in	  
patients	  with	  recurrent	  HCV	  post	  liver	  transplantation.	  I	  plan	  to	  determine	  the	  role	  of	  
both	  recipient	  and	  donor	  IL-­‐28B	  genotype	  on	  HCV	  recurrence	  and	  on	  response	  to	  AVT	  
in	  the	  post	  transplant	  period.	  I	  will	  also	  investigate	  the	  role	  of	  CXCL10	  as	  predictor	  of	  
fibrosis,	  and	  given	  its	  role	  as	  a	  marker	  of	  ISG	  activation,	  alone	  and	  combination	  with	  IL-­‐
28B	   genotype	   to	   predict	   treatment	   response	   to	   AVT.	   Finally,	   I	   will	   investigate	   as	   to	  
whether	   miRNAs	   can	   help	   predict	   HCV	   recurrence	   and	   investigate	   their	   role	   as	  
potential	  biomarkers	  for	  HCV	  recurrence	  post	  transplantation.	  
	  
The	  following	  hypotheses	  will	  be	  tested:	  
	  
Hypothesis	   1:	   Recipient	   and	   donor	   rs12979860	   IL-­‐28B	   genotype	   predict	   the	  
development	  of	  fibrosis	  and	  HCV	  recurrence	  post	  liver	  transplantation.	  
Hypothesis	  2:	  CXCL10	   levels	  predict	   the	  development	  of	   fibrosis	  and	  HCV	  recurrence	  
post	   liver	   transplantation,	   and	   in	   combination	   with	   recipient	   rs12979860	   IL-­‐28B	  
genotype	  help	  predict	  response	  to	  anti-­‐viral	  therapy.	  
Hypothesis	  3:	  miRNA	  expression	  profiles	  from	  liver	  grafts	  can	  distinguish	  the	  severity	  
of	  HCV	  recurrence	  post	  liver	  transplantation.	  











1.	  Patients	  and	  specimens	  
	  
Using	   the	   prospectively	  maintained	   Institute	   of	   Liver	   Studies,	   King’s	   College	  Hospital	  
post	   liver	   transplant	   database,	   all	   patients	   that	   had	   undergone	   transplantation	   for	  
chronic	  hepatitis	  C	  virus	  infection	  were	  identified.	  This	  database	  provides	  demographic	  
and	   clinical	   data	  pre-­‐	   transplantation.	  Key	  donor	  data	   is	   also	  provided	   (age,	  weight).	  
Data	   from	   the	   post-­‐transplant	   period	   includes	   choice	   of	   immunosuppression	   as	  well	  
episodes	  of	  acute	  cellular	  rejection	  and	  survival	  (patient	  and	  graft).	  Although	  data	  was	  
available	   from	   1996	   –	   2011,	   data	   was	   excluded	   from	   1996-­‐2000	   due	   to	   paucity	   of	  
clinical	   data	   and	   availability	   of	   liver	   biopsies,	   DNA,	   plasma	   and	   serum	   samples.	  
Therefore	  only	  data	  from	  2000-­‐2011	  was	  included.	  	  	  
	  	  
1.1 Liver	  biopsies	  
	  
In	   the	   immediate	   post	   transplant	   period	   (0-­‐4	   weeks),	   the	   need	   for	   liver	   biopsy	   is	  
dictated	   by	   clinical	   need.	   Indications	   for	   liver	   biopsy	   impaired	   graft	   function	   and/or	  
concerns	  regarding	  the	  possibility	  of	  acute	  cellular	  rejection.	  Thereafter,	  protocol	  liver	  
biopsies	  are	  performed	  at	  12	  months	  post	  liver	  transplantation	  and	  then	  on	  an	  annual	  
basis	  in	  all	  patients	  that	  have	  undergone	  liver	  transplantation	  for	  HCV	  at	  King’s	  College	  
Hospital.	  Liver	  tissue	  specimens	  are	  dissected	  and	  stored	  in	  paraffin	  before	  being	  sliced	  
at	  8mm	  intervals	  and	  placed	  on	  slides.	  An	  adequate	  sized	  biopsy	  was	  defined	  as	  having	  







1.2 Recurrent	  hepatitis	  C	  virus	  
	  
Recurrence	  of	  hepatitis	  C	  in	  the	  allograft	  was	  diagnosed	  when	  there	  was	  biochemical	  
evidence	   of	   allograft	   hepatitis	   associated	   with	   histological	   changes	   consistent	   with	  
hepatitis	   due	   to	   HCV	   in	   the	   absence	   of	   other	   causes.	   Biopsies	   were	   performed	  
routinely	  at	  7	  days	  and	  12	  months	  or	   in	  the	  presence	  of	  graft	  dysfunction	  in	  patients	  
with	  HCV.	  In	  non-­‐HCV	  patients,	  biopsies	  were	  performed	  at	  7	  days	  or	  in	  the	  presence	  
of	  graft	  dysfunction.	  All	  biopsies	  in	  patients	  with	  HCV	  were	  read	  by	  a	  single	  pathologist	  
(AQ)	  who	  was	   blinded	   to	   the	   diagnosis	   of	   clinical	   data	   and	   scored	   according	   to	   the	  
modified	  Ishak	  score	  with	  0	  as	  no	  fibrosis	  and	  6	  as	  frank	  cirrhosis	  (Ishak	  et	  al.,	  1995).	  
For	  purposes	  of	  the	  studies	   included	  in	  this	  thesis,	  biopsies	  taken	  at	  12	  months	  were	  
graded	   as	   demonstrating	   either	   slow	   fibrosis	   progression	   (F<2)	   or	   fast	   fibrosis	  
progression	  (F≥2).	  	  
	  
1.3 DNA	  samples	  
	  
Samples	  of	  DNA	  are	  extracted	  from	  whole	  blood	  from	  recipients	  and	  donor	  at	  the	  time	  
of	  liver	  transplantation.	  These	  are	  stored	  at	  -­‐20oC.	  Donor	  and	  recipient	  samples	  were	  
identified	   by	   using	   the	   HCV	   post	   transplant	   database.	   DNA	   concentrations	   were	  
measured	   using	   the	   Nanodrop	   (ND1000	   spectrophometer)	   to	   ensure	   adequate	  
template	  concentration	  prior	  to	  amplification.	  A	  DNA	  concentration	  of	  10-­‐20	  ng/μl	  was	  
required.	  	  A	  minimum	  volume	  of	  6µl	  was	  required	  for	  each	  PCR	  experiment.	  




1.4 Plasma	  and	  serum	  samples	  
	  
Plasma	  and	  serum	  samples	  were	  stored	  at	  -­‐80oC.	  	  Plasma	  samples	  are	  routinely	  taken	  
at	  the	  time	  of	  HCV	  viral	  load	  quantification.	  Recipient	  serum	  samples	  are	  taken	  at	  the	  
time	   of	   liver	   transplantation	   assessment	   and	   time	   of	   liver	   transplantation.	   Donor	  
serum	  samples	  are	  taken	  at	  the	  time	  of	  donor	  organ	  procurement.	  
	  
1.5	  HCV	  treatment	  and	  outcomes	  
	  
HCV	  anti-­‐viral	  therapy	  consisted	  of	  pegylated	  interferon	  (PEG-­‐IFN)	  α-­‐2a	  180mcg/week	  
and	  weight-­‐based	  ribavirin	  (1000mg/day	  <	  75kg	  or	  1200mg/day	  >	  75kg)	  for	  48	  weeks	  
irrespective	  of	   genotype.	  A	   low	  dose	  accelerating	   regimen	   (LADR)	  was	   considered	   in	  
patients	   deemed	   high	   risk	   for	   hepatic	   decompensation.	   Treatment	   outcomes	   were	  
classified	   according	   to	   EASL	   guidelines	   (European	   Association	   for	   the	   Study	   of	   the,	  
2011).	  A	  rapid	  virological	  response	  (RVR)	  was	  defined	  as	  serum	  HCV	  RNA	  negativity	  at	  
week	  4;	  an	  early	  virological	  response	  (EVR)	  was	  defined	  as	  serum	  HCV	  RNA	  negativity	  
or	  >2	  log10	  decline	  in	  HCV	  RNA	  compared	  to	  baseline	  at	  week	  12;	  a	  non	  responder	  (NR)	  
was	  defined	  as	  a	  <2	  log10	  drop	  in	  HCV	  RNA	  at	  week	  12	  compared	  to	  baseline	  and	  those	  
with	   detectable	   HCV	   RNA	   in	   serum	   at	   week	   24;	   and	   a	   responder-­‐relapser	   (RR)	   was	  
defined	  as	  an	  undetectable	  HCV	  RNA	  at	   the	  end	  of	   treatment	   (EOTR)	  but	  detectable	  
HCV	  RNA	  at	  24	  weeks	  post	  cessation	  of	  therapy;	  	  a	  sustained	  virological	  response	  (SVR)	  







The	   experiments	   performed	   in	   this	   thesis	   were	   in	   accordance	   with	   the	   Helsinki	  
Principles.	  As	  the	  samples	  used	  were	  stored,	  archived	  material,	  individual	  consent	  was	  
not	  obtained.	   The	   study	  protocols	  were	  approved	  by	   the	  Ethics	  Committee	  of	  King’s	  
College	  Hospital,	  London,	  United	  Kingdom	  before	  commencement	  of	  the	  experiments.	  
	  
Chapter	  VI	  
Ethics	  number:	  11/NE/0322.	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Ethics	  number:	  08/H0704/117	  
	  
Chapter	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Ethics	  number:	  05/Q0703/329.	  




3.	  rs12979860	  IL-­‐28B	  allele	  specific	  polymerase	  chain	  reaction	  	  
3.1	  Agarose	  gel	  production	  
A	  2%	  agarose	  gel	   (12	  x	  24	  well)	  was	  prepared	   (8g	  Agarose	   in	  400ml	  of	  TE	   (Tris-­‐EDTA	  
buffer)).	   10`ul	   of	   Nancy-­‐520	   DNA	   gel	   stain	   was	   added	   to	   the	   gel,	   which	   acted	   as	   a	  
fluorescent	  stain	  for	  dsDNA	  on	  the	  agarose	  electrophoresis	  gel.	  	  
	  
3.2	  Primers	  
For	   each	   allele,	   there	   is	   a	   primer	   with	   the	   variant	   encoded	   at	   the	   5’	   end,	   and	   a	  
common	  primer,	  at	  a	  final	  concentration	  of	  5uM	  in	  the	  reaction	  mixture.	   In	  addition,	  
each	  polymerase	  chain	   reaction	   (PCR)	  contains	  an	   invariant	  DRB	  primer	  pair	  at	  2uM,	  
serving	  as	  an	  internal	  control.	  Each	  reaction	  thus	  contains	  4	  individual	  primers:	  
Il28B(60)3_T_F	  GCTCCCCGAAGGCGT	  	  	  
Il28B(60)3_C_F	  GCTCCCCGAAGGCGC	  	  	  
Il28B	  (60)3_R	  	  	  CACAATTCCCACCACGAGAC	  	  	  	  	  
POS	  (DRB)	  F	  	  	  	  	  tgccaagtggagcacccaa	  	  	  	  	  0.025	  	  	  DST	  	  








3.3	  Chemicals	  and	  reagents	  
3.3.1	  Taq	  polymerase	  
Supplied	  at	  5U/ul	  by	  Qiagen.	  Stored	  at	  -­‐20oC.	  
	  
3.3.2	  PCR	  mix	  
1	  part	  10x	  buffer	  (Qiagen),	  0.2	  part	  DNTP	  100um	  (Roche),	  1.7	  part	  Q	  solution	  (Qiagen)	  
+	  1	  part	  glycerol	  (50%)	  	  +	  0.1	  part	  Mg.	  This	  was	  stored	  at	  4oC	  for	  up	  to	  a	  week	  before	  
being	  changed.	  
	  
3.3.3	  96	  well	  PCR	  plates	  
Thermo-­‐fast,	  non	  skirted	  sterile	  96	  well	  PCR	  plates	  (Sigma-­‐Aldrich	  company	  Ltd,	  Poole,	  
UK)	  were	  used	  for	  these	  experiments.	  
	  
3.3.4	  DNA	  extraction	  
Transplant	  donor	  and	  recipient	  DNA	  is	  extracted	  and	  stored	  as	  per	  legislative	  
requirements.	  	  In	  10	  cases,	  DNA	  was	  extracted	  from	  stored	  samples	  by	  myself.	  The	  
Qiagen	  QIAMP	  DNA	  Blood	  Mini	  Kit	  was	  used	  for	  DNA	  extraction.	  
1. Suspension	  of	  spleen	  cells/blood	  were	  brought	  to	  room	  temperature.	  
2. The	  heating	  block	  was	  turned	  on	  to	  56oC.	  
3. The	  Equilibrate	  Buffer	  AE	  and	  distilled	  water	  were	  brought	  to	  room	  
temperature.	  
4. 	  100μL	  proteinase	  K	  solution	  was	  added	  to	  250μL	  homogenous	  suspension	  of	  




5. 250μL	  Qiagen	  buffer	  AL	  was	  then	  added	  and	  mixed	  well,	  using	  a	  1mL	  filter	  tip	  
pipette.	  
6. The	  sample	  was	  then	  incubated	  for	  10	  minutes	  at	  56o	  C.	  	  
7. The	  sample	  was	  then	  centrifuged	  using	  a	  microcentrifuge	  to	  remove	  drops	  from	  
the	  inside	  lid.	  
8. For	  each	  sample,	  a	  spin	  column,	  4	  collection	  tubes	  and	  a	  1.5mL	  specimen	  tube	  
was	  labeled.	  
9. 200μL	  of	  ethanol	  (100%)	  was	  added	  to	  the	  sample	  and	  mixed	  well	  with	  a	  filter	  
tipped	  pipette.	  
10. The	  samples	  were	  then	  transferred	  to	  spin	  columns,	  ensuring	  not	  to	  wet	  
the	  rims.	  
11. The	  samples	  were	  then	  centrifuged	  (microcentrifuge)	  at	  13000	  rpm	  for	  1	  
minute,	  
12. The	   collection	   tube	   containing	   the	   filtrate	   was	   then	   discarded	   into	   a	  
yellow	   incineration	   bin	   lined	   with	   appropriate	   absorbent	   material	   for	  
disposal.	  
13. AW1	  and	  AW2	  buffers	  were	  then	  decanted	  into	  clean	  20mL	  tubes.	  	  
14. 500μL	  buffer	  AW1	  was	  then	  added	  to	  each	  column.	  
15. Samples	  were	  then	  centrifuged	  at	  13000	  rpm	  for	  1	  minutes.	  The	  collection	  
tube	  containing	  the	  filtrate	  was	  then	  discarded	  into	  a	  yellow	  incineration	  
bin	  lined	  with	  appropriate	  absorbent	  material	  for	  disposal.	  




17. Samples	  were	  then	  centrifuged	  at	  13000	  rpm	  for	  1	  minute.	  The	  collection	  
tube	  containing	  the	  filtrate	  was	  then	  discarded	  into	  a	  yellow	  incineration	  
bin	  lined	  with	  appropriate	  absorbent	  material	  for	  disposal.	  
	  
18. Samples	  were	  then	  centrifuged	  at	  13000	  rpm	  for	  2	  minutes.	  The	  collection	  
tube	  containing	  the	  filtrate	  was	  then	  discarded	  into	  a	  yellow	  incineration	  
bin	  lined	  with	  appropriate	  absorbent	  material	  for	  disposal.	  	  
19. The	  spin	  column	  was	  then	  transferred	  to	  a	  clean	  labeled	  1.5mL	  collection	  
tube	  (not	  a	  microcentrifuge	  tube).	  
20. 100μL	  buffer	  AE	  was	  added	  to	  the	  column.	  
21. Samples	  were	  then	  Incubated	  at	  55o	  C	  for	  10minutes.	  
22. Samples	  were	  then	  centrifuged	  at	  13000	  rpm	  for	  1	  minute.	  
23. Samples	  from	  the	  collection	  tube	  were	  then	  transferred	  to	  a	  clean	  labeled	  
screw-­‐top	  tube,	  checking	  the	  sample	  ID	  .	  
24. 	  500μL	  of	  buffer	  AE	  was	  added	  to	  the	  column.	  
25. Samples	  were	  then	  incubated	  at	  55o	  C	  for	  10minutes.	  
26. Samples	  were	  then	  centrifuged	  at	  13000	  rpm	  for	  1	  minute.	  
27. The	   spin	   column	  was	   then	   discarded	   and	   the	   sample	  was	   transferred	  
from	  the	  collection	  tube	  to	  a	  clean	  labeled	  screw-­‐top	  tube,	  checking	  the	  
sample	  ID	  	  
28. The	   concentration	   and	   purity	   of	   each	   DNA	   extraction	   was	   calculated	  




3.4	  Preparing	  samples	  for	  genotyping	  
The	  IL-­‐28B	  PCR	  was	  performed	  with	  a	  volume	  of	  20µl,	  containing	  14µl	  of	  ‘mastermix’	  
and	  6ul	  of	  DNA	  template.	  	  	  
1. DNA	  samples	  were	  defrosted	  on	  ice	  and	  brought	  to	  room	  temperature.	  48	  
DNA	  samples	  were	  run	  at	  a	  time.	  	  
2. A	  work	  sheet	  was	  labelled	  with	  the	  samples	  that	  were	  going	  to	  be	  used.	  
3. 	  A	  sterile	  96	  well	  plate	  was	  placed	  on	  ice.	  	  
4. 8ul	  of	  cocktail,	  0.2µl	  of	  Taq	  polymerase	  and	  6µl	  of	  primer	  was	  prepared	  for	  
each	  sample	  in	  an	  Eppendorf	  tube	  e.g.	  for	  60	  samples,	  480ul	  cocktail,	  12µl	  
Taq	  polymerase	  and	  360µl	  primer.	  Samples	  were	  then	  vortexed.	  14µl	  of	  the	  
reaction	  mix	  was	  then	  added	  to	  each	  reaction	  well	  for	  each	  sample.	  
5. Next,	  6µl	  of	  DNA	  was	  added	  to	  each	  reaction	  well	  ensuring	  the	  samples	  
were	  mixed.	  
6. The	  PCR	  plate	  was	  then	  covered	  with	  a	  PCR	  plate	  sealer,	  ensuring	  that	  all	  
wells	  were	  covered.	  






3.5	  PCR	  reaction	  
	  
Touch	  down	  PCR:	  
94o	   60s	  
94o	   15s	  
70o	   60s	  (2	  degrees/cycle	  decrement)	  
(5	  cycles)	  
	  
94o	   15s	  
60o	   30s	  (0.5	  degrees	  /cycle	  decrement)	  
72o	   45s	  
(16	  cycles)	  
	  
94o	   15s	  
52o	   30s	  
72o	   60s	  
(12	  cycles)	  
	  
3.6	  Agarose	  gel	  electrophoresis	  
An	  8-­‐channel	  Pasteur	  pipette	  was	  used	  to	  load	  20µl	  of	  sample	  from	  the	  PCR	  plate	  onto	  
the	  gel	  and	  then	  run	  at	  250V	  (Hybaid	  PS250,	  Tank	  supplied	  by	  Alpha	  Laboratories)	  at	  
maximum	  amps	  for	  20	  minutes.	  
	  
3.7	  Interpretation	  of	  results	  
For	  each	  polymorphism	  (IL-­‐28B),	   two	  PCR’s	  were	  performed.	  At	   least	  one	  band	  must	  
be	  visible	   in	  each	  PCR	   for	  a	   result	   to	  be	  valid.	   If	  no	  band	   is	  visible	   in	  either	  PCR,	   the	  
result	   was	   repeated	   or	   discounted.	   A	   positive	   band	   corresponding	   the	   respective	  
alleles	   could	   only	   be	   interpreted	   as	   homozygous	   if	   the	   internal	   control	   band	   for	   the	  
other	   allele	  was	   clearly	   present	   and	   the	   allele	   specific	   band	  was	   absent.	  My	   results	  






Figure	  3.1	  Agarose	  gel	  electrophoresis	  photograph	  pf	  the	  PCR	  products	  obtained	  with	  
the	  IL-­‐28B	  forward	  and	  reverse	  primers.	  First	  lane	  demonstrates	  the	  negative	  control.	  






4.	  CXCL10	  quantification	  
	  
The	  commercially	  available	  R&D	  systems	  ELISA	  Quantikine	  kit	  was	  used.	  	  
4.1	  Reagent	  preparation	  
All	   reagents	  were	  brought	   to	   room	   temperature.	  Plasma	  samples	  were	  defrosted	  on	  
ice.	   20ml	   of	   wash	   buffer	   concentrate	   was	   diluted	   into	   500mls	   of	   deionised	   water.	  
Colour	  reagents	  A	  and	  B	  were	  mixed	  together	  within	  15	  minutes	  of	  use.	  200µL	  of	  the	  
resultant	   mixture	   was	   added	   to	   each	   well.	   The	   CXCL10	   Standard	   was	   reconstituted	  
with	  1.0ml	  of	  deionised	  water.	  A	  resultant	  stock	  solution	  of	  5000pg/ml	  was	  produced	  
which	  was	   allowed	   to	   sit	   for	   15	  minutes	  with	   gentle	   agitation.	   Seven	   polypropylene	  
tubes	   were	   taken	   and	   labelled	   500pg/mL,	   250mg/mL,	   125pg/mL,	   62.5pg/mL,	  
31.2pg/mL,	   15.6pg/mL	   and	   7.8pg/mL	   900uL	   of	   calibrator	   diluent	   RD6Q	   was	   then	  
pipetted	   into	  the	  tube	   labelled	  500pg/ml.	  500uL	  of	  calibrator	  diluent	  RD6Q	  was	  then	  
subsequently	  pipetted	  into	  the	  remaining	  tubes.	  100uL	  of	  the	  stock	  solution	  was	  then	  
pipetted	  into	  the	  500pg/mL	  tube	  before	  a	  serial	  dilution	  was	  performed	  taking	  500uL	  
from	  each	  tube	  and	  placing	  it	  into	  the	  next	  subsequent	  tube.	  The	  500pg/mL	  standard	  
served	  as	  the	  high	  standard	  whilst	  the	  calibrator	  diluent	  RD6Q	  served	  as	  zero	  standard	  
(0	  pg/mL).	  
	  




4.2	  Assay	  procedure	  
1. 75µL	  of	  assay	  diluent	  RD1-­‐56	  was	  added	  to	  each	  well.	  
2. 75µL	  of	  Standard	  and	  then	  75µL	  of	  plasma	  was	  added	  to	  each	  well.	  Patient	  
samples	  were	  performed	  in	  triplicate.	  A	  mean	  value	  of	  the	  triplicates	  were	  
used	  for	  analysis.	  The	  plate	  was	  then	  covered	  and	  incubated	  for	  2	  hours	  at	  
room	  temperature.	  	  
3. Each	  well	  was	  then	  aspirated	  and	  then	  washed	  using	  400µL	  of	  wash	  buffer.	  
Complete	  removal	  was	  performed.	  This	  process	  was	  repeated	  3	  times	  for	  a	  
total	  of	  4	  washes.	  After	  the	  last	  wash	  any	  remaining	  fluid	  was	  removed	  by	  
balloting	  the	  plate.	  
4. 200µL	   of	   CXCL10	   conjugate	   was	   then	   added	   to	   each	   well.	   The	   plate	   was	  
covered	   and	   then	   incubated	   for	   a	   further	   2	   hours	   at	   room	   temperature.	  
Each	  well	  was	  then	  aspirated	  and	  washed	  as	  explained	  above.	  	  
5. 200µL	   of	   substrate	   solution	   was	   then	   added	   to	   each	   well	   before	   being	  
incubated	   for	   30	   minutes	   at	   room	   temperature.	   Direct	   exposure	   to	   light	  
was	  avoided.	  	  
6. 50µL	   of	   stop	   solution	   was	   then	   added	   to	   each	   well.	   The	   colour	   of	   the	  
solution	  in	  the	  wells	  changed	  from	  blue	  to	  yellow.	  To	  ensure	  that	  adequate	  
mixing	  had	  occurred,	  the	  plate	  was	  gently	  tapped.	  	  
7. Within	  30	  minutes,	  the	  optical	  density	  was	  determined	  for	  each	  well	  using	  a	  
microplate	  reader	  set	  to	  450	  nm.	  








1. 10µm	  paraffin	  embedded	  liver	  tissue	  sections	  were	  selected.	  Sections	  were	  
placed	   in	  a	  1.5ml	   reaction	   tube.	  800µL	  of	  xylene	  was	  added	  and	  vortexed	  
for	  4	  seconds	  (3	  times).	  Samples	  were	  then	  incubated	  for	  2	  minutes	  at	  room	  
temperature	  (RT),	  vortexed	  for	  4	  seconds	  (3	  times)	  and	  then	  incubated	  for	  5	  
minutes	   at	  RT.	   Samples	  were	   then	   centrifuged	   for	   2	  minutes	   (13000rpm).	  
The	   supernatant	   was	   discarded	   by	   aspiration	   and	   tubes	   capped	   to	   avoid	  
tissue	  sections	  from	  drying.  
2. Step	  1.	  was	  then	  repeated.	  
3. 800uL	   of	   absolute	   ethanol	   (100%)	  was	   then	   added	   to	   each	   reaction	   tube	  
and	   then	   vortexed	   for	   4	   seconds	   (3	   times).	   Reaction	   tubes	   were	   then	  
centrifuged	  for	  2	  minutes	  (13,000	  x	  g).	   	  The	  supernatant	  was	  discarded	  by	  
aspiration.	  
4. 800ul	  of	  70%	  ethanol	  was	  then	  added	  to	  each	  reaction	  tube	  and	  vortexed	  
for	   4	   seconds	   (3	   times).	   Samples	   were	   then	   centrifuged	   for	   2	   minutes	  
(13,000	  x	  g).	  The	  supernatant	  was	  then	  discarded	  by	  aspiration.	  
5. 70%	  ethanol	  was	  removed	  and	  the	  reaction	  tubes	  were	  centrifuged	  for	  20	  
seconds	  and	   the	   residual	   fluid	  carefully	   removed	  with	  a	   fine	  bore	  pipette.	  
The	  reaction	  tubes	  were	  opened	  and	  incubated	  for	  5	  minutes	  at	  55o	  C	  (in	  a	  





5.2	  RNA	  isolation	  from	  liver	  tissue	  sections	  
	  
1. 60µL	  of	  tissue	  lysis	  buffer	  and	  10uL	  10%	  SDS	  (sodium	  dodecyl	  sulphate)	  was	  
added	  to	  each	  deparaffinised	  tissue	  pellet	  (sample).	  Each	  sample	  was	  then	  
vortexed	  for	  4	  seconds	  (3	  times)	  and	  centrifuged	  (13,000	  rpm).	  Then	  30µL	  
Proteinase	   K	   working	   solution	   was	   added	   and	   vortexed	   for	   4	   seconds	   (3	  
times),	   centrifuged	   and	   then	   incubated	   for	   12	   hours	   at	   55o	   C	   	   in	   a	  water	  
bath.	  
2. 200µL	  of	  binding	  buffer	  and	  200µL	  absolute	  ethanol	   (100%)	  was	  added	  to	  
each	  sample	  and	  then	  vortexed	  for	  4	  seconds	  (3	  times).	  
3. The	  high	  pure	  filter	  microtube	  (HPMT)	  was	  combined	  with	  a	  collection	  tube	  
and	   each	   lysate	   was	   individually	   pippetted	   into	   the	   upper	   reservoir	   and	  
then	  centrifuged	  for	  30	  seconds	  (8,000	  rpm)	  in	  a	  micro	  centrifuge.	  The	  flow-­‐
through	  was	  then	  discarded.	  	  
4. The	  samples	  were	  then	  centrifuged	  for	  1	  minute	  at	  maximum	  speed	  to	  dry	  
the	  filter.	  
5. 30µL	  DNase	   solution	   (3µL	  DNase	   Incubation	   Buffer	   and	   27µL	  DNase)	  was	  
then	  added	  and	  the	  samples	  were	  incubated	  for	  15	  minutes	  at	  RT.	  
6. 300µL	  Wash	  Buffer	  I	  working	  solution	  was	  added	  to	  the	  upper	  reservoir	  and	  
centrifuged	   for	   15	   seconds	   (8,000	   rpm).	   The	   follow	   through	   was	   then	  
discarded	   and	   300µL	   Wash	   Buffer	   II	   working	   solution	   was	   added	   to	   the	  
upper	   reservoir	   and	   then	   centrifuged	   for	   15	   seconds	   (8,000	   rpm).	   The	  




7. Again	   200µL	   Wash	   Buffer	   II	   working	   solution	   was	   added	   to	   the	   upper	  
reservoir	   and	   centrifuged	   for	   15	   seconds	   (8,000	   rpm).	   The	   follow	   through	  
was	  then	  discarded.	  
8. The	   HPMT	   tubes	   were	   then	   placed	   in	   a	   fresh	   collection	   tube	   and	   then	  
centrifuged	   for	   2	   minutes	   at	   maximum	   speed	   and	   then	   HPMT	   tube	   was	  
placed	   in	  a	   fresh	  1.5ml	   reaction	   tube	  and	  20µL	  Elution	  Buffer	  was	  added.	  
Samples	  were	  then	  incubated	  for	  1	  minute	  at	  room	  temperature.	  Samples	  
were	  then	  centrifuged	  for	  1	  minute	  (8,000	  rpm).	  
9. The	  eluate	  was	  reloaded	  (contents	  of	  the	  tube);	  incubated	  for	  1	  additional	  
minute	  at	  RT	  and	  then	  centrifuged	  for	  1	  minute	  (8,000	  rpm).	  
10. The	  micro-­‐centrifuge	   tube	   contained	   the	   eluted	   RNA.	   Samples	  were	   then	  
centrifuged	  for	  2	  minutes	  at	  13,000g	  and	  the	  supernatant	  was	  transferred	  
to	   a	   fresh	   1.5ml	   reaction	   tube	   without	   disturbing	   the	   glass	   fibres	   at	   the	  
bottom	  of	   the	  original	   tube	  before	  photometric	  determination	  of	   the	  RNA	  
concentration.	  	  
11. Then	  1.2µL	  of	  each	  sample	  was	  checked	  for	  purity	  (ratio	  of	  260	  to	  280	  nm)	  









5.3	  De-­‐paraffinisation	  and	  RNA	  isolation	  experiments	  using	  normal	  liver	  tissue	  
	  
Using	  the	  methods	  described	  in	  section	  5.1	  and	  5.2,	  normal	  liver	  tissue	  was	  taken	  and	  
used	  in	  order	  to	  ensure	  an	  adequate	  yield	  of	  RNA.	  	  6	  samples	  were	  used.	  The	  results	  
are	  listed	  below	  demonstrating	  suitable	  concentrations	  and	  purity.	  A	  minimum	  of	  1ng	  
per	  sample	  of	  total	  RNA	  was	  required.	  The	  ratio	  of	  absorbance	  at	  260nm	  and	  280	  nm	  
was	  used	  to	  assess	  the	  purity.	  
	  
	  
Sample	  Number	   Concentration	  (ng/µL)	   Purity	  (260nm/280nm)	  
1	   3.0	   1.39	  
2	   88.9	   2.11	  
3	   60.3	   2.14	  
4	   34.2	   1.38	  
5	   30.4	   1.42	  
6	   86.1	   1.87	  
	  
Table	  3.1	  Concentration	  and	  purity	  of	  RNA	  yield	  in	  normal	  liver	  tissue.	  




5.4	  De-­‐paraffinisation	  and	  RNA	  isolation	  from	  study	  samples	  
	  
Study	   samples	   used,	   were	   stored	   samples	   and	   although	   adequate	   RNA	   yields	   are	  
described	   in	  the	   literature	  we	  wanted	  to	  ensure	  an	  adequate	  yield	  was	  possible	  with	  
our	   samples.	   Using	   the	  methods	   described	   in	   5.1	   and	   5.3,	   samples	   from	   6	   patients	  
were	  processed	  initially.	  The	  results	  are	  listed	  below	  of	  the	  concentrations	  and	  purity	  
(Table	  3.2).	  Finally,	  the	  methods	  were	  repeated	  for	  the	  study	  cohort	  (Table	  3.3).	  
	  
	  
Sample	  Number	   Concentration	  (ng/µL)	   Purity	  (260nm/280nm)	  
1	   5.3	   6.0	  
2	   15.1	   2.21	  
3	   8.2	   1.43	  
4	   15.0	   1.78	  
5	   3.8	   1.63	  
6	   19.1	   1.97	  
	  










Sample	  Number	   Concentration	  (ng/uL)	   Purity	  (260nm/280nm)	  
Group	  A	  1	   5.0	   6.41	  2	   15.4	   2.33	  3	   8.2	   1.43	  4	   38.6	   2.12	  5	   15.7	   1.81	  6	   4.4	   2.0	  7	   5.0	   6.41	  8	   15.4	   2.33	  9	   8.2	   1.43	  10	   38.6	   2.12	  11	   15.7	   1.81	  
	  
Sample	  Number	   Concentration	  (ng/uL)	   Purity	  (260nm/280nm)	  
Group	  B	  
1	   19.1	   1.97	  
2	   5.5	   1.70	  
3	   20.8	   2.07	  
4	   8.3	   0.76	  
5	   19.1	   1.97	  
6	   6.9	   0.9	  
7	   5.5	   1.7	  
8	   20.8	   2.07	  
9	   3.8	   1.55	  
	  
Sample	  Number	   Concentration	  (ng/uL)	   Purity	  (260nm/280nm)	  
Group	  C	  
1	   14.9	   2.03	  
2	   16.1	   1.98	  
3	   7.5	   1.83	  
4	   15.0	   1.78	  
5	   52.5	   1.87	  
	  
Sample	  Number	   Concentration	  (ng/uL)	   Purity	  (260nm/280nm)	  
Group	  D	  
1	   5.8	   2.08	  
2	   12.9	   1.91	  
3	   1.3	   1.93	  
4	   3.8	   1.5	  
	  





6.	  FlashTag	  RNA	  labelling	  
	  
FlashTag	  labelling	  allows	  for	  the	  RNA	  to	  be	  used	  for	  analysis	  by	  Affymetrix	  GeneChips	  
miRNA	  Arrays.	  The	  process	  involves	  2	  parts:	  tailing	  followed	  by	  ligation	  of	  the	  
biotinylated	  signal	  molecule	  to	  the	  target	  RNA	  sample.	  
	  
	  
Figure	  3.2	  FlagTag	  RNA	  labelling	  	  






6.1	  Poly	  (A)	  Tailing	  
1. The	  volume	  of	  RNA	  was	  adjusted	  to	  8µL	  using	  nuclease	  free	  water	  and	  then	  
transferred	   to	   ice.	   2µL	   of	   RNA	   Spike	   Control	   Oligos	   	   (Genisphere	   Inc.	  
Hatfield)	  was	  added	  to	  each	  sample	  before	  returning	  to	  ice	  (total	  volume	  10	  
µL).	  
2. 	  The	   ATP	   mix	   was	   diluted	   to	   a	   1:500	   using	   1mM	   Tris	   and	   the	   following	  
components	   were	   added	   to	   the	   10µl	   RNA/Spike	   Control	   Oligos,	   for	   a	  
volume	  of	  15µl:	  	  
o 1.5	  µl	  10X	  reaction	  buffer	  
o 1.5	  µl	  25mM	  MnCl2	  
o 1.0	  µl	  diluted	  ATP	  Mix	  
o 1.0	  µl	  PAP	  enzyme	  
3. Samples	  were	   then	  mixed	   and	  microfuged	   and	   incubated	   at	   37oC	   using	   a	  
heat	  block	  for	  15	  minutes.	  
6.2	  FlashTag	  ligation	  
1. Samples	   containing	   15µl	   of	   the	   tailed	   RNA	   were	   microfuged	   and	   then	  
placed	  on	  ice.	  
2. 4	  µl	  5X	  flashTag	   ligatation	  mix	  Biotin	  (Genisphere	  Inc.	  Hatfield)	  was	  added	  
to	  each	  sample	  followed	  by	  the	  addition	  of	  2µl	  T4	  DNA	  ligase.	  
3. Samples	  were	  mixed	  gently	  but	  not	  vortexed	  and	  then	  incubated	  at	  RT	  for	  
30	  minutes.	  
4. The	   reaction	   was	   stopped	   by	   adding	   2.5µl	   Stop	   solution	   and	   the	   final	  
volume	  of	  the	  23.5µl	  ligated	  sample	  was	  mixed	  and	  then	  microfuged.	  
5. Samples	  were	  then	  stored	  at	  -­‐20oC	  for	  up	  to	  2	  weeks	  prior	  to	  hybridization	  




7.	  Affymetrix	  GeneChip	  miRNA	  Array	  procedure	  
	  
7.1	  Hybridization	  
Experiments	   were	   performed	   at	   the	   Genomics	   Centre,	   King’s	   College	   London,	  
Waterloo	  Campus,	  London,	  UK.	  
1. Affymetrix	  hybridisation	  (Genisphere	  Inc.	  Hatfield)	  oven’s	  temperature	  was	  
set	  to	  48oC.	  The	  rpm	  was	  set	  to	  60.	  
2. The	  arrays	  were	  unwrapped	  and	  allowed	  to	  warm	  to	  room	  temperature	  for	  
15	  minutes.	  The	  arrays	  were	  marked	  with	  the	  appropriate	  sample	  number.	  
3. A	  20µl	  pipette	  tip	  was	  inserted	  into	  the	  upper	  right	  septum	  to	  allow	  venting	  
when	  the	  hybridization	  cocktail	  was	  injected.	  
4. The	  following	  components	  were	  added	  (in	  the	  order	   listed)	  to	  each	  of	  the	  
21.5µl	   biotin-­‐labelled	   sample	   in	   order	   to	   prepare	   the	   array	   hybridisation	  
cocktail:	  
o 50	  µl	  2X	  hybridisation	  mix	  (GeneChip	  ®	  Hybridization,	  wash,	  
and	  stain	  kit;	  Affymetrix)	  
o 10	  µl	  nuclease	  free	  water	  
o 5µl	  deionised	  formamide,	  molecular	  biology	  grade	  
o 10	  µl	  DMSO	  (dimethyl	  sulphoxide)	  
o 5	  µl	  20X	  eukaryocyte	  hybridisation	  controls	  (GeneChip	  ®	  
Hybridization	  Control	  kit,	  Affymetrix)	  
o 1.7	  µl	  control	  oligonucleotide	  B2,	  3nM	  (GeneChip	  ®	  
Hybridization	  Control	  kit,	  Affymetrix)	  
5. The	  total	  volume	  of	  the	  sample	  was	  103.2µl	  which	  was	  then	  incubated	  at	  





6. 100	  µl	  was	  aspirated	  and	  then	  injected	  into	  the	  array.	  
7. The	  20µl	  pippette	  was	  removed	  from	  the	  upper	  right	  septum	  of	  the	  array.	  
8. Both	  septa	  were	  then	  covered	  to	  minimize	  evaporation	  and/or	  leaks	  
9. The	  arrays	  were	  placed	  into	  the	  hybridization	  oven	  trays	  and	  incubated	  for	  
48oC	  and	  60rpm	  for	  16	  hours.	  Samples	  were	  loaded	  at	  approximately	  1700	  
and	  left	  over	  night.	  	  
7.2	  Washing	  and	  staining	  
1. After	   the	   16	   hours	   of	   hybridization,	   the	   arrays	   were	   removed	   from	   the	  
oven.	  
2. The	   hybridization	   cocktail	   was	   removed	   from	   each	   array	   and	   transferred	  
into	  a	  new	  Eppendorf	  microtube	  	  (Hamburg,	  Germany).	  Samples	  were	  then	  
stored	  at	  -­‐80oC.	  
3. 120	  µl	  of	  the	  Array	  holding	  buffer	  was	  then	  inserted	  into	  each	  array.	  
4. The	  arrays	  were	  checked	  for	  bubbles	  and	  dust.	  Both	  septa	  were	  covered	  to	  
minimize	   leakage.	  The	  array	  glass	   surface	  was	  also	   inspected	   for	  dust	  and	  
cleaned	  appropriately.	  	  
5. The	  fluidics	  station	  was	  prepared	  appropriately	  with	  the	  following:	  
o 600	  µl	  of	  Stain	  Cocktail	  1	  was	  inserted	  into	  sample	  holder	  1	  
o 600	  µl	  of	  Stain	  Cocktail	  2	  was	  inserted	  into	  sample	  holder	  2	  
o 800	  µl	  of	  Array	  Holding	  buffer	  was	  inserted	  in	  sample	  holder	  
3	  
6. The	  fluidics	  station	  was	  washed	  and	  stained	  as	  below:	  
Post	  Hyb	  wash♯1	  	   10	  cycles	  of	  2	  mixes/cycle	  with	  Wash	  Buffer	  A	  at	  25oC	  
Post	  HyB	  Wash♯2	   8	  cycles	  of	  15	  mixes/cycle	  with	  Wah	  Buffer	  B	  at	  50oC	  




Post	  Stain	  wash	   	   10	  cycles	  of	  4	  mixes/cycle	  with	  wash	  Buffer	  A	  at	  30oC	  
2nd	  Stain	  	   	   Stain	  the	  probe	  array	  for	  10	  minutes	  with	  Stain	  cocktail	  2	  at	  25oC	  
3rd	  Stain	  	   	   Stain	  the	  probe	  array	  for	  10	  minutes	  with	  Stain	  cocktail	  1	  at	  25oC	  
Final	  wash	   	   15	  cycles	  of	  4	  mixes/cycle	  with	  Wash	  Buffer	  A	  at	  35oC	  
Array	  holding	  buffer	   Fill	  the	  probe	  array	  with	  Array	  holding	  buffer	  
	  
7.3	  Scanning	  
Scanning	   was	   performed	   using	   the	   Affymetrix	   command	   console	   software.	   The	  
software	   is	   able	   to	   summarise	   probe	   cell	   intensity	   data	   (CEL	   file	   generation)	   and	  
enables	  sample	  and	  array	   registration,	  data	  management,	   instrument	  control	  as	  well	  
as	  automatic	  and	  manual	  image	  gridding.	  	  
	  
7.4	  GeneChip	  miRNA	  2.0	  Arrays	  
GeneChip	  miRNA	  2.0	  arrays	  (Affumetrix)	  were	  used.	  	  
	  
7.5	  	  Analysis	  of	  scanned	  miRNA	  arrays	  
The	   array	   images	   (CEL	   files)	   were	   processed	   using	   the	   Affymetrix’s	  miRNA	  QC	   Tool,	  
applying	   the	   default	  workflow,	  which	   includes	   background	   correction	   summarisation	  
of	   multiple	   probes	   into	   overall	   probeset	   intensity	   and	   normalistation	   based	   on	  
Quantile	   normalistation.	   The	   procedure	   generates	   log	   2	   intensities	   for	   the	   15,644	  
probe	   sets	   on	   the	   chips	   for	   each	   sample.	   	   The	  microarray	   data	   is	  MIAME	   (minimum	  
information	  about	  a	  microarray	  experiment)	  compliant	  and	  has	  been	  deposited	  in	  the	  






8.1	  Qlucore	  Omics	  explorer	  
The	  Qlucore	  omics	   explorer	   software	   at	   the	  Genomic	  Centre,	   King’s	   College	   London,	  
Waterloo	  Campus,	  London,	  UK	  was	  used.	  Data	  was	  exported	  from	  the	  miRNA	  QC	  Tool	  
and	  formatted	  as	  a	  ‘gedata’	  tab	  –delimited	  text	  file	  and	  imported	  into	  Qlucore’s	  Omics	  
Explorer	  2.1	   software	   for	   analysis.	  A	   simple	  1-­‐way	  ANOVA	   (analysis	   of	   variance)	  was	  
used	  to	  filter	  genes	  that	  were	  differentially	  regulated	  between	  the	  different	  groups.	  P	  
values	   were	   set	   to	   0.01.	   Data	   was	   checked	   for	   outliers	   by	   visual	   inspection	   using	  
principal	   component	   analysis	   (PCA)	   plots.	   Gene	   lists	   containing	   all	   regulated	   genes	  
were	  displayed	  as	  heatmaps	  to	  show	  gene	  expression	  patterns.	  	  
	  
8.2	  Metacore	  analysis	  
Metacore	   is	   an	   integrated	   web-­‐based	   software	   suite	   for	   functional	   analysis	   of	  
microarray,	   metabolic,	   proteomics	   and	   miRNA	   data.	   It	   is	   based	   on	   a	   high	   quality,	  
manually	   curated	  database	  of	   transcription	   factors,	   receptors,	   ligands,	  kinases,	  drugs	  
and	   endogenous	   metabolites.	   It	   also	   provides	   data	   on	   signalling	   and	   metabolic	  
pathways	  represented	  on	  maps	  and	  networks.	  	  Gene	  lists	  identified	  were	  exported	  as	  
excel	  files.	  	  The	  enrichment	  analysis	  performed	  by	  Metacore	  examines	  the	  intersection	  
between	  one’s	  data	  and	  prebuilt	  pathway	  maps	  and	  networks	  in	  Metacore.	  Networks	  
are	  then	  created	  providing	  a	  p-­‐value,	  Z-­‐score	  and	  G-­‐score.	  The	  p-­‐value	  represent	  the	  
probability	  of	   these	  networks	  occurring	  purely	  by	   chance.	   The	  Z-­‐score	   calculates	   the	  
level	  of	   saturation	  of	   the	  networks	   taking	   into	  account	   the	   size	  of	   the	  database,	   the	  




construct	   the	   network.	   The	   higher	   the	   Z-­‐score	   the	  more	   saturated	   a	   sub-­‐network	   is	  
with	  ones	  data.	  The	  G-­‐score	  modifies	  the	  Z	  score	  where	  possible	  based	  on	  the	  number	  
of	  the	  linear	  canonical	  pathway	  fragments	  contained	  within	  the	  network.	  The	  genetic	  
pathways	  known	  to	  be	  regulated	  by	  these	  miRNAs	  were	  therefore	  interrogated.	  
	  
9.	  RNA	  purification	  from	  serum	  
	  
RNA	  was	  extracted	  from	  serum	  according	  to	  Qiagen’s	  miRNeasy	  mini	  kit	  protocol.	  
9.1	  Materials	  
o miRNeasy	  mini	  kit	  (50)	  (Qiagen).	  
o Extra	  RPE-­‐buffer,	  (Qiagen)	  	  
o MS2	  RNA	  (0.8	  μg/μl)	  (Roche)	  	  
o Chloroform	  (Sigma	  Aldrich)	  	  
o Absolute	  ethanol	  (99.9%)	  	  
o RNase-­‐free	  filtertips	  	  
o RNase-­‐free	  1.5	  ml	  and	  2	  ml	  tubes,	  (e.g.	  Non-­‐Stick	  RNase-­‐free	  Microfuge	  
Tubes)	  (Ambicon)	  	  
o Table-­‐top	   micro	   centrifuge	   with	   cooling,	   capable	   of	   13,000	   rpm	  
centrifugal	  force	  	  
9.2	  Protocol	  	  
1. Serum	  	  and	  MS2	  RNA	  were	  thawed	  on	  ice.	  Samples	  were	  kept	  on	  ice.	  	  
2. The	  centrifuge	  was	  cooled	  to	  4°C.	  
3. 250	  μl	  of	   serum	  was	  placed	   	   into	  a	  1.5	  ml	   tube.	  And	  centrifuged	  at	  3,000	  
rpm	  for	  5	  minutes	  at	  4°C	  to	  remove	  debris	  and	  then	  200	  μl	  of	  serum	  was	  




4. QIAzol	  master	  mix	  (800	  μl	  QIAzol	  +	  1.25	  μl	  MS2)	  was	  made	  per	  sample	  and	  
vortexd	  briefly	  to	  mix.	  	  
5. 750μl	  QIAzol	  master	  mix	  was	  then	  added	  to	  each	  200	  μl	  serum	  sample	  and	  
vortexed.	  
6. The	  samples	  were	  incubated	  for	  5	  minutes	  at	  room	  temperature	  and	  then	  
200μl	  chloroform	  was	  added	  	  to	  each	  sample	  and	  vortexed.	  	  
7. Samples	  were	  then	  incubated	  for	  2	  minutes	  at	  room	  temperature	  and	  then	  
centrifuged	  at	  12,000	  rpm	  for	  15	  minutes	  at	  4°C.	  	  
8. The	  centrifuge	  was	  then	  heated	  to	  room	  temperature	  (20°C)	  and	  the	  upper	  
aqueous	  phase	  was	  transferred	  to	  a	  2	  ml	  tube.	  
9. 1.5	  volumes	  (525	  µl)	  of	  100%	  ethanol	  were	  added	  and	  mixed	  by	  pipetting.	  
750μl	   of	   the	   solution	  was	   transferred	   to	   a	   RNeasy	  mini	   spin	   column	   and	  
carefully	  marked.	  
10. Samples	  were	   centrifuged	   	   for	  30	   sec	  at	   room	   tempertaure	   (13,000	   rpm).	  
The	  flow-­‐through	  was	  discarded.	  
11. Step	   10	   was	   repeated	   until	   all	   of	   the	   sample	   was	   used	   (samples	   were	  
remixed	  by	  pipetting	  before	  loading	  again).	  	  
12. 700	  μl	   RWT	  wash	   solution	  was	   added	   and	   centrifuged	   for	   1	  min	   at	   room	  
temperature	  (13,000	  rpm).	  The	  flow-­‐through	  was	  then	  discarded.	  
13. 	  500μl	   RPE	   was	   added	   to	   wash	   the	   samples	   and	   repeated	   3	   times.	   After	  
each	   addition	   samples	   were	   centrifuged	   for	   1	   min	   at	   room	   temperature	  
(13,000	  rpm)	  and	  flow-­‐through	  discarded.	  	  
14. Columns	   were	   then	   transferred	   to	   a	   new,	   labelled	   collection	   tube	   and	  




15. The	  tubes	  were	   left	  open	  for	  1	  min	  and	  columns	  were	  transferred	  to	  new	  
non-­‐stick	   RNase-­‐free	   Microfuge.	   Then	   50μl	   DNase/RNase-­‐free	   water	   was	  
added,	   making	   sure	   the	   liquid	   was	   centered	   on	   the	   membrane	   and	  
incubated	  for	  1	  min	  and	  then	  centrifuged	  for	  1	  min	  at	  room	  temperature,	  
(13,000	  rpm).	  	  
16. The	  final	  RNA	  solution	  obtained	  was	  stored	  at	  -­‐80°C.	  	  
10.	  cDNA	  synthesis	  
	  
For	  each	  RNA	   sample,	   the	   concentration	  was	  adjusted	   to	  5ng/µl	   using	  nuclease	   free	  
water.	  The	  reagents	  were	  prepared.	  The	  5x	  Reaction	  buffer	  (Exiqon	  Inc.)	  and	  nuclease	  
free	   water	   were	   gently	   thawed	   by	   placing	   them	   on	   ice	   before	   being	   vortexed	   and	  
mixed.	  The	  RNA	  spike	  was	  re-­‐suspended	  by	  adding	  in	  40	  µl	  of	  nuclease	  free	  water	  to	  
the	   tube	   before	   vortexing	   prior	   to	   use	   (left	   on	   ice	   for	   15-­‐20	  minutes).	   Immediately	  
before	  use,	   the	  enzyme	  mix	  was	   removed	   from	   the	   freezer	  by	   flicking	   the	   tubes.	  All	  











Reagent	   Volume	  (µ l),	  RT	  reaction	  
5x	  Reaction	  buffer	   4	  
Nuclease	  free	  water	   10	  
Enzyme	  mix	   2	  
Template	  total	  RNA	  (5ng/µl)	   4	  
	  	  	  
Table	  3.4	  	  Reverse	  transcription	  (RT)	  reaction	  setup	  
	  
The	  RT	  master	  mix	  was	  prepared	  and	  placed	  on	  ice	  before	  being	  dispensed	  (16µl)	  into	  
nuclease	  free	  tubes.	  The	  samples	  were	  gently	  vortexed	  and	  then	  centrifuged.	  Samples	  
were	  incubated	  for	  60	  minutes	  at	  42oC.The	  RT	  was	  then	  heat	  inactivated	  by	  placing	  the	  
samples	  at	  95oC	  for	  5	  minutes.	  Samples	  were	  then	  cooled	  to	  4oC	  and	  stored	  at	  4oC.	  	  
11.	  Real-­‐time	  quantitative	  PCR	  (qPCR)	  
	  
Selected	  miRNAs	  were	  analysed	  using	   liver	   tissue	  and	   serum	  using	   the	  miRCURY	  TM	  
LNA	  Universal	  RT	  microRNA	  PCR	  system	  (Exiqon).	  	  
	  
Primers	  were	  re-­‐suspended	  and	  mixed	  by	  adding	  110	  µl	  nuclease	   free	  water	   to	  each	  
tube.	  Tubes	  were	  then	  vortexed	  and	  centrifuged	  down	  before	  being	  left	  on	  ice	  for	  30	  
minutes.	  The	  PCR	  primer	  was	  prepared	  by	  adding	  110	  µl	  of	  the	  Fwd	  (forward)	  primer	  
to	  110	  µl	  of	  the	  Rev	  (reverse)	  primer.	  Before	  using	  the	  reference	  gene	  primer	  for	  the	  




each	  tube.	  All	  tubes	  were	  vortexed	  and	  centrifuged	  before	  then	  being	  left	  on	  ice	  for	  30	  
minutes.	  Negative	  controls	  of	  nuclease	  free	  water	  were	  also	  used.	  
	  	  
11.1	  Real-­‐time	  PCR	  amplification	  
1. The	  prepared	  cDNA,	  nuclease	  free	  water	  and	  SYBR®	  Green	  master	  mix	  were	  
placed	  on	   ice	  and	   thawed	   for	  20	  minutes.	   SYBR	  Green	  master	  mix	   is	   light	  
sensitive	   and	   was	   therefore	   protected	   from	   light	   by	   using	   a	   cover.	  
Immediately	  before	  use,	   the	  SYBR®	  Green	  Master	  was	  mixed	  by	  pipetting	  
up	  and	  down.	  
2. 2.5	  µl	  of	  cDNA	  was	  taken	  and	  added	  to	  197.5	  µl	  of	  nuclease	  free	  water	  to	  
achieve	  a	  1:80	  dilution.	  ‘Low-­‐nucleic	  acid	  binding’	  tubes	  were	  used.	  Rox	  dye	  
was	  used	  as	  a	  passive	  reference	  dye	  in	  the	  cDNA	  solution.	  
3. A	   PCR	   master	   mix	   of	   the	   PCR	   primers	   and	   SYBR®	   Green	   master	   mix	  
(QiIAGEN)	  was	  made	  as	  follows:	  
Reagent	  
	  
Volume	  (µ l),	  384	  well	  plate	  
SYBR®	  Green	  Master	  mix	  
	  
5	  










Table	  3.5	  Real-­‐time	  PCR	  reaction,	  for	  a	  10ul	  reaction	  
	  
4. The	  reaction	  was	  then	  mixed	  gently	  by	  pipetting	  to	  ensure	  all	  the	  reagents	  




5. 	  Real-­‐time	   PCR	   amplification	   was	   performed	   followed	   by	   melting	   curve	  
analysis	  with	  the	  following	  settings:	  
-­‐	  Polymerase	  Activation/	  Denaturation	  	  	  	  	  	  	  	  	  	  	  	  	  	   95˚C,	  10	  min	  	  
-­‐	  Amplification	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   40	  amplification	  cycles	  at	  	   	  
95˚C,	  10	  s,	  	  
60˚C,	  1	  min,	  
ramp-­‐rate	  1.6˚C/s7)	  Optical	  read	  	  	  
-­‐	  Melting	  curve	  analysis	   	   	   	   Yes	   	  
6. Samples	  were	  run	  in	  triplicate.	  
12.	  Statistical	  analysis	  
	  
Continuous	  variable	  were	  expressed	  as	  medians	  and	  ranges	  (minimum	  and	  maximum).	  
Comparison	   was	   made	   using	   non-­‐parametric	   tests.	   Categorical	   variables	   were	  
compared	  using	  the	  Chi-­‐square,	  Mann-­‐Whitney	  U	  test	  or	  Fisher’s	  Exact	  test.	  A	  2-­‐tailed	  
P-­‐value	   <	   0.05	   was	   considered	   to	   indicate	   statistical	   significance.	   Analysis	   was	  
performed	  by	  myself	  using	  SPSS	  for	  Windows	  18	  (SPSS,	  Chicago,	  IL,	  USA).	  	  
	  
Chapter	  IV	  
The	  independent	  effects	  of	  recipient	  IL-­‐28B	  genotype,	  	  donor	  age	  and	  diabetes	  mellitus	  
on	   histological	   recurrence	   (F≥2	   at	   12	   months)	   were	   determined	   using	   logistic	  
regression	  analysis.	  Recipient	  IL-­‐28B	  genotype,	  diabetes	  mellitus,	  donor	  age,	  recipient	  
age,	   SVR	   and	   HCV	   viral	   genotype	   were	   included	   in	   a	   Cox-­‐regression	   model	   to	   help	  






Correlation	   coefficients	   of	   CXCL10	   with	   aspartate	   transaminase	   (AST),	   alanine	  
transaminase	   (ALT),	   necro-­‐inflammatory	   (NI)	   score	   and	   fibrosis	   (F)	   score	   using	   the	  
Spearman	  rank	  correlation.	  The	  ability	  of	  variables	   to	  predict	  F≥2	  at	  12	  months	  was	  
assessed	  using	  the	  area	  under	  the	  curve	  generated	  by	  receiver	  operator	  characteristic	  
analysis.	  The	  area	  under	  the	  receiver	  operating	  curve	  (AUROC)	  was	  used	  to	  assess	  the	  
ability	   to	   distinguish	   categorical	   state.	   Receiver-­‐operator	   characteristic	   (ROC)	   curves	  
were	  compared	  using	  the	  Hanley	  McNeil	  method	  (Hanley	  and	  McNeil,	  1983).	  The	  point	  
of	   highest	   sensitivity	   and	   specificity	  was	  defined	  using	   the	  Youden	  method	   (Youden,	  
1950).	  The	   independent	  effects	  of	  CXCL10	   levels,	  donor	  age	  and	  diabetes	  mellitus	  on	  
histological	  recurrence	  (F≥2	  at	  12	  months)	  were	  determined	  using	  logistic	  regression	  
analysis.	  CXCL10,	  diabetes	  mellitus,	  donor	  age,	   recipient	  age	  and	  HCV	  viral	   genotype	  
were	   included	   in	   a	   Cox-­‐regression	   model	   to	   help	   predict	   F≥4	   post	   transplant.	   The	  
independent	   effects	   of	  HCV	   genotype,	   CXCL10	   levels,	   recipient	   age,	   IL-­‐28B	   genotype	  




For	  qPCR	  statistical	  analysis,	  data	  was	  expressed	  as	  mean+/-­‐	   standard	  deviation.	  The	  
Student’s	  t-­‐test	  was	  used	  to	  determine	  statistical	  difference	  between	  group	  A	  and	  B.	  





The	  role	  of	  donor	  and	  recipient	  rs12979860	  IL-­‐28B	  
polymorphisms	  in	  HCV	  recurrence	  post	  liver	  transplantation	  





Large	   epidemiological	   studies	   have	   identified	   a	   number	   of	   candidate	   genes	   that	  
influence	   fibrosis	   (Huang	  et	   al.,	   2007).	   Single	  nucleotide	  polymorphisms	   (SNP)	   in	   the	  
interleukin	   (IL)-­‐28B	   gene	   located	   on	   chromosome	   19,	   rs12979860,	   have	   been	  
demonstrated	  to	  strongly	  influence	  HCV	  clearance	  and	  treatment	  response	  (Ge	  et	  al.,	  
2009).	  In	  particular	  post	  transplant,	  recipient	  IL-­‐28B	  TT	  genotype	  was	  associated	  with	  a	  
more	   rapid	   fibrosis	   progression	   rate	   (Lange	   and	   Zeuzem,	   2011,	   Coto-­‐Llerena	   et	   al.,	  
2011,	   Eurich	   et	   al.,	   2011).	   The	   role	   of	   donor	   IL-­‐28B	   genotype	   appears	   to	   be	   less	  
established	   with	   regards	   to	   fibrosis	   progression	   with	   conflicting	   data.	   There	   is	   no	  
published	   data	   regarding	   the	   role	   of	   IL-­‐28B	   genotype	   and	   fibrosis	   rates	   post	  
transplantation	   from	   the	   UK.	   I	   therefore,	   aimed	   to	   examine	   the	   role	   of	   rs12979860	  	  	  	  	  
IL-­‐28B	  polymorphisms	  in	  both	  donor	  and	  recipient	  DNA	  on	  outcomes	  in	  patients	  with	  
HCV	  recurrence	  post-­‐transplantation.	  Institutionally,	  performing	  the	  IL-­‐28B	  genotyping	  
on	   recipient	   and	   donor	   DNA	   was	   important	   step	   in	   order	   to	   characterise	   our	   large	  
cohort	  of	  patients.	  
2.	  Subjects	  
Between	  January	  2000	  and	  January	  2011,	  303	  adult	  patients	  (>	  18	  years)	  with	  chronic	  
HCV	   underwent	   primary	   liver	   transplantation	   at	   King’s	   College	   Hospital	   NHS	  
Foundation	   Trust,	   London,	   UK.	   Patients	   were	   identified	   using	   the	   Institute	   of	   Liver	  
Studies	   viral	   hepatitis	   computerized	   database.	   Patients	   with	   a	   fibrosing	   cholestatic	  
hepatitis	  (FCH)	  (n=5),	  those	  undergoing	  re-­‐transplantation	  (n=13)	  were	  excluded	  along	  
with	   individuals	  co-­‐infected	  with	  human	  immunodeficiency	  virus	  (HIV,	  n	  =	  8),	  chronic	  




(n=1).	   Patients	   that	   did	   not	   survive	   a	   minimum	   of	   12	   months	   were	   also	   excluded	  
(n=74).	  57	  patients	  did	  not	  have	  a	   liver	  biopsy	  performed	  at	  12	  months	  as	  they	  were	  
not	  followed	  up	  at	  our	  institution.	  Of	  the	  remaining	  patients,	  133	  had	  a	  12	  month	  liver	  
biopsy	  performed.	  Median	  number	  of	  biopsies	  per	  patient	  was	  2	  (range	  1-­‐4).	  Patients	  
were	  considered	  for	  AVT	  once	  there	  was	  evidence	  of	  progressive	  fibrosis	  (F≥2,	   Ishak)	  
on	  liver	  biopsy.	  Institutional	  ethical	  approval	  was	  obtained	  prior	  to	  commencement	  of	  
the	  study.	  
3.	  Results	  
3.1	  Patient	  characteristics	  
303	  patients	  (82%	  male)	  underwent	  liver	  primary	  liver	  transplantation	  during	  the	  study	  
period.	  All	  patients	  had	  virological	  recurrence	  of	  HCV	  infection	  post	  transplant.	  Patient	  
demographics	  are	  listed	  in	  Table	  4.1.	  236	  patients	  survived	  for	  greater	  than	  12	  months.	  
133	  patients	  were	   included	   in	   the	   final	   analysis.	   	  Median	   recipient	  age	  was	  53	  years	  
(range	   19-­‐67	   years)	   and	   median	   donor	   age	   was	   46	   years	   (range	   15-­‐87	   years).	  
Tacrolimus	  based	  immunosuppression	  was	  used	  in	  the	  majority	  of	  patients	  (98%).	  
	  
3.2	  Donor	  &	  recipient	  rs12979860	  IL-­‐28B	  genotype	  
Donor	  and	   recipient	   rs12979860	   IL-­‐28B	  genotyping	  was	  performed	  successfully	   in	  63	  
and	   126	   patients	   respectively	   (Table	   4.2	   and	   4.3).	   The	   IL-­‐28B	   CT	   genotype	   was	   the	  
most	  prevalent	  amongst	  donors	  and	  recipient,	  44%	  and	  48%	  respectively.	  Paired	  donor	  




CC/recipient	   non-­‐CC	   =	   24%	   (n=14),	   donor	   CC/recipient	   non-­‐CC	   =	   34%	   (n=20),	   donor	  
non-­‐CC/recipient	  CC	  =	  32%	  (=19),	  donor	  CC/recipient	  CC	  =	  10%	  (n=6).	  
	   N=133	  
Recipient	  Age	  (years)	   53,	  19-­‐67	  
Male	  (n/%)	   110/82	  
Caucasian	  (n/%)	   109/81	  
BMI	  (kg/m2)	   26,	  18-­‐41	  
HBcAb	  (n/%)	   31/23	  
ALD	  (n/%)	   23/23	  
HCV	  genotype	  1	  (n/%)	   73/55	  
HCC	  (n/%)	   51/38	  
Diabetes	  (n/%)	   73/55	  
Donor	  age	  (years)*	   46,	  15-­‐87	  
DRI	   1.7,	  1.1-­‐3.1	  
DBD	  (n/%)	   90/68	  
CIT	  (hours)	   10.8,	  1.6-­‐19.0	  
Tacrolimus	  (n/%)	   130/98	  
MELD	   13,	  5-­‐40	  
CPS	   9,	  5-­‐14	  
Patient	  Survival	  (m)	   35,	  1-­‐145	  
Time	  to	  F≥2	  (m)	   22,	  3-­‐124	  
Time	  to	  F≥4	  (m)	   34,	  5-­‐124	  
	  
Table	   4.1	   Patient	   demographics	   and	   characteristics	   at	   the	   time	   of	   liver	  
transplantation.	  
BMI,	  body	  mass	   index;	  ALD,	  alcohol	   induced	   liver	  disease;	  HCV,	  hepatic	  C	  virus;	  HCC,	  hepatocellular	   carcinoma;	  DRI,	  donor	   risk	  
index;	  DBD,	  donation	  after	  brain	  death;	  CIT,	  cold-­‐ischaemia	  time;	  MELD,	  model	  for	  end	  stage	  liver	  disease;	  CPS,	  Child	  Pugh	  score;	  










Genotype	  SNP	   HCV	  patients	  post	  transplant	  
	  IL-­‐28B	  (n)	   63	  
TT	  (n/%)	   8/13	  
CT	  (n/%)	   28/44	  
CC	  (n/%)	   27/43	  
T	  allele	  frequency	  (%)	   70%	  
C	  allele	  frequency	  (%)	   87	  
	  
Table	  4.2	  Donor	  rs12979860	  IL-­‐28B	  genotype	  frequency.	  
	  
Genotype	  SNP	   HCV	  patients	  post	  transplant	  
IL-­‐28B	  (n)	   126	  
TT	  (n/%)	   20/16	  
CT	  (n/%)	   60/48	  
CC	  (n/%)	   46/36	  
T	  allele	  frequency(%)	   80	  
C	  allele	  frequency(%)	   84	  
	  
Table	  4.3	  Recipient	  rs12979860	  IL-­‐28B	  genotype	  frequency.	  




3.3	  Patient	  and	  graft	  survival	  
No	  difference	   in	  patient	   (83%	  vs.	  71%,	  p	  =0.2)	  or	  graft	   (81%	  vs.	  67%,	  p=0.2)	   survival	  
was	   observed	   according	   to	   recipient	   IL-­‐28B	   genotype	   (CC	   vs.	   non-­‐CC)	   at	   5	   years.	  
Patient	   (93%	   vs.	   82%,	   p=0.3)	   and	   graft	   (82%	   vs.	   68%,	   p=0.2)	   survival	   did	   not	   differ	  
statistically	  according	  to	  donor	  IL-­‐28B	  genotype	  (CC	  vs.	  non-­‐CC)	  at	  5	  years.	  	  
	  
3.4	  Fibrosis	  progression	  
Recipient	  non-­‐CC	  rs12979860	  IL-­‐28B	  genotype	  was	  more	  likely	  to	  be	  associated	  with	  a	  
rapid	  fibrosis	  progression	  rate	  (F≥2	  at	  12	  months);	  26%	  vs.	  41%,	  p=0.05.	  Multivariate	  
regression	  identified	  recipient	  rs12979860	  IL-­‐28B	  non-­‐CC	  genotype	  to	  be	  predictive	  of	  
F≥2	  at	  12	  months	  (Table	  4.4).	  The	  number	  of	  donor	  IL28B	  samples	  that	  were	  available	  
were	  small	  and	  so	  it	  was	  not	  included	  in	  the	  model	  to	  help	  predict	  F≥2	  at	  12	  months	  or	  
F≥4.	  The	  recipients	  with	   the	  CC	   IL-­‐28B	  genotype	  were	   less	   likely	   to	  develop	  F≥4	  post	  
transplant	   compared	   to	   patients	   with	   non-­‐CC	   genotype	   (11%	   vs.	   48%,	   p<0.0001).	  
Progression	   to	   F≥4	   was	   also	   attenuated	   at	   5	   years	   (19%	   vs	   56%,	   p=0.004)	   amongst	  
recipient	  CC	  IL2-­‐8B	  patients.	  On	  multivariate	  regression	  analysis,	  recipient	  rs12979860	  
IL-­‐28B	  CC	  genotype	  vs.	  non-­‐CC	  genotype	  was	  predictive	  of	  progression	  to	  F≥4	  (OR	  0.4,	  
0.04-­‐0.45,	  p=0.007)	  along	  with	  donor	  age	  and	  diabetes	  mellitus	  (Table	  4.5).	  The	  donor	  
CC	   IL-­‐28B	   genotype	  was	   not	   statistically	   associated	  with	   F>2	   at	   12	  months	   (35%	   vs.	  
38%,	  p=0.7)	  but	  were	  less	  likely	  to	  develop	  F≥4	  in	  the	  post	  transplant	  period	  (48%	  vs.	  
83%,	   p=0.03).	   	   Patients	   with	   the	   donor/recipient	   12979860	   IL-­‐28B	   CC	   combination	  
were	   less	   likely	   to	   develop	   rapid	   fibrosis	   compared	   to	   the	   donor/recipient	   non-­‐CC	  
rs12979860	   IL-­‐28B	   genotype	   (24%	   vs.	   53%,	   p=0.05).	   Donor	   /recipient	   IL-­‐28B	   CC	  





Parameter	   Odds	  ratio	   95%	  CI	   P	  value	  
	  
Univariate	  
Recipient	  age	   0.9	   0.9-­‐1.09	   0.1	  
Donor	  age	  	   1.9	   0.68-­‐5.6	   0.2	  
Recipient	  IL28B	  CC	  vs	  
non	  CC	  
0.3	   0.13-­‐0.67	   0.003	  
DM	   1.6	   0.82-­‐2.9	   0.17	  
MELD	   0.9	   0.92-­‐1.03	   0.4	  
	  
Multivariate	  
Recipient	  age	   0.9	   0.9-­‐1.02	   0.24	  
Recipient	  IL28B	  CC	  vs	  
non	  CC	  
0.28	   0.13-­‐0.66	   0.03	  
	  










Parameter	   Odds	  ratio	   95%	  CI	  	  	  	   P	  value	  
	  
Univariate	  
Recipient	  age	   0.96	   0.93-­‐0.99	   0.03	  
Donor	  age	   6.3	   2.3-­‐17.1	   <0.0001	  
MELD	   1.04	   0.98-­‐1.11	   0.13	  
Recipient	  IL28B	  CC	  vs	  
non	  CC	  
0.2	   0.04-­‐0.42	   <0.0001	  
Diabetes	   2.1	   0.9-­‐3.6	   0.05	  
SVR	   0.43	   0.03-­‐0.77	   0.001	  
	  
Multivariate	  
Recipient	  Age	   0.9	   0.84-­‐1.02	   0.1	  
Donor	  age	  	   3.3	   2.7-­‐15.4	   0.04	  
Diabetes	   2.9	   0.1-­‐	  2.27	   0.05	  
Recipient	  IL28B	  CC	  vs	  
non	  CC	  
0.4	   0.04-­‐0.45	   0.007	  
SVR	   0.38	   0.02-­‐0.72	   0.01	  
	  
Table	  4.5	  Factors	  predictive	  of	  F≥4	  post	  transplant.	  
	  
	  




3.5	  Treatment	  response	  
56	   of	   the	   59	   patients	   that	   had	   donor	   and	   recipient	   IL-­‐28B	   genotypes	   available	   had	  
been	  exposed	  to	  AVT,	  the	  majority	  (89%)	  with	  PEG/RBV.	  Pre-­‐transplant	  treatment	  data	  
was	   only	   available	   in	   7	   patients	   (3	   responder	   relapsers,	   2	   non	   responders	   and	   2	  
patients	   intolerant	   of	   AVT).	  Median	   time	   to	   treatment	  was	   24	  months	   (range	   12-­‐68	  
months).	  SVR	  rates	  according	  to	  donor/recipient	  combination	  are	  shown	  in	  Figure	  4.1.	  
Donor	  and	   recipient	   IL-­‐28B	  CC	  genotype	  had	  100%	  SVR	   rates	   (n=6)	   in	   comparison	   to	  




Figure	  4.1	  Treatment	  outcome	  according	  to	  rs12979860	  IL-­‐28B	  donor/recipient	  
combination	  (d,	  donor;	  r,	  recipient).	  
	  






Various	   risk	   factors	   predicting	   HCV	   recurrence	   post	   transplantation	   are	   well	  
established.	   Interactions	   of	   recipient	   phenototypic	   and	   genotypic	   factors	   have	   long	  
been	  postulated.	   	   The	   recently	   discovered	   SNP	   (rs12979860)	   in	   the	   IL-­‐28B	   (IFN	   -­‐	   λ3)	  
gene	   on	   chromosome	   19	   has	   been	   well	   validated	   as	   a	   powerful	   pre-­‐treatment	  
predictor	  of	   SVR	  pre-­‐transplantation.	   European	  and	  North	  American	   centres	  have	  all	  
recently	   published	   their	   experience	   of	   recipient	   and	   donor	   IL-­‐28B	   genotypes	   on	  
outcomes	  post	  transplantation	  for	  HCV	  (Charlton	  et	  al.,	  2011,	  Coto-­‐Llerena	  et	  al.,	  2011,	  
Eurich	  et	   al.,	   2011,	   Firpi	   et	   al.,	   2013).	   	  Our	  patient	   cohort	   at	   King’s	  College	  Hospital,	  
London	   are	   typical	   of	   centres	   in	   Northern	   Europe:	  male,	   predominately	   genotype	   1	  
disease	  and	  with	  co-­‐existing	  diabetes	  in	  the	  majority.	  
	  
IFN-­‐λ	  plays	  an	  integral	  role	  in	  the	  modulation	  of	  the	  adaptive	  immune	  system	  and	  has	  
strong	   pro-­‐inflammatory	   properties.	   IFN-­‐λ	   also	   interacts	   with	   natural	   killer	   cells	   and	  
increases	  CXCL10	  production	  by	  monocytes,	  endothelial	  cells	  and	  fibroblasts.	  CXCL10	  is	  
produced	   directly	   by	   hepatic	   stellate	   cells	   and	   has	   been	   shown	   to	   be	   predictive	   of	  
fibrosis	  progression	  post-­‐LT	  (Berres	  et	  al.,	  2011).	  Attention	  has	  therefore	  turned	  to	  the	  
role	  of	  IL-­‐28B	  genotype	  on	  HCV	  recurrence	  post	  transplant.	  At	  present,	  differing	  data	  
exist	  regarding	  the	  impact	  of	  IL-­‐28B	  genotype	  on	  HCV	  recurrence	  post	  transplant	  exists	  
(Charlton	   et	   al.,	   2011,	   Eurich	   et	   al.,	   2011).	   In	   a	   study	   of	   220	   patients,	   time	   to	  
recurrence	  of	  HCV	  (histologic	  and	  detectable	  HCV	  RNA	  within	  serum)	  was	  delayed	   in	  
recipients	  with	  the	  rs12979860	  CC	  IL28B	  genotype	  compared	  to	  those	  with	  CT	  and	  TT	  




al.,	   2011).	  On	  multivariate	   analysis,	   the	   recipient	   IL28B	   C	   allele	  was	   an	   independent	  
predictor	  of	  delayed	  recurrence	  of	  HCV	  at	  2	  years	  (HR	  0.6,	  CI	  0.4-­‐0.9,	  p=0.008)	  and	  5	  
years	   	   (HR	  0.6,	   CI	   0.5-­‐0.9,	   p=0.003).	   	  Donor	   IL28B	  genotype	  was	  not	   associated	  with	  
time	  to	  recurrence	  of	  HCV	  at	  2	  years	  or	  5	  years.	  	  In	  another	  study,	  this	  time	  performed	  
in	   Europe,	   demonstrated	   that	   the	   mean	   duration	   to	   the	   development	   of	   advanced	  
fibrosis	   (>F3)	  was	  associated	  with	   recipient	   IL28B	  genotype	   (CC	  65	  months	  vs.	  CT	  46	  
months	  vs	  TT	  30	  months;	  p=0.02)	  (Eurich	  et	  al.,	  2012).	  	  Another	  study,	  failed	  to	  identify	  
the	  presence	  of	  IL28B	  CC	  genotype	  in	  the	  donor	  as	  a	  protective	  factor	  (Cisneros	  et	  al.,	  
2012).	  In	  stark	  contrast,	  the	  presence	  of	  allele	  IL28B	  T	  in	  the	  donor	  was	  not	  associated	  
with	  a	  higher	  risk	  of	  sever	  recurrence	  in	  the	  graft	  but	  possibly	  a	  protective	  	  effect	  (OR	  
0.46)	   although	   this	  was	   not	   statistically	   significant.	  Mechanisms	   for	   this	   observation	  
offered	   by	   the	   authors	   were	   sparse	   but	   included	   that	   other	   studies	   which	   have	  
demonstrated	   the	   opposite	   performed	   donor	   genotyping	   using	   DNA	   isolated	   from	  
implanted	   liver	   biopsies	   which	   could	   contain	   recipient	   –derived	   DNA	   thereby	  
confounding	   the	   results	   (Lange	   et	   al.,	   2011,	   Coto-­‐Llerena	   et	   al.,	   2011).	   My	   results	  
demonstrated	  that	  recipient	  non-­‐CC	  rs12979860	  IL-­‐28B	  genotype	  were	  more	  likely	  to	  
develop	  F≥2	  at	  12	  months	  and	  progress	  to	  F≥4.	  Donor	  CC	  rs12979860	  IL-­‐28B	  genotypes	  
were	  also	   less	   likely	  to	  develop	  F≥4.	   	  Donor	  DNA	  was	  extracted	  prior	  to	   implantation	  
into	   the	   recipient	   and	   therefore	   there	   was	   no	   possibility	   of	   any	   recipient	   DNA	  
confounding	  the	  results.	  
	  
Newly	  published	  data	  has	  identified	  a	  novel	  SNP	  at	  position	  469415590	  (ss469415590	  




response	  (Prokunina-­‐Olsson	  et	  al.,	  2013).	  Using	  primary	  human	  hepatocytes,	  the	  novel	  
SNP	   (ss469415590	  ΔG)	   resulted	   in	  a	   frame	  shift	  mutation	  and	  production	  of	   the	   full-­‐
length	   protein	   designated	   IFN-­‐	   λ4.	   Using	   several	   large	   independent	   clinical	   studies,	  
possession	   of	   the	   ss469415590	   ΔG	   allele	  was	   associated	  with	   a	   reduced	   association	  
with	   spontaneous	   HCV	   clearance	   and	   reduced	   response	   rates	   to	   IFN-­‐α	   based	  
treatment.	   In	   particular,	   the	   study	   also	   suggested	   that	   ss469415590	   was	   a	   more	  
sensitive	  marker	  than	  rs12979860	  in	  predicting	  treatment	  response	  and	  HCV	  clearance	  
particularly	   in	   African	   Americans	   (Prokunina-­‐Olsson	   et	   al.,	   2013).	   Proposed	  
mechanisms	   of	   action	   include	   refractoriness	   to	   IFN	   signalling.	   At	   present,	   further	  
studies	  are	  required	  to	  determine	  the	  function	  of	  IFN-­‐	  λ4	  and	  its	  role	  in	  HCV	  infection	  
and	  treatment.	  	  
	  
Given	  the	  slower	  fibrosis	  rates	  associated	  with	  recipient	  and	  donor	  IL-­‐28	  CC	  genotypes,	  
I	   assessed	   this	   combination	   with	   regards	   to	   F≥2	   at	   12	   months	   and	   F≥4	   post	  
transplantation.	  My	  data	  demonstrated	   that	  patients	  with	  donor/recipient	   IL-­‐28B	  CC	  
combination	   were	   less	   likely	   to	   develop	   F≥2	   at	   12	   months	   and	   F≥4	   post	  
transplantation.	   Recipient	   IL-­‐28B	   CC	   vs.	   non	   CC	   genotype	   was	   the	   only	   significant	  
factor	   identified	   that	   was	   associated	   with	   a	   rapid	   fibrosis	   progression	   i.e.	   F≥2	   at	  
12months.	   	   Factors	   associated	   with	   the	   development	   of	   F≥4	   post	   transplantation	  
included	  donor	  age,	  diabetes	  mellitus	  and	  recipient	  IL28B	  	  non	  CC	  genotype.	  The	  use	  of	  
anti-­‐viral	  therapy	  resulting	  in	  a	  SVR	  and	  recipient	  IL-­‐28B	  CC	  vs.	  non	  CC	  genotype	  were	  
both	  associated	  with	  a	  reduced	  risk	  of	  developing	  F≥4	  post	  transplantation.	  The	  IL28B	  




liver	   biopsy	   (Firpi	   et	   al.,	   2013).	   The	   favourable	   CC	   genotype	   being	   associated	   with	  
lower	   HAI	   scores	   and	   less	   fibrosis	   compared	   to	   the	   non-­‐CC	   genotypes.	   This	   finding	  
suggests	   the	   IL28B	   SNP	   affects	   HCV	   outcome	   through	   interacting	   with	   the	   host	  
immune	  system.	  
	  
In	   keeping	   with	   published	   data,	   my	   results	   demonstrated	   no	   association	   between	  	  	  	  	  	  	  	  
IL-­‐28B	  genotype	  (recipient	  or	  donor)	  and	  graft	  or	  patient	  survival	  when	  censored	  at	  5	  
years.	  Studies	  to	  date	  including	  our	  own	  have	  had	  limited	  follow-­‐up	  and	  small	  numbers	  
and	  are	   therefore	  probably	  not	  powered	  sufficiently	   to	  address	   these	   issues.	  Studies	  
with	  longer	  follow	  up	  are	  therefore	  warranted.	  
	  
The	  IL-­‐28B	  SNP	  is	  an	  established	  predictor	  of	  response	  to	  anti-­‐viral	  therapy	  both	  in	  the	  
pre-­‐	   and	   post-­‐liver	   transplant	   period.	   Certainly	   the	   combination	   of	   IL-­‐28B	   CC	  
donor/recipient	  genotype	  appears	  to	  be	  associated	  with	  a	  SVR	  with	  PR	  based-­‐therapy.	  
Although	  only	  6	  of	  our	  patient	  group	  carried	  this	  combination,	  all	  6	  patients	  achieved	  a	  
SVR.	   The	   data	   are	   limited	   with	   regards	   to	   the	   number	   of	   patients	   included	   and	  
therefore	   require	   further	   validation	   using	   larger	   prospective	   cohorts.	   However,	  
published	  data	  would	  certainly	  support	  a	  higher	  SVR	  rate	  in	  individuals	  with	  the	  IL-­‐28B	  
CC	   donor/recipient	   genotype	   (Charlton	   et	   al.,	   2011).	   Proposed	   mechanisms	   for	   this	  
beneficial	  response	  are	  associated	  with	  changes	  in	  the	  immune	  response	  and	  also	  the	  
level	  of	  interferon	  sensitive	  gene	  activation	  (Honda	  et	  al.,	  2010).	  The	  advent	  of	  newer	  




sensitivity,	  will	  potentially	  negate	  the	  use	  of	  IL-­‐28B	  genotype	  with	  regards	  to	  predicting	  
treatment	  response.	  	  
	  
The	  number	  of	  patients	  that	  underwent	  AVT	  were	  relatively	  small.	  These	  patients	  had	  
been	   treated	   predominately	   in	   the	   later	   part	   of	   the	   study	   cohort	   (after	   2005).	  
Consequently,	   donor	   and	   recipient	   DNA	  were	  more	   readily	   available	   and	   I	   was	   also	  
able	  to	  extract	  DNA	  from	  stored	  blood/tissue.	  To	  determine	  whether	  donor/recipient	  
IL28B	  genotype	  was	  predictive	  of	  treatment	  response,	  I	  needed	  to	  ensure	  the	  numbers	  
included	   in	   the	   analysis	   were	   as	   robust	   as	   possible.	   This	   may	   have	   introduced	   a	  
potential	  confounder	  but	  my	  results	  are	  in	  keeping	  with	  other	  published	  data.	  	  
	  
Some	  authors	  have	  suggested	  that	  allocation	  of	  donor	  grafts	  should	  be	  to	  those	  with	  
the	  favourable	   IL-­‐28B	  CC	  genotype.	  My	  data	  would	  certainly	  suggest	  a	  slower	  rate	  of	  
fibrosis	  progression	  and	  improved	  response	  rates	  to	  AVT	  and	  SVR	  rates.	  In	  the	  rapidly	  
changing	  landscape	  of	  DAAs	  how	  long	  this	  holds	  true	  remains	  to	  be	  seen.	  Clearly	  this	  
selection	  policy	  would	  also	  add	  further	  strain	  onto	  an	  already	  pressured	  donor	  pool.	  	  It	  
is	  likely	  that	  given	  the	  evolution	  of	  DAA	  therapy,	  patients	  awaiting	  liver	  transplantation	  
will	  undoubtedly	  be	  more	   likely	  to	  be	  treated	  on	  the	  waiting	   list	   (McCaughan,	  2012).	  
This	   will	   hopefully	   result	   in	   more	   patients	   entering	   liver	   transplantation	   with	   an	  





Strengths	   of	   this	   work	   include	   stored	   donor	   DNA	   taken	   at	   the	   time	   of	   liver	  
transplantation.	  In	  addition,	  recipient	  DNA	  was	  also	  readily	  available.	  The	  experiments	  
were	  performed	  by	  myself	  and	  then	  validated	  by	  Dr	  James	  Underhill	  ensuring	  that	  the	  
experiments	   and	   interpretation	  were	   correct.	   The	   results	   of	   the	  donor	   and	   recipient	  
IL28B	   genotype	  were	   then	   interpreted	  using	   the	  HCV	  post	   liver	   transplant	  database.	  	  
Weaknesses	   include	  DNA	  degradation	  and	  suitable	  concentrations	  of	  both	  donor	  and	  
recipient	  DNA	  available.	  All	  samples	  were	  assessed	  for	  suitability	  but	  unfortunately	  in	  
some	   cases	   further	   DNA	   extraction	  was	   required.	   In	   total,	   I	   had	   to	   extract	   recipient	  
DNA	  for	  10	  patients	  from	  stored	  samples	  in	  order	  to	  try	  and	  improve	  the	  concentration	  
of	  DNA.	  Other	  weakness	  clearly	  include	  the	  retrospective	  design	  which	  also	  limited	  the	  
number	  of	  samples	  available,	  especially	  of	  donor	  DNA.	  	  Another	  area	  of	  interest	  which	  
was	   not	   possible	   was	   the	   determination	   of	   donor	   and	   recipient	   IL28B	   genotype	   in	  
patients	   that	   develop	   FCH.	   One	   would	   hypothesise	   that	   patients	   that	   develop	   FCH	  
would	   have	   the	   donor/recipient	   rs12979860	   TT	   genotype.	   At	   the	   time	   of	   my	  
experiments	   and	   analysis,	   treatment	   for	   FCH	  was	   very	   limited	   and	   often	   FCH	  was	   a	  
terminal	   occurrence.	   FCH	   now	   however	   can	   be	   treated	   and	   is	   rare.	   Patients	   who	  
remain	  viraemic	  entering	  liver	  transplantation	  could	  be	  highlighted	  as	  high	  risk	  for	  FCH	  
and	  for	  early	  exposure	  to	  treatment	   if	   the	  donor	  and	  recipient	  rs12979860	  genotype	  
was	  TT.	  
	  
In	  conclusion,	  my	  data	  demonstrates	  that	  the	  recipient	  rs12979860	  IL-­‐28B	  genotype	  is	  
a	   strong	   predictor	   of	   rapid	   HCV	   recurrence	   and	   fibrosis	   at	   12	   months	   post	  




less	   likely	   to	   respond	   to	   AVT	   and	   are	   more	   likely	   to	   develop	   F>4	   post	   LT.	   The	  
combination	  of	  both	  recipient	  and	  donor	  rs12979860	  IL-­‐28B	  CC	  genotype	  is	  associated	  
with	  better	  SVR	  rates.	  It	  is	  likely	  that	  treatment	  options	  for	  this	  population	  will	  evolve	  
rapidly	  negating	  the	  use	  of	  interferon	  based	  therapies.	  





The	  role	  of	  CXCL10	  in	  predicting	  HCV	  recurrence	  and	  treatment	  
response	  post	  liver	  transplantation	  






The	  role	  of	  CXCL10	  has	  been	  discussed	  previously	   in	  Chapter	   II.	  Two	  of	  CXCL10	  roles	  
appealed	  to	  me	  and	  led	  me	  to	  conduct	  the	  next	  series	  of	  experiments.	  Firstly,	  CXCL10	  
is	   produced	   by	   hepatocytes	   and	   HSC,	   suggesting	   it	   may	   have	   a	   role	   in	   predicting	  
fibrosis	   progression.	   Secondly,	   CXCL10	   is	   a	   valid	   marker	   of	   ISG	   activation.	   To	  
summarise,	   lower	   levels	  of	  CXCL10	  are	  associated	  with	  a	   lower	   level	  of	   activation	  of	  
the	   innate,	   interferon	   associated	   immune	   response.	   Therefore,	   when	   exogenous	  
interferons	  are	   introduced,	  CXCL10	  and	   ISGs	  are	  up-­‐regulated	  resulting	   in	  higher	  SVR	  
rates.	   Having	   determined,	   the	   recipient	   and	   donor	   IL-­‐28B	   genotype	   in	   Chapter	   IV,	   it	  
seemed	   logical	   to	   therefore	  determine	   the	   role	  of	  CXCL10	  alone	  and	   in	   combination	  
with	   IL-­‐28B	   genotype.	   Although	   there	   was	   some	   data	   on	   the	   use	   of	   CXCL10	   in	  
predicting	   treatment	   response	   in	   cohorts	   before	   transplantation,	   there	  was	   no	   data	  




Between	  January	  2000	  and	  January	  2011,	  303	  adult	  patients	  (>	  18	  years)	  with	  chronic	  
HCV	   underwent	   primary	   liver	   transplantation	   at	   King’s	   College	   Hospital	   NHS	  
Foundation	   Trust,	   London,	   UK.	   Patients	   were	   identified	   using	   the	   Institute	   of	   Liver	  
Studies	   viral	   hepatitis	   computerized	   database.	   Patients	   with	   a	   fibrosing,	   cholestatic	  
hepatitis	  (FCH)	  (n=5),	  those	  undergoing	  re-­‐transplantation	  (n=13)	  were	  excluded	  along	  
with	   individuals	  co-­‐infected	  with	  human	  immunodeficiency	  virus	  (HIV,	  n	  =	  8),	  chronic	  




(n=1).	   Patients	   that	   did	   not	   survive	   a	   minimum	   of	   12	   months	   were	   also	   excluded	  
(n=74).	  57	  patients	  did	  not	  have	  a	   liver	  biopsy	  performed	  at	  12	  months	  as	  they	  were	  
not	  followed	  up	  at	  our	  institution.	  Of	  the	  remaining	  patients,	  133	  had	  a	  12	  month	  liver	  
biopsy	  performed.	  Median	  number	  of	  biopsies	  per	  patient	  was	  2	  (range	  1-­‐4).	  Patients	  
were	  considered	  for	  AVT	  once	  there	  was	  evidence	  of	  progressive	  fibrosis	  (F≥2,	   Ishak)	  
on	  liver	  biopsy.	  Institutional	  ethical	  approval	  was	  obtained	  prior	  to	  commencement	  of	  
the	  study.	  	  
3.	  Results	  	  
3.1	  Patient	  characteristics	  
133	   patients,	   111	   (83%)	  male,	  who	   had	   undergone	   primary	   liver	   transplantation	   for	  
HCV	  related	  cirrhosis	  had	  a	  liver	  biopsy	  performed	  12	  months	  post	  transplantation	  and	  
were	   included	   in	   the	   analysis.	   HCV	   genotype	   1	   (49%)	   was	   the	   most	   prevalent	   viral	  
genotype.	  Median	  recipient	  age	  at	   time	  of	   liver	   transplantation	  was	  53	  years	   (19-­‐67)	  
and	  median	  donor	  age	  was	  46	  years	  (15-­‐87).	  The	  majority	  (81%)	  were	  Caucasian.	  HCC	  
at	   the	   time	   of	   transplantation	   was	   evident	   in	   50	   (38%)	   patients	   and	   a	   significant	  
alcohol	   history	   was	   evident	   in	   30	   (23%)	   patients.	   HBV	   core	   antibody	   positivity	   was	  
evident	  in	  30	  (23%)	  patients.	  Median	  follow	  up	  was	  46	  months	  (12-­‐142).	  	  
	  
3.2	  Slow	  (F<2)	  versus	  fast	  (F≥2)	  fibrosis	  recurrence	  at	  12	  months	  
Patients	  were	  stratified	  according	  to	  their	  fibrosis	  stage	  at	  12	  months	  to	  either	  a	  slow	  
(F<2)	  fibrosis	  group	  (n=77)	  or	  a	  fast	  (F≥2)	  fibrosis	  group	  (n=56).	  The	  characteristics	  of	  




were	  male	  sex,	  donor	  age,	  donor	  risk-­‐index	  (DRI),	  diabetes	  mellitus	  (pre-­‐transplant	  and	  
new	  onset	  post-­‐transplant)	  and	  necro-­‐inflammatory	  scores.	  
	  
	  





Recipient	  Age	  (years)*	   54,	  (35-­‐67)	   52,	  (19-­‐67)	   0.8	  
Male	  (n/%)**	   69/90	   42/75	   0.03	  
Caucasian	  (n/%)**	   61/79	   47/84	   0.5	  
BMI	  (kg/m2)*	   27,	  20-­‐35	   25,	  20-­‐35	   0.167	  
HBcAb	  (n/%)**	   19/25	   11/20	   0.51	  
ALD	  (n/%)**	   16/21	   14/25	   0.41	  
HCV	  genotype	  1	  (n/%)**	   36/48	   29/62	   0.5	  
HCC	  (n/%)**	   24/31	   26/46	   0.07	  
Diabetes	  (n/%)**	   31/40	   38/69	   0.001	  
Donor	  age	  (years)*+	   41,	  (15-­‐67)	   56,	  (23-­‐85)	   <0.0001	  
DRI*	   1.65,	  (1.1-­‐2.5)	   1.8,(1.2-­‐3.0)	   0.006	  
DBD	  (n/%)**	   59/76	   33/60	   0.3	  
CIT	  (hours)*	   9.9	  (4.5-­‐18.3)	   9.7(5.7-­‐15.5)	   0.72	  
Tacrolimus	  (n/%)**	   74/96	   56/100	   0.4	  
ACR	  (n/%)**	   23/30	   17/30	   0.9	  
Fibrosis*	  (Ishak)	   1,	  (0-­‐1)	   2,	  (2-­‐5)	   <0.0001	  
NI*	   4,	  (0-­‐7)	   5,	  (0-­‐10)	   <0.0001	  
CXCL10	  (pg/ml)*	   112,	  (51-­‐189)	   245,	  (90-­‐556)	   <0.0001	  
MELD*^	   14,	  (6-­‐40)	   13,	  ((6-­‐24)	   0.14	  
CPS*^	   9,	  (5-­‐14)	   9,	  (5-­‐13)	   0.56	  
Patient	  Survival	  (m)*	   50,	  (13-­‐131)	   49	  (18-­‐143)	   0.8	  
Patients	  that	  developed	  
F≥4	  **	  (n/%)	  
16/21	   32/57	   0.001	  
Time	  to	  F≥4*	   43,	  (14-­‐124)	   29,	  (14-­‐120)	   0.04	  
	  
	  
Table	  5.1	  .Patient	  characteristics	  dependent	  on	  their	  fibrosis	  stage	  at	  12	  months	  	  
(Slow,	  F<2	  versus	  Fast,	  F≥2).	  	  
	  
ACR,	  acute	  cellular	  rejection;	  ALD,	  alcohol	  related	  liver	  disease;	  BMI,	  body	  mass	  index;	  CIT,	  Cold	  ischaemia	  time;	  CPS,	  Child	  Pugh	  
Score;	  DRI,	  donor-­‐risk	  index;	  F,	  fibrosis;	  HCC,	  hepatocellular	  carcinoma;	  NI,	  necro-­‐inflammatory	  score.	  
Values	  expressed	  as	  either	  median	  with	  range	  (min-­‐max)	  or	  frequency	  and	  %.	  *	  Mann	  Whitney;	  **	  Chi	  square	  .	  




CXCL10	   levels	   were	   significantly	   lower	   in	   slow	   fibrosis	   group	   (112,	   51-­‐189	   pg/ml)	  
compared	   to	   the	   fast	   fibrosis	   group	   (245,	   90-­‐556	   pg/ml,	   p<0.0001)	   and	   differed	  
according	  to	  the	  necro-­‐inflammatory	  score	  (Figure	  5.1).	  CXCL10	  levels	  also	  correlated	  
with	   fibrosis	   stage	   (r=0.86,	  p<0.0001),	  necro-­‐inflammatory	   score	   (r	  =	  0.52,	  p<0.0001)	  
serum	   AST	   at	   6	   months	   (r=0.42,	   P<0.0001)	   and	   serum	   ALT	   at	   6	   months	   (r=0.67,	  




Figure	   5.1.	   CXCL10	   levels	   according	   to	   fibrosis	   and	   necro-­‐inflammatory	   score	   at	   12	  












Figure	  5.2.	  Correlation	  of	  CXCL10	  with	  fibrosis,	  necro-­‐inflammatory	  score,	  aspartate	  









3.3	  Predictors	  of	  F≥2	  at	  12	  months	  
CXCLI0	   predicted	   the	   development	   of	   F≥2	   at	   12	   months	   with	   high	   accuracy	   (Area	  
under	  curve,	  AUC	  0.95,	  95%	  confidence	  interval	  (CI)	  0.90	  –	  0.98,	  p<0.0001)	  along	  with	  
donor	  age	  (AUC	  0.73,	  0.62	  -­‐0.85,	  p	  =	  0.001)	  and	  diabetes	  mellitus	  (AUC	  0.66,	  0.53-­‐0.79,	  
p	   =	   0.02)	   (Figure	   5.3).	   A	   CXCL10	   cut-­‐off	   value	   of	   163	   pg/ml	  was	   associated	  with	   the	  




Figure	   5.3.	   Receiver	   operating	   curves	   for	   performance	   of	   CXCL10,	   donor	   age	   and	  





In	   a	   univariate	   logistic	   regression	   model	   (Table	   5.2),	   CXCL10,	   IL28B	   CC	   genotype,	  
diabetes	  mellitus	  pre-­‐transplantation	  and	  donor	  age	  were	  significant	  predictors	  of	  F≥2	  
at	  12	  months.	  In	  a	  multivariate	  logistic	  regression	  model,	  CXCL10	  (Odds	  ratio,	  OR	  1.05,	  
95%	  CI	  1.03	  –	  1.08,	  p	  =	  0.01),	  IL28B	  CC	  genotype	  (OR	  0.3,	  0.13-­‐0.66,	  p=0.03)	  and	  donor	  
age	   (OR	   1.07,	   1.02-­‐1.14,	   p=0.05)	   remained	   significant.	   HCV	   viral	   genotype	   was	   not	  








Donor	  age	  	   1.07	   1.03-­‐1.12	   <0.0001	  
Diabetes	  mellitus	   3.3	   1.64-­‐7.24	   0.001	  
IL28B	  CC	  genotype	   0.6	   0.13-­‐0.67	   0.003	  
CXCL10	  	   1.5	   1.3	  -­‐1.77	   0.0001	  
Multivariate	  
Donor	  age	   1.07	   1.02-­‐1.14	   0.05	  
Diabetes	  mellitus	   2.43	   0.4-­‐16.7	   0.3	  
IL28B	  CC	  genotype	   0.3	   0.13-­‐0.66	   0.03	  
CXCL10	   1.05	   1.03-­‐1.08	   0.01	  
	  
	  
Table	  5.2.	  Factors	  predictive	  of	  F≥2	  at	  12	  months.	  




3.4	  Risk	  factors	  for	  F≥4	  post	  transplant	  
Sixteen	   patients	   (21%)	   who	   had	   F<2	   at	   12	   months	   went	   onto	   develop	   F≥4	   post	  
transplantation	   compared	   to	   32	   patients	   (57%)	  who	   had	   F≥2	   (p=0.001)	   (Figure	   5.4).	  
Diabetes	  mellitus	  was	  the	  strongest	  predictor	  of	  F≥4	  post	  transplant	  (AUC	  0.86,	  0.76-­‐
0.95,	   p<0.0001	   compared	   to	  CXCL10	   (AUC	  0.79,	   0.68-­‐0.89,	   p<0.0001)	   and	  donor	   age	  
(AUC	  0.65,	  0.52-­‐0.78,	  p	  =0.04)	  (Figure	  5.5).	  
	  
	  
Figure	  5.4.	  The	  development	  of	  F≥4	  post	   liver	  transplantation	  according	  to	  F<2	  or	  F	  










Figure	   5.5.	   Receiver	   operating	   curves	   for	   performance	   of	   CXCL10,	   donor	   age	   and	  
diabetes	  mellitus	  (DM)	  to	  predict	  F	  ≥ 	  4	  post	  liver	  transplantation.	  
	  
	  
Using	   a	   univariate	   Cox	   regression	   model,	   CXCL10,	   diabetes	   mellitus	   post	  
transplantation,	   donor	   age	   and	   HCV	   genotype	   1	   influenced	   the	   time	   to	   F≥4	   post	  
transplantation	   (Table	   5.3).	   On	   multivariate	   analysis,	   diabetes	   mellitus	   remained	   a	  
strong	  predictor	  of	  F≥4	  (HR	  2.4,	  1.01-­‐5.76,	  p=0.04)	  along	  with	  CXCL10	  (HR	  2.5,	  1.03-­‐




pg/ml	   had	   a	   quicker	   time	   to	   development	   of	   F≥4	   post	   transplantation	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(Log	  rank	  p	  <	  0.0001,	  Figure	  5.5).	  
	  





Donor	  age	   2.5	   1.4-­‐4.4	   0.002	  
Diabetes	  mellitus	   2.6	   1.4-­‐5.0	   0.003	  
Recipient	  age	   0.9	   0.9-­‐1.01	   0.14	  
HCV	  genotype	  1	   2.1	   1.02-­‐4.2	   0.05	  
CXCL10	   3.3	   2.0-­‐7.7	   <0.0001	  
Multivariate	  
Donor	  age	   2.2	   1..06-­‐7.9	   0.05	  
Diabetes	  mellitus	   2.4	   1.04-­‐5.8	   0.04	  
Recipient	  age	   -­‐	   -­‐	   -­‐	  
HCV	  genotype	  1	   1.6	   0.65-­‐4.1	   0.31	  
CXCL10	   2.5	   1.03-­‐5.3	   0.04	  
	  










Figure	  5.6	  Cumulative	  risk	  for	  development	  of	  F≥4	  post	  transplantation	  according	  to	  
CXCL10	  levels	  measured	  at	  6	  months	  post	  transplant	  
	  
3.5	  Patient	  and	  graft	  survival	  
Using	  the	  CXCL10	  cut-­‐off	  of	  <163	  pg/ml,	  no	  differences	  in	  patient	  survival	  at	  12	  (98%	  
versus	   98%),	   36	   (89%	   versus	   87%)	   and	   60	   (79%	   versus	   71%)	  months	  were	   observed	  
respectively	   (Log	  rank	  p	  =	  0.5).	  There	  was	  a	  trend	  towards	   improved	  graft	  survival	   in	  
patients	  with	  a	  CXCL10	  level	  <	  163pg/ml	  at	  12	  (98%	  versus	  98%),	  36	  (90%	  versus	  80%)	  
and	  60	  (82%	  versus	  63%)	  months	  respectively	  but	  this	  was	  not	  statistically	  significant	  





3.6	  Anti-­‐viral	  therapy	  post	  transplant	  
Demographic	   and	   clinical	   data	   of	   91	   patients	   that	   underwent	   anti-­‐viral	   therapy	   for	  
recurrent	  HCV	  post-­‐transplantation	   is	   shown	   in	  Table	  5.3.	  Median	   time	   to	   treatment	  
was	   32	   months	   (15-­‐166	   months).	   Median	   CXCL10	   levels	   taken	   immediately	   pre-­‐
treatment	   (time	  0)	  were	  272	  pg/ml	   (74-­‐614).	  12	  patients	  had	  been	  treated	  with	  PEG	  
and	  RBV	  pre-­‐	  transplantation	  unsuccessfully	  (5	  x	  RR,	  6	  x	  NR	  and	  1	  intolerant	  to	  therapy	  
due	   to	   visual	   disturbance).	   71	   (78%)	   patients	  were	   commenced	   on	   a	   LADR	   protocol	  
(median	   dose	   of	   PEG-­‐IFN	   135mcg/week,	  median	   dose	   of	   ribavirin	   800mg/day).	   80%	  
achieved	  full	  dose	  of	  PEG-­‐IFN	  whilst	  only	  73%	  of	  patients	  achieved	  the	  full	  target	  dose	  
of	  ribavirin.	  Median	  treatment	  duration	  was	  48	  weeks	  (range	  1-­‐72).	  12	  patients	  (13%)	  
experienced	   PEG	   induced	   graft	   dysfunction	   requiring	   augmentation	   of	  
immunosuppression.	   No	   patients	   developed	   acute	   cellular	   rejection	   and	   required	  
boluses	  of	  corticosteroids	  or	  interruption	  of	  anti-­‐viral	  therapy.	  Baseline	  CXCL10	  levels	  
correlated	  with	  serum	  AST	  (r=0.4,	  p=0.001),	  ALT	  (r=0.4,	  p=0.006),	  Fibrosis	  (F)	  score	  on	  
liver	  biopsy	   (r=0.3,	  p=0.02)	  and	  necro-­‐inflammatory	   (NI)	   score	  on	   liver	  biopsy	   (r=0.7,	  
p<0.0001).	  CXCL10	   levels	  varied	  according	  to	  recipient	   IL28B	  genotype	  (CC,	  132pg/ml	  

























Recipient	  age	  (years)	   55(36-­‐67)	   54(40-­‐63)	   55(36-­‐67)	   0.5	  
Donor	  age	   51(32-­‐71)	   52(32-­‐71)	   50(36-­‐65)	   0.5	  
Sex	  (M/F)	   55/15	   23/7	   32/8	   -­‐	  
MELD	   8(6-­‐21)	   8(6-­‐9)	   9(6-­‐21)	   0.49	  
ALT	  (IU/ml)	   109(32-­‐383)	   93(32-­‐383)	   119(32-­‐325)	   0.17	  
AST	  (IU/ml)	   91(27-­‐388)	   81(27-­‐267)	   111(28-­‐388)	   0.34	  
Bilirubin	  (mg/dL)	   13(5-­‐127)	   12(6-­‐18)	   15(5-­‐127)	   0.8	  













18/54/15	   10/29/0^	   8/25/15	   -­‐	  
Time	  to	  treatment	  
(months)	  
32(15-­‐166)	   34(15-­‐166)	   33(18-­‐156)	   0.4	  
NI	  score	  on	  liver	  
biopsy	  
6	  (2-­‐11)	   5	  (1-­‐9)	   7(2-­‐11)	   <0.0001	  
F	  score	  on	  liver	  
biopsy	  
3(2-­‐6)	   3(2-­‐6)	   4(3-­‐6)	   0.002	  
F≥4	  (%)	   42	   27	   53	   0.008	  
CXCL10	  (pg/ml)	   272(74-­‐614)	   132(97-­‐612)	   400(74-­‐614)	   <0.0001	  
	  
	  
Table	   5.4.	   Baseline	   demographic,	   clinical	   and	   biochemical	   data	   parameters	   in	  
patients	   that	   underwent	   anti-­‐viral	   therapy	   (expressed	   as	   median,	   minimum	   and	  
maximum)	  
*Chi-­‐squared;	  Performed	  between	  non-­‐genotype	  1	  and	  genotype	  1	  patients.	  





3.7	  Virologic	  response	  
Overall,	  35	  patients	  achieved	  an	  EVR	  (10	  genotype-­‐1	  patients	  and	  25	  non-­‐genotype-­‐1	  
patients)	  (Table	  5.5).	  CXCL10	  levels	  were	  significantly	  lower	  in	  those	  that	  achieved	  an	  
EVR	  compared	  to	   those	   that	  did	  not	   (134	  vs.	  422	  pg/ml,	  p=0.004).	  26	  patients	   (29%)	  
achieved	   SVR	   (18	   non	   genotype-­‐1	   patients	   and	   8	   genotype-­‐1	   patients.	   45	   patients	  
(49%)	  were	  NR	  and	  20	  patients	  (22%)	  were	  RR.	  Treatment	  was	  terminated	  due	  to	  side	  
effects	  in	  23	  (25%)	  patients.	  The	  commonest	  side	  effects	  were	  neutropenia	  and	  sepsis.	  
13	   patients	   required	   admission	   for	   red	   blood	   cell	   transfusion.	   	   In	   the	   total	   patient	  
cohort,	  CXCL10	  levels	  were	  significantly	  lower	  in	  those	  that	  achieved	  SVR	  (121	  vs.	  374	  
pg/ml,	   p<0.0001)	   compared	   to	   those	   that	   did	   not.	   	   CXCL10	   levels	   were	   higher	   in	  
patients	  who	  had	  a	  NR	  compared	  to	  those	  who	  were	  RR	  or	  those	  who	  achieved	  a	  SVR	  
(441	  vs.	  202	  vs.	  121	  pg/ml,	  p<0.0001).	  
	  
In	  genotype-­‐1	  patients,	  32	  patients	  (68%)	  were	  NR	  and	  8	  (17%)	  were	  RR.	  	  No	  significant	  
differences	  were	  found	  in	  patients	  that	  achieved	  SVR	  compared	  to	  those	  that	  did	  not	  
achieve	  SVR	  with	  regards	  to	  recipient	  age,	  baseline	  HCV	  viral	  load,	  MELD	  score,	  fibrosis	  
score	   and	   percentage	   that	   were	   cirrhotic.	   AST	   (55,	   28-­‐88	   vs.	   121,	   30-­‐388	   IU/ml,	  
p=0.014),	  ALT	   (55,	  32-­‐100	  vs.	  124,	  35-­‐325	   IU/ml	  p=0.005),	  NI	  scores	  on	  biopsy	   (3,2-­‐8	  
vs.	   8,	   3-­‐11,	   p=0.003)	   and	   CXCL10	   levels	   were	   significantly	   lower	   in	   patients	   that	  
achieved	   SVR	   (106,	   74-­‐134	   vs.	   411,178-­‐614	   pg/ml,	   p<0.0001).	   	   CXCL10	   levels	   also	  






In	  non	  genotype-­‐1	  patients,	  10	  patients	  (23%)	  were	  NR	  and	  15	  patients	  (35%)	  were	  RR.	  
CXCL10	   levels	  were	   lower	   in	  patients	   that	  achieved	  SVR	   (122,	  99-­‐144	  vs	  220,	  97-­‐612	  
pg/ml,	   p=0.004).	   CXCL10	   levels	  were	   again	   highest	   in	   the	  NR	   group	   compared	   to	  RR	  
and	  those	  that	  achieved	  SVR	  (385	  vs.	  201	  vs.	  122,	  p=0.002).	  
	  








EVR	  (n/%)	   35/39	   25/58	   10/21	  
SVR	  (n/%)	   26/29	   18/42	   8/17	  
CXCL10	  (pg/ml)	  
according	  to	  SVR	  
(Yes	  vs.	  No)	  
	  
	  
121	  vs.	  374**	   122	  vs.	  220*	   106	  vs	  411**	  
NR	  (n/%)	   45/49	   10/23	   32/68	  




(NR	  vs.	  RR	  vs.	  SVR)	  
441	  vs.202	  vs.	  121**	   385	  vs.	  201	  vs.	  122*	   441	  vs.	  231.	  106**	  
	  
Table	  5.5.	  Treatment	  response	  and	  CXCL10	  levels.	  
EVR,	  early	  virologic	  response;	  SVR,	  sustained	  virologic	  response;	  NR,	  non	  response;	  RR,	  responder	  relapser	  
*	  p<0.05,	  **	  p<0.0001	  
	  
	  
3.8	  Predictors	  of	  sustained	  virologic	  response	  
Univariate	   logistic	   regression	   analysis	   identified	   non-­‐genotype-­‐1,	   EVR,	   adherence	   to	  
treatment,	  fibrosis	  score	  <4,	  IL28B	  CC	  genotype	  and	  pre-­‐treatment	  CXCL10	  levels	  to	  be	  
predictors	  of	  a	  SVR	  (Table	  5.6).	  	  Only	  HCV	  non	  genotype-­‐1,	  fibrosis	  <	  4,	  EVR,	  IL28B	  CC	  
genotype	  and	  CXCL10	   levels	   remained	  significant	  predictors	  of	  a	  SVR	  on	  multivariate	  




(AUROC	  0.96,	  95%	  CI	  0.9-­‐1.0,	  p<0.0001)	  with	  a	  sensitivity	  of	  94%	  and	  specificity	  of	  55%	  
for	  predicting	  a	  SVR.	  	  
	  
Parameter	   Hazard	  
ratio	  
95%	  CI	   P	  value	  
Univariate	  
Recipient	  age	   0.9	   0.9-­‐1.02	   0.2	  
Non	  Genotype-­‐1	   5.4	   1.8-­‐16.9	   0.003	  
EVR	   1.7	   1.28-­‐2.38	   <0.0001	  
Adherence	  to	  treatment*	   10.7	   1.32-­‐86.6	   0.03	  
HCV	  VL	  <800,000	   0.3	   0.087-­‐1.32	   0.12	  
Fibrosis	  <4	   4.9	   1.273-­‐19.0	   0.02	  
Recipient	  rs12979860	  IL-­‐28B	  	  CC	  
genotype	  
1.6	   4.2-­‐7.7	   0.003	  
CXCL10	   1.2	   1.02-­‐1.9	   0.003	  
	  
Multivariate	  
Non	  Genotype-­‐1	   4.1	   3.1-­‐22.6	   0.007	  
EVR	   2.5	   1.5-­‐10.2	   0.009	  
Fibrosis	  <	  4	   3.1	   2.3-­‐26.1	   0.04	  
CXCL10	   1.3	   1.3-­‐2.1	   0.04	  
Recipient	  rs12979860	  IL-­‐28B	  CC	  
genotype	  




Table	  5.6.	  Predictors	  of	  sustained	  virologic	  response	  
	  




3.8.1	  Genotype-­‐1	  patients	  
CXCL10	  levels	  differed	  according	  to	  recipient	  rs129870	  IL28B	  genotype	  (CC,	  132	  pg/ml	  
vs.	  CT,	  250pg/ml	  vs.	  TT,	  532	  pg/ml,	  p<0.0001).	   In	  genotype	   -­‐1	  patients	   (n=48)	  alone,	  
ROC	   analysis	   identified	   a	   cut-­‐off	   of	   154	   pg/ml	   (AUROC	   0.84,	   95%	   CI	   0.71-­‐0.97,	  
p<0.0001)	  with	  a	   sensitivity	  of	  95%	  and	  a	   specificity	  of	  79%	   for	  predicting	  a	   SVR.	   To	  
determine	   the	   performance	   of	   the	   recipient	   rs12979860	   IL28B	   genotype	   alone	   and	  
then	   in	   conjunction	   with	   pre-­‐treatment	   CXCL10	   levels	   <154	   pg/ml	   for	   genotype-­‐1	  
patients	  respectively,	  the	  sensitivity,	  specificity,	  positive	  predictive	  value	  (PPV)	  and	  the	  
negative	  predictive	  values	  (NPV)	  were	  calculated.	  In	  genotype-­‐1	  patients,	  using	  non	  TT	  
(CC	  or	  CT)	  vs.	  TT	  recipient	  rs12979860	  IL28B	  genotype	  to	  predict	  SVR,	  the	  sensitivity,	  
specificity,	  PPV	  and	  NPV	  were	  23%,	  100%,	  100%	  and	  41%	  respectively.	  The	  addition	  of	  
an	  CXCL10	  level	  <	  154	  pg/ml	  significantly	  increased	  the	  sensitivity	  and	  NPV	  from	  23%	  
to	  55%	  and	  41%	  to	  86%	  respectively	  (<0.0001).	  	  
	  
	   Sensitivity	  %	   Specificity	  %	   PPV	  %	   NPV	  %	  
	  
Non	  TT	  vs.	  TT	  recipient	  











Non	  TT	  vs.	  TT	  recipient	  
rs12979860	  IL28B	  genotype	  











Table	  5.7.	  Performance	  of	  rs12979860	  IL28B	  genotype	  and	  CXCL10	  in	  predicting	  a	  sustained	  
virologic	  response	  in	  genotype	  1	  patients	  
PPV,	  positive	  predictive	  value,	  NPV,	  negative	  predictive	  value	  
*	  Comparative	  increase	  in	  sensitivity	  and	  NPV,	  p<0.0001	  	  






Identifying	  patients	  early	  with	  rapid	  fibrosis	  progression	  or	  more	  importantly	  who	  are	  
deemed	  at	   risk	   for	  developing	   rapid	   fibrosis	   seems	  a	   sensible	  management	   strategy.	  
These	   patients	   would	   therefore	   be	   candidates	   for	   early	   AVT	   also.	   A	   liver	   biopsy	  
performed	   at	   12	   months	   readily	   identifies	   patients	   with	   a	   fast	   fibrosis	   (F≥2)	  
phenotype.	  A	  fibrosis	  stage	  ≥2	  at	  12	  months	  has	  also	  been	  identified	  as	  an	  important	  
factor	   associated	  with	   inferior	   patient	   survival	   post-­‐transplantation	   (Gallegos-­‐Orozco	  
et	   al.,	   2009).	   	   In	   our	   study,	   we	   evaluated	   the	   role	   of	   CXCL10	   as	   a	   predictor	   of	   the	  
development	  of	   slow	   fibrosis	   (F<2)	  and	   fast	   fibrosis	   (F≥2)	  progression	  at	  12	  months,	  
and	   the	   development	   of	   F≥4	   post	   transplantation	   in	   patients	   with	   HCV	   recurrence.	  
Our	  results,	   in	  keeping	  with	  previous	  studies,	  demonstrated	  CXCL10	   levels	  taken	  at	  6	  
months	   post	   transplant	   were	   predictive	   F≥2	   at	   12	   months	   with	   a	   high	   degree	   of	  
accuracy	   and	   also	   predicted	   the	   development	   of	   F≥4	   post-­‐transplantation.	   An	  	  	  	  	  	  	  	  
CXCL10	  level	  >	  163	  pg/ml	  at	  6	  months	  post	  LT	  was	  identified	  as	  a	  significant	  predictor	  
for	  the	  development	  F≥4	  and	  was	  associated	  with	  a	  quicker	  time	  to	  the	  development	  
of	   F≥4	   post-­‐transplant.	   Figure	   5.5	   demonstrates	   the	   cumulative	   risk	   for	   the	  
development	  of	  F≥4 according	  to	  CXCL10	  at	  6	  months.	  	  
	  
There	  was	  certainly	  a	  trend	  towards	  improved	  survival	   in	  patients	  with	  CXCL10	  <	  163	  
pg/ml	  which	  may	  become	  evident	  with	   longer	   follow-­‐up.	  This	   finding	   is	   important	  as	  




a	  more	  aggressive	   fibrosis	  phenotype	  and	   individuals	  who	  would	  require	  AVT	  earlier.	  
This	  finding	  needs	  to	  be	  validated	  using	  larger	  cohorts.	  	  
	  
Given	  that	  CXCL10	  is	  produced	  by	  endothelial	  cells,	  monocytes	  and	  by	  HSCs	  attention	  
has	  therefore	  turned	  to	  assessing	  the	  role	  of	  CXCL10	  in	  predicting	  fibrosis	  progression.	  
Our	   results	   are	   in	   keeping	   and	   confirm	   a	   recent	   study	   that	   evaluated	   the	   role	   of	  	  	  	  	  	  
CXCL-­‐10	  amongst	  other	  chemokines	  in	  predicting	  fibrosis	  progression	  in	  HCV	  patients-­‐
post	   transplant	   (Berres	   et	   al.,	   2011).	   In	   a	   study	   of	   90	   patients	   with	   predominately	  
genotype	  1	  disease,	  the	  authors	  demonstrated	  significant	  correlation	  of	  CXCL10	  levels	  
with	   the	   severity	   of	   fibrosis	   and	   necro-­‐inflammatory	   activity	   at	   1-­‐year	   post	  
transplantation	  and	  found	  CXCL10	  to	  be	  a	  significant	  predictor	  of	  fibrosis	  stage	  at	  year	  
3	   post-­‐transplantation	   (Berres	   et	   al.,	   2011).	   An	   CXCL10	   value	   of	   >	   140	   pg/ml	   was	  
predictive	  of	  the	  development	  of	  F2	  fibrosis	  (p	  =	  0.0013)	  whilst	  a	  level	  of	  >	  220	  pg/ml	  
predicted	   the	   development	   of	   F3	   fibrosis	   (p	   =	   0.04).	   Given	   the	   small	   numbers	   of	  
patients	  (n	  =	  10)	  that	  developed	  F4	  during	  the	  follow-­‐up	  period,	  life	  table	  analysis	  was	  
targeted	  towards	  those	  that	  developed	  F≥3.	  Our	  study	  however	  differs	  as	  we	  aimed	  to	  
establish	  whether	  CXCL10	  levels	  at	  6	  months	  post	  transplant	  were	  predictive	  of	  F≥2	  at	  
12	  months	  and	  the	  development	  of	  F≥4.	  
	  
CXCL10	  is	  a	  pro-­‐inflammatory	  chemokine	  responsible	  for	  the	  recruitment	  of	  activated	  
lymphocytes	   to	   the	   liver.	   It	   would	   therefore	   appear	   counter-­‐intuitive	   why	   elevated	  
levels	  of	  CXCL10	  would	  be	  associated	  with	  a	  poor	  treatment	  response.	  One	  hypothesis	  




al.,	   2011).	   Dipeptidyl	   peptidase	   IV	   (DPP4	   or	   CD26),	   expressed	   by	   hepatocytes,	  
fibroblasts	  and	  endothelial	  cells,	  truncates	  CXCL10.	  	  The	  resultant	  negative	  form	  of	  the	  
protein	  can	  bind	  CXCR3	  but	  does	  not	  induce	  signalling	  (Casrouge	  et	  al.,	  2011).	  	  Studies	  
have	  been	  performed	  in	  patients	  with	  acute	  HCV	  which	  have	  measured	  the	  truncated	  
form	   of	   CXCL10,	   DDP4	   activity	   and	   the	   functionality	   of	   HCV-­‐	   specific	   T	   cells	   and	   NK	  
cells.	  (Riva	  et	  al.,	  2014).	  	  The	  data	  demonstrated	  that	  elevated	  total	  CXCL10	  levels	  were	  
associated	   with	   inferior	   treatment	   outcomes	   resulting	   in	   chronic	   infection.	   DDP4	  
activity	   correlated	   with	   concentrations	   of	   truncated	   CXCL10	   (r=0.53,	   p<0.001)	   and	  
lower	  plasma	  concentrations	  of	  truncated	  CXCL10	  and	  decreasing	  DDP4	  activity	  were	  
therefore	  a	   feature	  of	  spontaneously	  resolving	  HCV	   infection	  (Riva	  et	  al.,	  2014).	   	  The	  
same	   study	   also	   demonstrated	   a	   higher	   frequency	   of	   HCV-­‐specific	   IFN-­‐γ	   producing	  	  	  	  	  	  	  	  	  
T-­‐cells	  and	  more	  cytotoxic	  CD56	  dim	  NK	  cells	  and	  less	  cytokine-­‐producing	  CD56	  bright	  
NK	  cells	   in	  those	  who	  spontaneously	  resolved	  infection.	   	  These	  data	  could	  be	  applied	  
to	  post	  liver	  transplant	  cohorts	  in	  a	  similar	  fashion	  to	  determine	  whether	  the	  truncated	  
form	   of	   CXCL10	   results	   in	   impaired	   host	   immunity	   and	   HCV	   infection	   persistence.	  
Further	  studies,	  analysing	  the	  expression	  of	  CXCR3,	  the	  CXCL10	  receptor	  on	  NK	  and	  T	  
cell	   populations	   would	   provide	   further	   insights	   into	   the	   pathogenesis	   of	   HCV	   post	  
transplantation.	  	  
	  
As	  eluded	  to	  earlier,	  different	  forms	  of	  CXCL10	  exist.	  Using	  standard	  ELISA	  and	  Luminex	  
assays,	   studies	   have	   measured	   total	   CXCL10	   and	   truncated	   CXCL10	   levels.	   Single	  
molecule	   array	   (Simoa)	   technology	   are	   now	   available	   and	   can	   potentially	   overcome	  
this	   limitation	  and	  provides	   increased	   sensitivity	   (Rissin	   et	   al.,	   2010).	   Total,	   long	  and	  





In	  our	  cohort,	  CXCL10	  levels	  varied	  according	  to	  IL28B	  genotype;	  higher	  values	  noted	  in	  
CT	   and	   TT	   genotypes.	   This	   relationship	   was	   statistically	   significant	   and	   has	   been	  
demonstrated	  in	  other	  cohorts	  albeit	  in	  pre	  liver	  transplantation	  cohorts	  (Fattovich	  et	  
al.,	  2011).	  The	  strength	  of	  the	  relationship	  demonstrated	  in	  my	  data	  is	  probably	  due	  to	  
the	  combination	   	  of	  CXCL10	  being	  a	  marker	  of	   fibrosis	  and	   ISG	  upregulation.	  CXCL10	  
levels	  vary	  according	  to	  fibrosis	  stage	  as	  demonstrated	  earlier,	  and	  the	  median	  fibrosis	  
stage	  pre	  treatment	  was	  F3.	  Median	  pre-­‐treatment	  CXCL10	  levels	  were	  272	  pg/ml	  at	  a	  
median	  time	  of	  32	  months	  post	  transplant.	  A	  pre-­‐treatment	  CXCL10	  level	  <	  126	  pg/ml	  
was	   associated	  with	   a	   SVR.	   In	   genotype	   1	   patients	   alone,	   the	   cut-­‐off	   value	  was	   154	  
pg/ml.	  Established	  pre-­‐treatment	  predictors	  of	  SVR	  with	  PR	  include	  a	  low-­‐baseline	  HCV	  
viral	   load,	   non-­‐genotype	   1	   disease,	   female	   gender	   and	   the	   absence	   of	   advanced	  
fibrosis	  (F<4)	  (Watt	  et	  al.,	  2009).	  In	  genotype-­‐1	  patients,	  the	  addition	  of	  a	  recipient	  non	  
TT	  rs12979860	  IL28B	  genotype	  and	  an	  CXCL10	  level	  <	  154	  pg/ml	  significantly	  improved	  
the	  negative	  predictive	  value	  from	  41%	  to	  86%	  (p<0.0001).	  	  This	  data	  could	  therefore	  
identify	   patients	   who	  more	   likely	   to	   respond	   and	   benefit	   from	   AVT.	   At	   the	   time	   of	  
conducting	   these	   experiments,	   DAA	   therapy	   was	   not	   readily	   available.	   Minimising	  
patients	  to	  the	  long	  duration	  and	  potential	  harmful	  side-­‐effects	  of	  pegylated	  interferon	  
based	  therapy	  were	  therefore	  very	  relevant.	  	  
	  
EVR	   was	   a	   significant	   predictor	   of	   success	   with	   AVT	   but	   data	   regarding	   a	   RVR	   was	  
limited	   partly	   due	   to	   the	   use	   of	   a	   LADR	   regimen.	   Treatment	   currently	   is	   with	   dual	  
therapy	  (PR)	  but	   is	  associated	  with	   inferior	  SVR	  rates,	  an	   increased	  side-­‐effect	  profile	  




tolerated	  compared	  to	  patients	  pre-­‐transplantation	  (Watt	  et	  al.,	  2009).	  The	  use	  of	  the	  
newer	  directly	  acting	  anti-­‐viral	  agents	  (DAA)	   in	  post-­‐transplant	  patients	   is	   limited	  but	  
preliminary	   data	   is	   encouraging	   although	   meticulous	   attention	   is	   required	   to	   avoid	  
drug-­‐drug	   interactions	   between	   calcineurin	   inhibitors	   and	   the	   protease	   inhibitors	  
(Coilly	   et	   al.,	   2012).	   For	   the	   immediate	   future,	   AVT	   appears	   to	   be	   with	   a	   PEG/RBV	  
backbone	  suggesting	  a	  possible	  role	  for	  CXCL10.	  
	  
	  
Our	  study	  has	  several	  limitations	  related	  to	  its	  retrospective	  and	  mono-­‐centric	  design.	  
Another	  potential	   source	  of	  bias	   is	   that	  although	  we	  excluded	  certain	  patient	  groups	  
(HBV,	  HIV	  co-­‐infected,	  patients	  undergoing	  re-­‐transplantation,	  those	  that	  underwent	  a	  
combined	  liver-­‐kidney	  procedure	  and	  those	  that	  did	  not	  survive	  12	  months),	  a	  further	  
57	  patients	  predominately	  transplanted	  in	  the	  early	  part	  of	  the	  study	  were	  not	  eligible	  
for	   inclusion	  as	   they	  had	  not	  undergone	  a	   liver	  biopsy	  at	   12	  months.	   It	   is	   likely	   that	  
these	  patients	  will	  have	  had	  unrecognised	  fibrosis	  and	  may	  have	  added	  to	  the	  number	  
of	  patients	  with	  fast	  fibrosis	  progression	  at	  12	  months	  and	  F≥4	  post-­‐transplantation.	  
Measurement	  of	  CXCL10	  in	  patients	  with	  FCH	  would	  have	  provided	  interesting	  data	  on	  
the	  host	   immune	   response.	  Our	  numbers	  were	   small	   and	  our	   results	   require	   further	  
validation	  in	  larger	  cohorts	  especially	  using	  the	  CXCL10	  cut-­‐off	  values	  we	  describe.	  
	  
In	   conclusion,	   CXCL10	   levels	   measured	   at	   6	   months	   post	   transplant	   predict	   the	  
development	   of	   rapid	   fibrosis	   at	   12	  months	   (F≥2)	   and	   F≥4	   post-­‐transplantation	   in	  
patients	  with	  recurrent	  HCV.	  In	  addition,	  pre-­‐treatment	  CXCL10	  levels	  identify	  patients	  




with	   rapid	   fibrosis	   and	   those	   requiring	   early	   exposure	   to	   AVT	   in	   the	   post-­‐transplant	  
period	  but	  also	  importantly,	  those	  that	  are	  likely	  to	  respond	  successfully.	  	  	  
	  
	  




Chapter	  VI	  	  
Defining	   the	   role	   of	   microRNA	   in	   predicting	   HCV	   recurrence	  
post	  liver	  transplantation	  and	  their	  role	  as	  biomarkers	  for	  HCV	  
recurrence.	  






miRNAs	   have	   been	   shown	   to	   play	   an	   essential	   role	   in	   HSC	   function,	   activation	   and	  
hepatic	   fibrosis	   (Moreira,	   2007,	   Atzori	   et	   al.,	   2009).	   	   To	   date,	   there	   are	   a	   paucity	   of	  
studies	  performed	   in	   the	  post-­‐transplant	   setting	  especially	   in	  patients	  with	   recurrent	  
HCV.	   HCV	   recurrence	   post	   liver	   transplantation	   represents	   a	   unique	   model	   of	  
accelerated	  fibrosis	  and	  therefore	  I	  aimed	  to	  delineate	  possible	  pathways	  involved.	  In	  
addition,	   I	   aimed	   to	   identify	   possible	   miRNAs	   could	   act	   as	   serum	   biomarkers	   for	  
fibrosis.	   Finally,	   I	   aimed	   to	   delineate	   the	   different	  miRNA	   profiles	   involved	   in	   acute	  
cellular	  rejection	  (ACR)	  and	  recurrent	  HCV.	  
2.	  Subjects	  
All	   adult	   patients	   (>	   18	   years)	   transplanted	   for	  HCV	   related	   cirrhosis	   that	   received	   a	  
heart	   beating	   donor	   between	   January	   2000	   and	   January	   2010	   at	   King’s	   College	  
Hospital,	   London	   were	   identified.	   Protocol	   liver	   biopsies	   are	   performed	   at	   our	  
Institution	  at	  12	  months	  or	  earlier	  in	  the	  event	  of	  graft	  dysfunction.	  	  Specimens	  were	  
assessed	  and	  scored	  according	  to	  the	  modified	  Ishak	  classification	  (0	  -­‐	  no	  fibrosis	  and	  6	  
–	  cirrhosis).	  A	  fibrosis	  score	  ≥	  2	  at	  12	  months	  classified	  the	  patient	  as	  a	  fast-­‐	  progressor	  
with	  regards	  to	  HCV	  recurrence	  (Firpi	  et	  al.,	  2004).	  
	  
Patients	  with	   recurrent	  HCV	  post-­‐transplant	  were	  divided	   into	  2	  groups	  according	   to	  
their	  fibrosis	  score;	  Group	  A,	  slow-­‐	  progressors	  (n	  =	  11)	  –	  F	  <2	  at	  12	  months;	  and	  Group	  
B,	   fast-­‐	   progressors	   (n=9)	   -­‐	   F	   ≥	   2	   at	   12	   months.	   Patients	   in	   Groups	   A	   and	   B	   were	  
matched	  according	  to	  the	  following	  variables:	  recipient	  age,	  donor	  age,	  MELD	  score	  at	  




evidence	  of	  CMV	  viraemia,	  and	  immunosuppression	  regimen.	  	  Patients	  were	  selected	  
prior	  to	  the	  miRNA	  expression	  studies	  and	  were	  identified	  from	  a	  total	  cohort	  of	  133	  
patients.	  All	  patients	  received	  dual	  therapy	  with	  tacrolimus	  (target	  trough	  levels	  8-­‐10	  
mg/ml)	   and	   a	   reducing	   dose	   of	   corticosteroid	   following	   transplantation.	   No	   patient	  
received	   OKT-­‐3	   or	   an	   interleukin-­‐2	   blocker.	   Data	   capture	   included	   post-­‐operative	  
clinical	   course,	   immunosuppression,	   number	   of	   methylprednisolone	   boluses,	  
occurrence	   of	   biopsy-­‐proven	   acute	   cellular	   rejection	   and	   serum	   liver	   graft	   function	  
tests.	  Group	  C	   (n	  =	  5)	   consisted	  of	  biopsies	   taken	   from	  patients	  with	  HCV	  and	  acute	  
cellular	  rejection	  (according	  to	  the	  Banff	  criteria).	  Group	  D	  (n	  =	  4)	  consisted	  of	  biopsies	  
taken	   from	  patients	   transplanted	   for	   alcohol	   related	   liver	   disease	   and	   served	   as	   the	  
control	  group.	  All	  biopsies	  were	  performed	  and	  driven	  by	  clinical	  necessity.	  Exclusion	  
criteria	   included	   hepatocellular	   carcinoma	   at	   time	   of	   transplant,	   co-­‐infection	   with	  
hepatitis	  B	  virus	  or	  human	  immunodeficiency	  virus	  types	  1	  and	  2,	  and	  liver	  disease	  of	  
other	  origin	   than	  HCV	   infection	   (except	   for	  patients	   in	  Group	  D).	   Stored	   serum	   from	  
patients	  in	  group	  A,	  slow	  –	  progressors	  and	  group	  B,	  fast	  progressors	  were	  analysed	  for	  
miRNA	   identified	   using	   quantitative	   PCR	   analysis.	   	   Serum	   samples	   were	   taken	   at	  
median	  of	  6	  months	  post	  transplantation	  (range	  4-­‐10	  months)	  
	  
	  





In	   total,	   29	  patients	  were	   included	   in	   the	  analysis:	  patient	  demographics	  and	  clinical	  
data	  are	   listed	   in	  Table	  6.1.	  As	  expected	  genotype	  1	  disease	  was	   the	  most	  prevalent	  
and	   represents	   the	  HCV	  population	   seen	   in	  our	   centre.	   The	   recipient	   rs12979860	   IL-­‐
28B	  TT	  haplotype	  was	  equally	  represented	  across	  Groups	  A,	  B	  and	  C.	  	  Median	  HCV	  viral	  






Table	  6.1.	  Patient	  demographics	  for	  Groups	  A-­‐D.	  
	  
	  
(the control group) showed essentially normal post-LT
histology (Fig. 1F).
miRNA Expression Distinguishes Between Slow
nd Fast HCV F brosis Progressors After Trans-
plantation as Well as ACR
Principal component analysis (PCA) resolves a multi-
dimensional data set by identifying key variables
that explain the observed differences. Intragraft
miRNA in all 29 patients included in our study was
resolved into 3 principal components represented in
a 3-dimensional scatter plot. This demonstrated a
clear segregation of all 4 groups according to miRNA
expression profiles at a P value of 0.01 (Fig. 2B).
The supervised hierarchical cluster analysis (HCA)
for miRNA expression demonstrated that a greater
similarity of expression existed in each group (Fig.
2A). The graphical tree (cladogram) above the heat
map also confirms this observation because it
reveals stronger clustering within each group than
between different groups. It also demonstrates a
greater degree of similarity between groups A and B
than the other 2 groups by miRNA expression. The
unequivocal separation of patient groups by both
PCA and HCA clearly demonstrates that these
groups are functionally distinct with respect to
miRNA expression. The list of miRNAs identified in
this analysis and their P values are shown in
Supporting Table 1.
miRNA Expression Distinguishes Between Slow
and Fast HCV Progressors After
Transplantation
In order to determine whether there was a difference
in the miRNA expression profiles of patients with
slow fibrosis and patients with fast fibrosis, we
refined our analysis by directly comparing groups A
and B. Patients in both groups were rigorously
matched for factors known to influence the rate of
HCV recurrence. Therefore, as expected, there were
no demonstrable statistical differences between the 2
groups (see Table 1). At the time of liver biopsy, the
patients were clinically well with satisfactory liver
graft function. The median HCV viral loads were
comparable both before and after LT. No patient had
been exposed to antiviral therapy in the posttrans-
plant period at the time of liver biopsy. PCA and
HCA performed to a P value of 0.01 demonstrated a
clear segregation of the 2 groups with respect to
miRNA expression (Supporting Fig. 2). One hundred
fifty-two miRNAs of statistical significance that were
differentially regulated between groups A and B were
identified.
TABLE 1. Patient Demographics for Slow Fibrosis Progressors (Group A), Fast Fibrosis Progressors (Group B), HCV and
ACR Patients (Group C), and Controls (Group D)
Patient Groups*
A (n511) B (n59) C (n55) D (n54)
Recipient age at transplant (years)† 52 (36-62) 46 (35-57) 45 (26-56) 50 (26-62)
Donor age (years)† 45 (44-58) 46 (29-73) 55 (29-62) 59 (55-69)
MELD score at transplant † 15 (11-19) 14 (11-18) 14 (11-21) 9 (8-14)
HCV genotype 1a (%) 55 56 40 N/A
IL-28B rs12979860 TT genotype (%) 18 22 20 N/A







Methylprednisone boluses (n) 4 3 5 3
Cold ischemia time (hours)† 9.0 (7.6-15.3) 10.8 (7.8-18.9) 8.8 (7.9-19.2) 14.5 (12.8-15.6)
Biopsy-proven ACR (%) 18 11 100 25
Donor risk index† 1.6 (1.2-2.3) 1.7 (1.5-2.1) 2 (1.8-2.4) 1.8 (1.4-2.1)
Diabetes (%) 45 44 40 50
Cytomegalovirus viremia (%) 18 11 0 25
Variables at biopsy
Time from transplant (months)† 12 (8-15) 15 (8-17) 8 (5-90)‡ 20 (10-56)
Tacrolimus monotherapy (%) 64 77 100 100
Aspartate aminotransferase (IU/mL)† 55 (17-362) 62 (21-263) 227 (105-325) 77 (38-257)
Bilirubin (mg/dL)† 12 (8-23) 17 (7-44) 73 (48-171) 16 (9-32)
Fibrosis score (0-6)†§ 1 (0-1) 3 (3-4) 0 (0-1) N/A







*There was no statistical difference between groups A and B.
†The data are expressed as medians and ranges.
‡The data are expressed in days.
§Fibrosis score 0-6.







Figure	   6.1	   Histological	   analysis	   of	   slow	   fibrosis	   progressors	   (group	   A),	   fast	   fibrosis	  
progressors	   (group	   B),	   ACR	   patients	   (group	   C)	   and	   controls	   (group	   D).	   (A,B)	  
Representative	  reiculin	  staining	  for	  (A)	  group	  A	  and	  (B)	  group	  B.	  (C-­‐F)	  Representative	  
H&E	  staining	  for	  (C)	  group	  A,	  (D)	  group	  B,	  (E)	  group	  C	  and	  (F)	  group	  D.	  
	  
	  
miRNA Expression Is Associated With Slow
HCV Progression After LT
Seventy-six of the 152 miRNAs differentially
expressed between groups A and B were down-regu-
lated, and 76 were up-regulated in group A versus
group B. The data sets of both down-regulated and
up-regulated miRNAs were individually analyzed with
MetaCore to examine the genetic pathways known to
be regulated by these miRNAs. This algorithm recog-
nizes coregulated components of pathways or biologi-
cal processes that are affected by increased or
decreased expression of specific miRNAs. Up-regula-
tion of a given miRNA results in increased inhibition
(down-regulation) of its target genes, whereas reduced
miRNA expression reverses this inhibition and leads
to target gene up-regulation.
A MetaCore analysis of up-regulated and down-
regulated miRNAs in slow progressors versus fast
progressors identified 7 networks (6 up-regulated net-
works and 1 down-regulated network) of high statisti-
cal significance (Fig. 3A). The identification of these
genetic pathways is based on known target gene regu-
lation by miRNAs that are differentially expressed
between slow and fast progressors. These networks
regulate many pathways that have been implicated in
mediating HCV progression, and they are outlined
next.
Antifibrotic Pathways (Fig. 3Ai)
Three statistically significant networks of miRNAs
associated with antifibrotic pathways were identified:
miRNA-200a and miRNA-141 (P52.39 3 10218),
miRNA-203 and miRNA-146a (P52.3331025), and
miRNA-146a and miRNA-19a (P52.67 3 1029).
Increased expression of both miRNA-203 and miRNA-
146a is known to lead to the down-regulation of
SMAD4. This acts as a tumor suppressor that func-
tions in the regulation of the transforming growth
factor b (TGFb) signal transduction pathway, which is
an important profibrotic pathway. Increased
miRNA200a and miRNA-141 expression is known to
mediate direct down-regulation of transforming
growth factor b receptor 2 (TGFbR2). Increased
expression of miRNA-146a and miRNA-19a leads to
the down-regulation of epidermal growth factor recep-
tor (EGFR).
Antiangiogenic Pathways (Fig. 3Aii)
One miRNA network that is known to inhibit angio-
genesis was identified: increased expression of
miRNA-20a, miRNA-20b, and miRNA-205 (P52.02 3
10211) leads to the down-regulation of vascular endo-
thelium factor A (VEGFA) activity.
Anti-Inflammatory Pathways (Fig. 3Aiii)
One network was associated with regulating the
expression of genes promoting anti-inflammatory
pathways: miRNA-146a, miRNA-33a, and let-7e
(P51.96 3 10215). Increased miRNA-146a expression
is known to inhibit the expression of proinflammatory
mediators, including IL-8, IL-6, chemokine ligand 8
(CCL8), and CD40 ligand (CD40L). In addition,
increased miRNA-33a expression leads to decreased
insulin receptor substrate 2 (IRS2) activity, and
increased let-7e expression leads to decreased toll-
like receptor 4 (TLR4) expression.
Antiapoptotic Pathways (Fig. 3Aiv)
A single statistically significant network of down-regu-
lated miRNAs that regulates antiapoptotic pathways
was identified: miRNA 19a and miRNA 150 (P51.84 3
10218). Decreased miRNA-150 expression causes up-
regulation of c-Myb, and decreased miRNA-19a expres-
sion leads to the up-regulation of N-Myc expression.
Other Pathways (Fig. 3Av)
An additional network of differentially expressed miR-
NAs that we identified (miRNA-205, miRNA-204,
miRNA-20a, miRNA-146a, and miRNA-328; P51.25
3 10213) inhibits the expression of genes known to
Figure 1. Histological analysis of slow fibrosis progressors
(group A), fast fibrosis progressors (group B), ACR patients
(group C), and controls (group D). (A,B) Representative reticulin
staining for (A) group A and (B) group B. (C-F) Representative
H&E sta ning for (C) group A, (D) group B, (E) group C, and (F)
group D. The Ishak fibrosis and NI scores were (A) F1 and NI3
and (B) F3 and NI5.




3.1	  miRNA	  expression	  distinguishes	  slow	  and	  fast	  fibrosis	  progressors	  of	  HCV	  post-­‐
transplant	  as	  well	  as	  acute	  cellular	  rejection	  
	  
Principal	  component	  analysis	  (PCA)	  resolves	  a	  multidimensional	  data	  set	  by	  identifying	  
key	  variables	  that	  explain	  the	  observed	  differences.	  Intragraft	  miRNA	  in	  all	  29	  patients	  
included	  in	  our	  study	  was	  resolved	  in	  to	  three	  principal	  components	  represented	  in	  the	  
three-­‐dimensional	  scatter	  plot.	  This	  demonstrated	  a	  clear	  segregation	  of	  all	  4	  groups	  
according	   to	   miRNA	   expression	   profiles	   at	   a	   P	   value	   of	   0.01	   (Figure	   6.2B).	   The	  
supervised	  hierarchical	  cluster	  analysis	  (HCA)	  for	  miRNA	  expression	  demonstrated	  that	  
a	   greater	   similarity	   of	   expression	   existed	   in	   each	   group	   (Figure	   6.2A).	   The	   graphical	  
tree	   (cladogram)	   above	   the	   heat	   map	   also	   confirms	   this	   observation,	   as	   it	   reveals	  
stronger	   clustering	   within	   each	   group	   than	   between	   different	   groups.	   It	   also	  
demonstrates	  a	  greater	  degree	  of	  similarity	  between	  Groups	  A	  and	  B	   than	  the	  other	  
two	   groups	   by	   miRNA	   expression.	   The	   unequivocal	   separation	   of	   patient	   groups	   by	  
both	   PCA	   and	   HCA	   analysis	   clearly	   demonstrates	   that	   these	   groups	   are	   functionally	  







Figure	   6.2:	   miRNA	   expression	   distinguishes	   Groups	   A-­‐D.	   (A)	   Hierarchical	   cluster	  
analysis	   for	   Groups	   A-­‐D	   (P<.01).	   The	   cladogram	   shown	   above	   the	   heatmap	  
demonstrates	   the	   degree	   of	   similarity	   between	   the	   samples	   in	   terms	   of	   miRNA	  
expression.	  (B)	  Principal	  Component	  Analysis	  for	  the	  same	  data-­‐set.	  
	   	  promote HCV disease progression. Increased miRNA-146a leads to decreased signal transducer and
activator of transcription 1 (STAT1) expression, and
increased miRNA-20a leads to decreased expression
of TGFbR2.
Validation and Quantification of miRNA
Expression by PCR
In order to independently validate the changes in






Figure 2. miRNA expression distinguishes slow fibrosis progressors (group A), fast fibrosis progressors (group B), ACR patients
(group C), and controls (group D). (A) HCA for groups A to D (P<0.01). The cladogram above the heat map demonstrates the degree
of similarity between the samples in terms of miRNA expression. (B) PCA for the same data set. An miRNA list and associated P val-
ues are shown in Supporting Table 1.AQ17
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3.2	  miRNA	  expression	  distinguishes	  between	  slow-­‐	  and	  fast-­‐	  progressors	  of	  HCV	  
post-­‐transplant	  	  
	  
In	   order	   to	   determine	  whether	   there	  was	   a	   difference	   in	  miRNA	   expression	   profiles	  
between	   patients	   with	   slow	   and	   fast	   fibrosis,	   we	   refined	   our	   analysis	   by	   directly	  
comparing	  Groups	  A	  and	  B.	  Patients	  in	  both	  groups	  were	  matched	  for	  factors	  that	  are	  
known	  to	  influence	  the	  rate	  of	  HCV	  recurrence.	  	  Therefore,	  as	  expected	  there	  was	  no	  
demonstrable	   statistical	   difference	   between	   the	   two	   groups	   (see	   Table	   6.1).	   	   At	   the	  
time	  of	   liver	  biopsy,	  patients	  were	  clinically	  well	  with	  satisfactory	   liver	  graft	  function.	  
Median	  HCV	  viral	  loads	  were	  comparable	  both	  pre-­‐	  and	  post-­‐liver	  transplantation.	  No	  
patient	   had	   been	   exposed	   to	   anti-­‐viral	   therapy	   in	   the	   post-­‐transplant	   period	   at	   the	  
time	  of	  liver	  biopsy.	  PCA	  and	  HCA	  performed	  to	  a	  value	  of	  0.01	  demonstrated	  a	  clear	  
segregation	  of	  the	  2	  groups	  with	  respect	  to	  miRNA	  expression	  (Figure	  6.3).	  152	  miRNAs	  
of	   statistical	   significance	   were	   identified	   that	   were	   differentially	   regulated	   between	  
















Figure	   6.3	   miRNA	   expression	   distinguishes	   slow	   and	   fast	   progressors	   of	   HCV	   post	  
transplant.	   (A)	   Hierarchical	   cluster	   analysis	   and	   cladogram	   for	   Groups	   A	   and	   B	  
(P<.01).	  (B)	  Principal	  Component	  Analysis	  for	  the	  same	  data-­‐set. 
	  




3.3	  miRNA	  expression	  is	  associated	  with	  slow	  progression	  of	  HCV	  post	  liver	  
transplant	  
	  
Of	  the	  total	  152	  miRNAs	  differentially	  expressed	  between	  Groups	  A	  and	  B,	  76	  miRNAs	  
were	  down	  regulated	  and	  76	  were	  up-­‐regulated	  in	  Group	  A	  relative	  to	  B.	  The	  data	  set	  
of	   both	   down-­‐regulated	   and	   up-­‐regulated	   miRNAs	   were	   individually	   analysed	   using	  
Metacore	   (GeneGo	   Inc.)	   to	   interrogate	   the	   genetic	   pathways	   regulated	   by	   these	  
miRNAs.	  This	  algorithm	  recognises	  co-­‐regulated	  components	  of	  pathways	  or	  biological	  
processes	   that	   are	   impacted	   on	   by	   increased	   or	   decreased	   expression	   of	   specific	  
miRNAs.	   	   Up	   regulation	   of	   a	   given	   miRNA	   results	   in	   increased	   inhibition	   (down	  
regulation)	   of	   its	   target	   genes,	   whilst	   reduced	   miRNA	   expression	   reverses	   this	  
inhibition	  leading	  to	  target	  gene	  up-­‐regulation.	  
	  
Analysis	   using	   Metacore	   of	   the	   up-­‐regulated	   and	   down-­‐regulated	   miRNAs	   between	  
slow-­‐	  progressors	   and	   fast-­‐	   progressors,	   identified	  7	  networks	   (6	  up-­‐regulated	  and	  1	  
down-­‐regulated)	  of	  high	  statistical	  significance	  (Figure	  6.4A).	  These	  networks	  regulate	  















Figure	  6.4.	  miRNA	  expression	  distinguishes	  slow	  HCV	  progressors	  (group	  A)	  from	  fast	  
HCV	  progressors	  (group	  B)	  after	  transplantation.	  (A)	  A	  MetaCore	  analysis	  of	  group	  A	  
versus	  group	  B	   (P < 0.01)	   identified	  statistically	   significant	  networks	  of	  miRNAs	  and	  
known	  target	  genes	  implicated	  in	  (i)	  fibrogenic,	  (ii)	  angiogenic,	  (iii)	  inflammatory,	  (iv)	  
apoptotic,	  and	  (v)	  mixed	  pathways.	  (B)	  A	  quantitative	  PCR	  analysis	  of	  a	  select	  group	  
of	  miRNAs	  that	  were	  identified	  by	  a	  MetaCore	  analysis	  confirmed	  the	  up-­‐regulation	  
of	  (i)	  miRNA-­‐19a,	  (ii)	  miRNA-­‐20a,	  (iii)	  let-­‐7e,	  and	  (iv)	  miRNA-­‐146a	  expression	  in	  group	  
A	  versus	   group	  B.	   Small	   nucleolar	  RNA	  SNORD66	  was	  used	  as	   a	   reference	  RNA	   for	  
normalization.	   Values	   are	   expressed	   as	   means	   and	   standard	   deviations	   and	   are	  
representative	  of	  3	  different	  experiments.	  P	   values	   for	  each	  miRNA	  are	   indicated	  on	  
the	  graphs.	  
B and to quantify miRNA expression, we selected a
subgroup of miRNAs from the GeneGo analysis out-
lined previ usly (Fig. 3A). A quantitative PCR analysis
confirmed the up-regulation of miRNA-19a, miRNA-
20a, let-7e, and miRNA-146a in group A versus group
B (Fig. 3B). In addition, we validated miRNA expres-
sion changes detected in the microarray analysis by
carrying out quantitative PCR for 30 randomly
selected miRNAs that showed no differential expres-
sion and concordance with the array data (data not
shown). In order to investigate whether any of the
miRNAs that we identified could represent tractable,
noninvasive, and prognostic biomarkers for HCV
recurrence, a quantitative PCR analysis was also per-
formed on serum samples taken at a median of
6 months after transplantation (range54-10 months)
Figure 3. miRNA expression distinguishes slow HCV progressors (group A) from fast HCV progressors (group B) after transplanta-
tion. (A) A MetaCore analysis of group A versus group B (P<0.01) identified statistically significant networks of miRNAs and known
target genes implicated in (i) fibrogenic, (ii) angiogenic, (iii) inflammatory, (iv) apoptotic, and (v) mixed pathways. HCA and PCA for
the same data set are shown in Supporting Fig. 1; an miRNA list and associated P values are shown in Supporting Table 2. (B) A
quantitative PCR analysis of a select group of miRNAs that were identified by a MetaCore analysis confirmed the up-regulation of (i)
miRNA-19a, (ii) miRNA-20a, (iii) let-7e, and (iv) miRNA-146a expression in group A versus group B. Small nucleolar RNA SNORD66
was used as a reference RNA for normalization. Values are expressed as means and standard deviations and are representative of
3 different experiments. P values for each miRNA are indicated on the graphs.
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3.3.1	  Anti-­‐fibrotic	  pathways	  (Figure	  6.4A,	  i)	  	  
Three	   statistically	   significant	   networks	   of	  miRNA	  were	   identified	   that	   are	   associated	  
with	  anti-­‐fibrotic	  pathways:	  miRNA-­‐200a	  and	  miRNA-­‐141	  (P	  value	  2.39	  x	  10-­‐18),	  miRNA-­‐
203	  and	  miRNA-­‐146a	   (P	   value	  2.33	   x	  10-­‐5)	   and	  miRNA-­‐146a	  and	  miRNA-­‐19a	   (P	   value	  
2.67x10-­‐9).	   Increased	   expression	   of	   both	  miRNA-­‐203	   and	  miRNA-­‐146a	   are	   known	   to	  
lead	  to	  down	  regulation	  of	  SMAD4.	  This	  acts	  as	  a	  tumour	  suppressor	  that	  functions	  in	  
the	   regulation	   of	   the	   TGFβ	   signal	   transduction	   pathway,	   an	   important	   pro-­‐fibrotic	  
pathway.	   Increased	  miR-­‐200a	  and	  miRNA-­‐141	  expression	   is	   known	   to	  mediate	  direct	  
down	   regulation	   of	   TGFβR2.	   Increased	   expression	   of	   miRNA-­‐146a	   and	   miRNA-­‐19a	  
leads	  to	  down-­‐regulation	  of	  EGFR.	  
	  
3.3.2	  Anti-­‐angiogenic	  pathways	  (Figure	  6.4A	  ii)	  
One	  miRNA	   network	   that	   is	   known	   to	   inhibit	   angiogenesis	  was	   identified:	   Increased	  
expression	   of	  miRNA-­‐20a,	  miRNA-­‐20b	   and	  miRNA-­‐205	   (P	   value	   2.02x	   10-­‐11)	   leads	   to	  
down-­‐regulation	  of	  VEGF-­‐A	  activity.	  	  
	  
3.3.3	  Anti-­‐inflammatory	  pathways	  (Figure	  6.4A	  iii)	  
One	  network	  was	  associated	  with	  regulating	  the	  expression	  of	  genes	  promoting	  anti-­‐
inflammatory	   pathways	   (miRNA-­‐146a,	   miRNA-­‐33a,	   let-­‐7e,	   P	   value	   1.96x10-­‐15).	  
Increased	  miRNA-­‐146a	  expression	  is	  known	  to	  inhibit	  expression	  of	  pro-­‐inflammatory	  
mediators	   including	   IL-­‐8,	   IL-­‐6,	   CCL8	   and	   CD40L.	   In	   addition,	   increased	   miRNA-­‐33a	  
expression	   leads	   to	   decreased	   IRS-­‐2	   activity	   and	   increased	   let-­‐7e	   expression	   to	  




3.3.4	  Anti-­‐apoptotic	  pathways	  (Figure	  6.4A	  iv)	  
A	  single	  statistically	  significant	  network	  of	  down-­‐regulated	  miRNAs	  was	  identified	  that	  
regulates	   anti-­‐apoptotic	   pathways	   (miRNA-­‐19a	   and	   miRNA-­‐150,	   P	   value	   1.84x10-­‐18).	  
Decreased	  miRNA-­‐150	  expression	  causes	  up	  regulation	  of	  cMyb	  and	  decreased	  miRNA-­‐
19a	  expression	  leads	  to	  up-­‐regulation	  of	  N-­‐Myc	  expression.	  
	  
3.3.5	  Other	  pathways	  (Figure	  6.4A	  v)	  
An	   additional	   network	   of	   differentially	   expressed	  miRNA	   that	  we	   identified	   (miRNA-­‐
205,	   miRNA-­‐204,	   miRNA-­‐20a,	   miRNA-­‐146a,	   miRNA-­‐328,	   P	   value	   1.25x10-­‐13)	   inhibits	  
expression	   of	   genes	   known	   to	   promote	   HCV	   disease	   progression.	   Increased	  miRNA-­‐
146a	   leads	   to	   decreased	   STAT-­‐1	   expression	   and	   increased	  miRNA-­‐20a	   to	   decreased	  
expression	  in	  TGFβR2.	  	  
	  
3.4	  Validation	  and	  quantification	  of	  miRNA	  expression	  by	  PCR.	  	  
In	  order	   to	   independently	   validate	   the	   changes	   in	  miRNA	  expression	  we	  observed	   in	  
Groups	  A	  and	  B	  and	  to	  quantify	  miRNA	  expression,	  we	  selected	  a	  subgroup	  of	  miRNAs	  
from	   the	   GeneGo	   analysis	   outlined	   above	   (Figure	   6.4A).	   Quantitative	   PCR	   analysis	  
confirmed	   the	   up	   regulation	   of	   miRNA-­‐19a,	   miRNA-­‐20a,	   let-­‐7e	   and	   miRNA-­‐146a	   in	  
Group	  A	   relative	   to	  Group	  B	   (Figure	  6.4B).	   In	   addition,	   I	   validated	  miRNA	  expression	  
changes	   detected	   in	   the	   microarray	   analysis	   by	   carrying	   out	   quantitative	   PCR	   for	   a	  







miRNA	   Group	  A	   Group	  B	   P	  value	  
4304	   29.69+/-­‐27.2	   24.91+/-­‐16.6	   0.69	  
1407-­‐3	   377.8	  +/-­‐	  314	   795.22	  +/-­‐	  376	   0.11	  
Let7f	   17.17+/-­‐15.14	   12.04+/-­‐10.25	   0.5	  
	  
Table	  6.2	  Random	  selection	  of	  miRNA	  expression	  changes	  using	  quantitative	  PCR	  
	  
In	   order	   to	   investigate	  whether	   any	   of	   the	  miRNAs	   that	   I	   identified	   could	   represent	  
tractable,	  non-­‐invasive,	  and	  prognostic	  biomarkers	  for	  HCV	  recurrence,	  a	  quantitative	  
PCR	   analysis	  was	   also	   performed	  on	   serum	   samples	   taken	   at	   a	  median	   of	   6	  months	  
after	  transplantation	  (range	  4-­‐10	  months)	  from	  fast	  and	  slow	  progressors.	  My	  results	  
demonstrated	   specific	   and	   statistically	   significant	   up-­‐regulation	   of	   miRNA-­‐19a	   and	  
















Figure	   6.5	   Serum	  miRNA	   expression	   distinguishes	   slow	   HCV	   progressors	   (group	   A)	  
from	   fast	   HCV	   progressors	   (groupB)	   after	   transplantation.	   Serum	   samples	   were	  
analysed	   by	   quantitative	   PCR	   to	   determine	   the	   expression	   of	   (A)	   miRNA-­‐19a,	   (B)	  
miRNA-­‐20a,	  and	  (C)	  miRNA-­‐150	  in	  groups	  A	  and	  B.	  SNORD66	  was	  used	  as	  a	  reference	  
RNA	   for	   normalisation.	   Values	   expressed	   as	   means	   and	   standard	   deviations	   and	  
representative	  of	  3	  different	  experiements.	  P	  values	  for	  each	  miRNA	  are	  indicated	  on	  
the	   graphs.	   (+)	   represents	   RNA	   extracted	   from	   cells	   	   that	   are	   transfected	   with	  
miRNA-­‐146a.	  
	  
	   	  
from fast and slow progressors. Our results demon-
strated specific and statistically significant up-regula-
tion of miRNA-19a and miRNA-20a (but not miRNA-150
or miRNA-146a) in group A versus group B (Fig. 4).
miRNA Expression Distinguishes Posttrans-
plant HCV-Related Fast Progression From ACR
Because of the known difficulties in distinguishing post-
transplant HCV recurrence from ACR, we investigated
miRNA expression in groups B and C. Groups B and C
were chosen because of their proximity on the PCA plot
(Fig. 2). We reasoned that differential miRNA expression
between these groups might not only elucidate mecha-
nistic insights but also identify potential biomarkers
that could discriminate between these clinical entities.
HCA demonstrated distinct miRNA expression pro-
files for groups B and C (P<0.01; Fig. 5A), with the
cladogram above the heat map (Fig. 5A) as well as the
associated PCA (Fig. 5B) confirming stronger similar-
ities within each group than between groups. One
hundred ninety miRNAs of statistical significance
were differentially regulated between the 2 groups (an
miRNA list and P values are shown in Supporting
Table 3), with 100 miRNAs down-regulated and 90
up-regulated in group B versus group C.
A MetaCore analysis revealed 2 highly statistically
significant networks of down-regulated miRNAs in
group B versus group C (Fig. 5C). The first network
consists of miRNA-1336 and miRNA-223 (P52.64 3
10214; Fig. 5Ci). The down-regulation of both miRNAs
is associated with increased expression of insulin-like
growth factor 1 (IGF1) receptor, which has been impli-
cated in promoting liver fibr genesis.16 The second
network consists of the down-regulation of miRNA-
210 and miRNA-503 (P51.6 3 1024; Fig. 5Cii) and is
associated with proangiogenic pathways through the
increased expression of VEGFA.
DISCUSSION
In this study, we demonstrated distinct intragraft
miRNA gene expression between patients with slow fi-
brosis and patients with fast fibrosis after transplan-
tation for HCV. Samples taken from groups A and B
were carefully selected and rigorously matched for
known factors that strongly influence HCV recurrence
after transplantation (ie, donor age, cold ischemia
time, donor risk index, IL-28B recipient genotype, and
immunosuppression; see Table 1). Although this
approach limited the sample size, it allowed us to
identify changes in the expression of miRNAs of high
statistical significance that are exclusively associated
with HCV recurrence and fibrosis progression.6,17
The clinical significance of identifying patients with
a fast fibrosis phenotype cannot be overstated. The re-
currence of HCV after transplantation is the leading
Figure 4. Serum miRNA expression distinguishes slow HCV progressors (group A) from fast HCV progressors (group B) after trans-
plantation. Serum samples were analyzed by quantitative PCR to determine the expression of (A) miRNA-19a, (B) miRNA-20a, and
(C) miRNA-150 in groups A and B. SNORD66 was used as a reference RNA for normalization. Values are expressed as means and
standard deviations and are representative of 3 different experiments. P values for each miRNA are indicated on the graphs. (+) rep-
resents RNA extracted from cells that are transfected with miRNA-146a.




3.5	  miRNA	  expression	  distinguishes	  post-­‐transplant	  HCV	  related	  fast-­‐	  progressors	  
from	  acute	  cellular	  rejection	  
	  
Given	   the	   known	   difficulties	   in	   distinguishing	   post-­‐transplant	   HCV	   recurrence	   from	  
acute	   cellular	   rejection,	   we	   investigated	   miRNA	   expression	   in	   Groups	   B	   and	   C.	   I	  
reasoned	   that	   differential	   miRNA	   expression	   between	   these	   groups	   may	   not	   only	  
elucidate	   mechanistic	   insights	   but	   identify	   potential	   biomarkers	   that	   discriminate	  
these	  clinical	  entities.	  
	  
HCA	   analysis	   demonstrated	   distinct	   miRNA	   expression	   profiles	   for	   Groups	   B	   and	   C	  
(Figure	  6.3A,	  P<.01),	  with	  the	  cladogram	  above	  the	  heatmap	  (Figure	  6.5A)	  as	  well	  the	  
associated	   PCA	   (Figure	   6.5B)	   confirming	   stronger	   similarity	   within	   each	   group	   than	  
between	   groups.	   190	  miRNAs	   of	   statistical	   significance	   were	   differentially	   regulated	  
between	   the	   two	   groups	   with	   100	   miRNAs	   down-­‐regulated	   in	   Group	   B	   relative	   to	  
Group	  C	  and	  90	  up-­‐regulated	  (See	  Appendix	  II,	  Table	  2).	  	  
	  
Metacore	  analysis	   (GeneGo	   Inc.)	   revealed	  two	  highly	  statistically	  significant	  networks	  
of	   down	   regulated	   miRNAs	   in	   Group	   B	   relative	   to	   Group	   C	   (Figure	   6.3C).	   The	   first	  
network	  consisted	  of	  miRNA-­‐1336	  and	  miRNA-­‐223	  (Figure	  6.4Ci,	  P	  =	  2.6x10-­‐14).	  Down	  
regulation	   of	   both	   these	   miRNAs	   is	   associated	   with	   increased	   expression	   of	   IGF-­‐1	  
receptor,	   which	   has	   been	   implicated	   in	   promoting	   liver	   fibrogenesis.	   The	   second	  
network	  consisted	  of	  down	  regulation	  of	  miRNA-­‐210	  and	  miRNA-­‐503	  (Figure	  5Cii,	  P	  =	  
1.6x10-­‐4)	   and	   is	   associated	   with	   pro-­‐angiogenic	   pathways	   through	   the	   increased	  






Figure	   6.6	   miRNA	   expression	   distinguishes	   fast	   HCV	   progressors	   (group	   B)	   after	  
transplantation	  from	  patients	  with	  ACR	  (group	  C).	  	  (A)	  HCA	  and	  cladogram	  fro	  groups	  
B	  and	  C	  (p<0.01).	  (B)	  PCA	  for	  the	  same	  data	  set.	  (C)	  A	  MetaCore	  analysis	  identified	  2	  
statistically	  significant	  networks	  of	  down	  regulated	  miRNAs	  and	  known	  target	  genes	  
for	  individual	  miRNAs.	  
	  
cause of graft loss and the commonest indication for
consideration of retransplantation.3 Although the
main aim of this study was to identify potential mech-
anisms related to HCV recurrence after transplanta-
tion, using q antitative PCR from serum, we were
also able to demonstrate that specific miRNAs
(miRNA-19a and miRNA-20a) could represent poten-
tial serum biomarkers for fibrosis progression. We
also found that intragraft miRNA expression in
patients with evidence of HCV recurrence after LT dif-
fers from that in patients with ACR and patients with
normal liver biopsy findings after LT.
Figure 5. miRNA expression distinguishes fast HCV progressors (group B) after transplantation from patients with ACR (group C).
(A) HCA and cladogram for groups B and C (P<0.01). (B) PCA for the same data set. An miRNA list and associated P values are
shown in Supporting Table 3. (C) A MetaCore analysis identified 2 statistically significant networks of down-regulated miRNAs and
known target genes for individual miRNAs.






In	  this	  study,	  I	  have	  demonstrated	  distinct	  intragraft	  miRNA	  gene	  expression	  between	  
patients	  with	  slow	  fibrosis	  and	  patients	  with	  fast	  fibrosis	  after	  transplantation	  for	  HCV.	  
Samples	   taken	   from	  Groups	  A	  and	  B	  were	  carefully	   selected	  and	   rigorously	  matched	  
for	   known	   factors	   that	   strongly	   influence	  HCV	   recurrence	   post-­‐transplant	   (i.e.	   donor	  
age,	   cold	   ischaemia	   time,	   donor	   risk	   index,	   IL-­‐28B	   recipient	   genotype	   and	  
immunosuppression).	  Although	  this	  approach	  limited	  the	  sample	  size,	  it	  allowed	  me	  to	  
identify	   changes	   in	   the	   expression	   of	  miRNAs	   of	   high	   statistical	   significance	   that	   are	  
exclusively	   associated	  with	   HCV	   recurrence	   and	   fibrosis	   progression	   (Charlton	   et	   al.,	  
2011,	   Berenguer	   et	   al.,	   2002).	   miRNA	   studies	   can	   sometimes	   be	   interpreted	   as	   a	  
‘fishing’	   exercise	   with	   a	   host	   of	   miRNAs	   randomly	   selected.	   By	   vigorously	   and	  
meticulously	   selecting	   the	   patient	   samples	   and	   matching	   them	   extensively	   for	   the	  
known	  risk	  factors	  that	   influence	  HCV	  fibrosis	  progression	  post	  transplantation,	   I	  was	  
able	   to	   identify	   specific	   miRNAs.	   Matching	   these	   cohorts	   was	   extremely	   time	  
consuming	  but	  was	  essential	  to	  the	  design	  of	  this	  study	  and	  therefore	  is	  one	  of	  the	  key	  
strengths.	  	  	  
	  
The	  clinical	  significance	  of	  identifying	  patients	  with	  a	  fast	  fibrosis	  phenotype	  cannot	  be	  
overstated.	   Recurrence	  of	  HCV	  post-­‐transplant	   is	   the	   leading	   cause	  of	   graft	   loss	   and	  
the	   commonest	   indication	   for	   consideration	  of	   re-­‐transplantation	   (Berenguer,	   2002).	  
Although	  the	  main	  aim	  of	  this	  study	  was	  to	  identify	  potential	  mechanisms	  relating	  to	  
HCV	   recurrence	   post-­‐transplantation,	   using	   quantitative	   PCR	   from	   serum,	   I	   was	   also	  




represent	  potential	  serum	  biomarkers	  for	  fibrosis	  progression.	  I	  also	  found	  that	  intra-­‐
graft	  miRNA	   expression	   in	   patients	  with	   evidence	   of	   HCV	   recurrence	   post	   LT	   differs	  
from	  that	  in	  patients	  with	  acute	  cellular	  rejection	  and	  patients	  with	  normal	  liver	  biopsy	  
findings	  after	  LT.	  
	  
The	  miRNAs	  networks	  I	  have	  demonstrated	  to	  correlate	  with	  HCV	  disease	  progression	  
identify	   molecular	   pathways	   of	   relevance	   to	   the	   pathogenesis	   of	   HCV	   recurrence.	  
Although	  these	  pathways	  are	   identified	  through	  the	  regulation	  of	  known	  target	  gene	  
expression,	   a	   MetaCore	   analysis	   revealed	   that	   these	   pathways	   have	   high	   statistical	  
significance	   and,	   therefore,	   relevance.	   According	   to	   miRNA	   expression,	   profibrotic	  
pathways	   would	   be	   down-­‐regulated	   in	   group	   A	   versus	   group	   B.	   Key	   fibrogenic	  
mediators	  including	  SMAD4	  and	  TGFβR2	  are	  known	  to	  be	  down-­‐regulated	  in	  response	  
to	   up-­‐regulation	   of	   miRNA-­‐203,	   miRNA-­‐146a,	   miRNA-­‐200a	   and	   miRNA-­‐141	  
respectively.	   TGFβ	   is	   the	  main	   fibrogenic	   chemokine	   and	   is	   activated	   in	   response	   to	  
liver	   injury,	  whereas	  SMAD	  proteins	  are	  intracellular	  mediators	  of	  signal	  transduction	  
pathways	  of	  the	  TGFβ	  super-­‐family	  members	  (Friedman,	  2008b).	  Increased	  expression	  
of	  miRNA-­‐20a	   is	   known	   to	   lead	   to	  decreased	  expression	  of	   TGFβR2,	  which	  has	  been	  
shown	   to	   attenuate	   the	   TGFβ	   signalling	   pathway	   and	   hepatic	   stellate	   cell	   (HSC)	  
activation	  (Nakamura	  et	  al.,	  2000).	  Another	  important	  pathway	  in	  the	  pathogenesis	  of	  
hepatic	   fibrosis	   is	   the	   deposition	   of	   the	   extracellular	  matrix	   (ECM),	  which	   originates	  
from	  myo-­‐fibroblastic	   cells	   derived	   from	  HSC	   and	  portal	   fibroblasts	   (Cassiman	   et	   al.,	  
2002).	  The	  activation	  of	  EGFR	  on	  ECM-­‐producing	  cells	  has	  been	  shown	  to	  contribute	  to	  




expression	   is	   inhibited	   by	   increased	   expression	   of	   miRNA-­‐146a	   and	   miRNA-­‐19a,	   as	  
exhibited	  by	  the	  slow-­‐progressor	  group.	  
	  
Angiogenesis	  and	  inflammation	  are	  also	  known	  to	  contribute	  to	  hepatic	  fibrosis.	  New	  
blood	   vessel	   formation,	   sinusoidal	  modelling	   and	   stellate	   cell	   expansion	   are	   integral	  
and	   are	   mediated	   by	   mediators	   such	   as	   VEGF	   and	   PDGF	   (Lee	   et	   al.,	   2007).	   Up-­‐
regulation	  of	  the	  network	  consisting	  of	  miRNA-­‐146a,	  miRNA-­‐205	  and	  miRNA-­‐20a	  in	  the	  
slow-­‐progressor	   phenotype	   would	   be	   expected	   to	   inhibit	   VEGFA	   expression.	  
Furthermore,	   increased	   expression	   of	   miRNA-­‐146a	   is	   known	   to	   negatively	   regulate	  
expression	  of	   IL-­‐8:	  high	   levels	  of	   IL-­‐8	  (CXCL8)	  are	  associated	  with	  disease	  progression	  
and	   poor	   response	   to	   interferon	   based	   treatment	   (Polyak	   et	   al.,	   2001b).	   The	  
expression	  of	  pro-­‐inflammatory	  mediators	  IL-­‐6,	  chemokine	  ligand	  8	  (CCL8)	  and	  CD40L	  
are	   also	   known	   to	   be	   inhibited	   by	   these	   changes	   in	   miRNA	   expression.	   TLR4	   is	   the	  
receptor	  for	  bacterial	  lipopolysaccharide	  on	  Kupffer	  cells	  and	  is	  also	  expressed	  on	  HSC.	  
It	   is	   essential	   in	   the	   inflammatory	   response	   and	   plays	   an	   important	   role	   in	   the	  
fibrogenic	   response.	   Specific	   single-­‐nulceotide	   polymorphisms	   of	   TLR4	   have	   been	  
shown	  to	  contribute	   to	   the	   rate	  of	   fibrosis	   in	  HCV	   infection	   (Huang	  et	  al.,	  2007).	  My	  
data	   also	   showed	   increased	   expression	   of	   let-­‐7e,	   a	   significant	   inhibitor	   of	   TLR4	  
expression.	  
	  
c-­‐Myb,	   the	   prototype	   oncogene,	   plays	   an	   essential	   role	   in	   the	   regulation	   of	   cell	  
development	  and	  differentiation	  (Oh	  and	  Reddy,	  1999).	  An	  elevation	  of	  miRNA-­‐150	  is	  
known	  to	  result	   in	  decreased	  expression	  of	  c-­‐Myb	  and	  thus	  in	  cell	  apoptosis	  (Ladu	  et	  




increased	   c-­‐Myb	   expression	   and	   reduced	   apoptosis,	   therefore,	   a	   reduced	   rate	   of	  
fibrosis	  in	  group	  A.	  
	  
My	   results	   identified	   an	   important	   role	   for	  miRNA-­‐146a	   in	   the	   pathogenesis	   of	   HCV	  
recurrence	   after	   LT.	  miRNA-­‐146a	   is	   up-­‐regulated	   in	   response	   to	   TLR4	   stimulation	   in	  
monocytes	   and	   controls	   endotoxin	   tolerance	   so	   that	   the	   innate	   immune	   response	  
favours	   cell	   survival	   (Taganov	  et	   al.,	   2006).	  Murine	  models	   also	   suggest	   that	  miRNA-­‐
146a	   is	   critical	   for	   regulatory	   T	   cell	   function	   and	   acts	   a	   ‘molecular	   brake’	   for	  
inflammation,	  myeloid	   cell	   proliferation	   and	  oncogenic	   transformation	   (Boldin	   et	   al.,	  
2011,	  Lu	  et	  al.,	  2010).	  Although	  intragraft	  miRNA-­‐146a	  expression	  was	  increased	  in	  the	  
slow	   fibrosis	   progression	   group,	   there	   was	   no	   comparable	   increase	   in	   miRNA-­‐146a	  
levels	  in	  the	  serum.	  This	  phenomenon	  of	  increased	  expression	  of	  miRNAs	  in	  tissue	  but	  
not	   serum	   or	   plasma	   is	   well	   described	   and	   arises	   due	   to	   the	   fact	   that	   only	   specific	  
miRNAs	   are	   released	   by	   the	   secretion	   of	   microsomes	   including	   exosomes,	   and	  
therefore	  only	  specific	  miRNAs	  are	  selectively	  packaged	  into	  microvesicles	  (Kosaka	  et	  
al.,	   2010b,	   Zhang	   et	   al.,	   2010).	   I,	   therefore	   hypothesise	   that	   miRNA-­‐146a	   plays	   an	  
integral	   role	   in	   determining	   the	   rate	   of	   HCV	   recurrence	   post-­‐transplant	   but	   is	   not	   a	  
suitable	   serum	  biomarker	   candidate.	  A	  possible	   therapeutic	   intervention	  could	  be	   to	  
increase	   miRNA-­‐146a	   which	   would	   result	   in	   a	   slower,	   less	   aggressive	   fibrosis	  
progression	  	  in	  HCV	  patients	  following	  liver	  transplantation.	  	  
	  
My	  results	  identify	  a	  panel	  of	  miRNAs	  that	  not	  only	  determine	  whether	  a	  patient	  has	  a	  




treatment	   of	   their	   HCV	   earlier.	   Assessment	   of	   these	  miRNAs	   once	   steady	   liver	   graft	  
function	  is	  achieved	  could	  lead	  to	  early	  consideration	  of	  anti-­‐viral	  therapy.	  
	  
Histology	   remains	   the	   gold	   standard	   for	   differentiating	   ACR	   from	   recurrent	   HCV	  
infection,	  although	  it	  remains	  non-­‐specific	  and	  subject	  to	  inter	  and	  intra-­‐observer	  bias	  
(Regev	   et	   al.,	   2004).	   HCV	   recurrence	   typically	   manifests	   as	   a	   lobular	   hepatitis	   with	  
hepatocyte	   changes	   including	   ballooning,	   acidophilic	   body	   formation	   and	   steatosis.	  
ACR	   is	   typically	   characterised	   by	   predominant	   portal	   changes	   consisting	   of	   a	   mixed	  
portal	   inflammatory	   cell	   infiltrate,	   bile	   duct	   damage	   and	   portal	   vein	   endotheliitis	  
(Snover	  et	  al.,	  1984).	  The	  two	  conditions	  may	  coexist,	  or	  even	  trigger	  each	  other,	  and	  
their	   histological	   manifestations	   may	   also	   overlap.	   It	   is	   a	   common	   clinical	   scenario	  
which,	  if	  diagnosed	  incorrectly,	  can	  have	  potentially	  deleterious	  consequences,	  such	  as	  
the	  inappropriate	  administration	  of	  corticosteroids	  for	  presumed	  ACR,	  resulting	  in	  the	  
potentiation	   of	   HCV	   viraemia.	   	   A	   limitation	   of	   the	  my	   study	   is	   that	   analysed	   biopsy	  
samples	  from	  individuals	  with	  histologically	  diagnosed	  ACR	  were	  obtained	  at	  the	  time	  
of	   suspected	   acute	   rejection	   and	   these	   were	   compared	   to	   protocol	   liver	   biopsy	  
samples	   at	   1	   year	   from	   individuals	   with	   rapid	   fibrosis.	   	   It	   is	   therefore	   unclear	   as	   to	  
whether	   the	   observed	   changes	   in	   miRNA	   expression	   predict	   the	   development	   of	   a	  
specific	  injury	  phenotype	  or	  occur	  as	  a	  result	  of	  an	  already	  established	  pattern	  of	  injury	  
within	   the	   allograft.	   A	   recent	   study	   demonstrated	   an	   increase	   in	   miRNA-­‐122	   and	  
miRNA-­‐148a	   in	   parallel	   with	   serum	   aspartate	   aminotransferase	   and	   alanine	  
aminotransferase	  levels	   in	  patients	  with	  ACR	  (Farid	  et	  al.,	  2012).	  Comparing	  groups	  B	  
and	   C,	   I	   was	   able	   to	   identify	   pro-­‐fibrogenic	   miRNAs,	   through	   regulation	   of	   IGF-­‐1	  




and	  ACR.	  The	  relatively	  small	  numbers	  in	  group	  C,	  however,	  make	  for	  statistically	  valid	  
but	   cautious	   conclusions	   and	   require	   validation	   in	   larger	   prospective	   cohorts.	   To	  
further	   investigate	   my	   findings,	   further	   comparisons	   of	   serial	   samples	   taken	   from	  
individuals	   during	   similar	   phases	   after	   liver	   transplantation	   are	   required.	   This	   should	  
also	  include	  early	  sampling	  before	  liver	  injury	  is	  established.	  
	  
From	  a	  review	  of	  the	  current	  literature,	  it	  is	  clear	  that	  miRNAs	  are	  viewed	  as	  attractive,	  
potential	  biomarkers	  because	  of	   their	  stable,	  cell-­‐free	   form	   in	  blood.	   	  Critically,	  what	  
remains	  unclear	  is	  how	  miRNAs	  make	  their	  way	  into	  the	  bloodstream:	  whether	  it	  is	  the	  
result	   of	   cell	   death	   or	   secondary	   to	   active	   secretion	   from	   tissue	   cells?	   There	   is	  
increasing	   evidence	   that	   serum/plasma	   concentrations	   of	   miRNAs	   are	   altered	   in	  
multiple	  disease	  pathologies,	  including	  HCC	  (Kosaka	  et	  al.,	  2010a,	  Xu	  et	  al.,	  2011,	  Fan	  
et	   al.,	   2008).	   Studies	   specific	   to	   HCV	   demonstrate	   that	   miRNA-­‐122	   expression	  
correlates	  with	  serum	  transaminases	  and	  necro-­‐inflammatory	  activity	  on	  liver	  biopsy,	  
but	  not	  with	  fibrosis	  stage	  or	  parameters	  of	  liver	  function	  in	  patients	  with	  chronic	  HCV	  
(Bihrer	   et	   al.,	   2011).	   miRNA-­‐122	   levels	   have	   also	   been	   shown	   to	   be	   decreased	   	   in	  
patients	  who	  do	  not	  respond	  to	  anti-­‐viral	  therapy	  compared	  to	  responders	  in	  the	  non-­‐
transplant	  setting	  (Sarasin-­‐Filipowicz	  et	  al.,	  2009).	  My	  analysis	  did	  not	  find	  miRNA-­‐122	  
to	   be	   expressed	   differentially	   between	   Group	   A	   and	   B,	   and	   this	   is	   not	   surprising	  
because	   these	   groups	   were	   selected	   exclusively	   by	   differential	   fibrosis	   rates.	  
Quantitative	   PCR	   performed	   on	   serum	   identified	   miRNA-­‐19a	   and	   miRNA-­‐20a	   to	   be	  
increased	  in	  group	  A	  versus	  group	  B.	  Because	  of	  their	  potential	  mechanistic	  role	  in	  the	  
pathogenesis	   of	   HCV	   recurrence,	   their	   detection	   in	   serum	   indicates	   that	   they	   may	  




recurrence	  after	  transplant.	  miRNA-­‐20a	  has	  been	  studied	  in	  HCV	  infected	  patients	  pre-­‐
transplantation	   and	   healthy	   controls	   (Shrivastava	   et	   al.,	   2013).	   	   Serum	   miRNA-­‐20a	  
correlated	  with	  HCV	  fibrosis	  stage	  especially	  in	  the	  setting	  of	  chronic	  infection	  further	  
highlighting	  its	  suitability	  as	  a	  biomarker	  for	  HCV	  mediated	  liver	  disease	  progression.	  	  
	  
	  
In	   addition	   to	   providing	   diagnostic	   information,	   miRNAs	   provide	   the	   possibility	   of	  
therapeutic	   intervention.	  Novel	   targeted	  anti-­‐miRNA	   therapies,	   so-­‐called	   antagamirs,	  
have	  been	  postulated	  as	   future	   therapeutic	   targets.	   In	   two	   separate	  murine	  models,	  
the	  introduction	  of	  an	  anti-­‐sense	  oligonucleotide/antagamir	  resulted	  in	  a	  reduction	  of	  
hepatic	   steatosis	   and	   tumorgenesis	   repression,	   respectively	   (Kota	   et	   al.,	   2009).	  
Although	   the	  use	  of	   antagamirs	   remains	   in	   its	   infancy,	   recently	  published	  data	  using	  
miravirsen,	   a	   potent	   inhibitor	   of	   miRNA-­‐122	   function,	   has	   demonstrated	   a	   dose-­‐
dependent	   reduction	   in	   HCV	   RNA	   titres	   (Janssen	   et	   al.,	   2013).	   To	   advance	   this	   field	  
further,	   extensive	   miRNA	   profiling	   of	   both	   diseased	   and	   healthy	   tissue	   is	   required.	  
Although	   I	   cannot	   definitively	   prove	   that	   loss	   of	   miRNA-­‐146a	   is	   a	   cause	   or	   a	  
consequence	  of	  HCV,	  a	  targeted	  antagamir	  or	  related	  therapeutic	  agent	  against	  HCV-­‐
related	  fibrosis	  and	  recurrence	  after	  LT	  would	  represent	  an	  exciting	  advance.	  	  
	  
miRNAs	  appear	  to	  have	  a	  complex	  role,	  more	  than	  just	  the	  simple	  inhibition	  of	  target	  
gene	   expression.	   Some	   questions	   remain	   unanswered	   including	  why	   and	   how	   some	  
miRNAs	  enter	   the	  systemic	  circulation,	   the	  association	  of	  miRNAs	  and	  exosomes	  and	  





In	  conclusion,	  this	  study	  has	  demonstrated	  that	  the	  fibrosis	  rate	  associated	  with	  HCV	  
recurrence	   post-­‐LT	   is	   associated	   with	   changes	   in	   networks	   of	   intragraft	   miRNA	  
expression	   that	   can	   regulate	   pro-­‐inflammatory,	   pro-­‐angiogenic	   and	   pro-­‐fibrogenic	  
pathways.	  Meticulous	   patient	   selection	   has	   enabled	   us	   to	   identify	   key	  miRNAs	   that	  
provide	  a	  unique	  insight	  into	  potential	  mechanisms	  involved	  in	  the	  recurrence	  of	  HCV	  
after	   transplantation.	   My	   data	   suggests	   a	   pivotal	   role	   for	   microRNA-­‐146a,	   in	   the	  
pathogenesis	  of	  HCV	  recurrence	  after	   transplantation	  as	   it	  was	   identified	   in	  different	  
mechanistic	   pathways.	   	   Using	   liver	   tissue	   and,	  more	   relevantly,	   serum,	   I	   identified	   a	  
panel	  of	  miRNAs	  associated	  with	  the	  severity	  of	  HCV	  recurrence	  that	  could	  be	  used	  as	  
a	  potential	  biomarker.	  Larger	  translational	  studies	  are	  required	  to	  investigate	  both	  the	  
role	   of	   miRNAs	   in	   the	   pathogenesis	   of	   HCV	   recurrence	   and	   to	   validate	   tractable	  
biomarkers	  that	  are	  predictive	  of	  aggressive	  recurrence	  after	  LT.	  Although	  the	  advent	  
of	   the	   new	   DAAs	   will	   undoubtedly	   transform	   the	   therapeutic	   landscape,	   the	   early	  
identification	   of	   patients	   with	   rapid	   fibrosis	   rates	   and	   the	   ability	   to	   distinguish	   viral	  
recurrence	  from	  ACR,	  remain	  pivotal	  clinical	  endpoints	  for	  selecting	  suitable	  patients	  in	  















The	  year	  2014	  marks	  the	  25th	  anniversary	  of	  the	  identification	  of	  HCV.	  Globally,	  HCV	  is	  
a	   major	   health	   burden	   and	   chronic	   HCV	   infection	   remains	   one	   of	   the	   leading	  
indications	   for	   liver	   transplantation	   worldwide.	   Following	   liver	   transplantation	  
outcomes	   amongst	   HCV	   positive	   patients	   is	   inferior	   compared	   to	   other	   aetiologies.	  
Recurrence	  of	  HCV	  and	   the	  ensuing	  accelerated	   fibrosis	  progression	   leads	   to	   inferior	  
patient	  and	  graft	  survival.	  Historically,	  the	  ‘Achilles	  heel’	  remained	  the	  inability	  to	  offer	  
efficacious	   and	   tolerable	   therapies	   in	   the	   post	   transplant	   period	   which	   could	   help	  
attenuate	  fibrosis	  progression.	  Naturally,	  attention	  has	  turned	  to	  the	  development	  and	  
identification	  of	  predictors	  of	  rapid	  fibrosis	  progression.	  	  	  
	  
When	  I	  started	  my	  thesis	  in	  2009,	  the	  landscape	  for	  the	  treatment	  of	  HCV	  was	  starting	  
to	   change.	   It	   was	   soon	   becoming	   obvious	   that	   pegylated	   interferon	   and	   ribavirin	  
(PEG/RBV),	  so-­‐long	  the	  stalwart,	  would	  not	  be	  the	  only	  therapeutic	  option	  available	  to	  
patients.	   In	   2011,	   the	   first	   generation	   protease	   inhibitors	   were	   introduced	   in	  
combination	  with	   PEG/RBV	   in	   patients	  with	   genotype	   1	   disease.	   Although	   SVR	   rates	  
improved	  in	  patients	  with	  minimal	  fibrosis	  and	  compensated	  disease,	  the	  applicability	  
in	  the	  post-­‐transplant	  setting	  was	  anticipated	  to	  be	  difficult	  due	  to	  the	  increased	  side-­‐
effect	   profile,	   long	   treatment	   durations	   and	   potential	   drug-­‐drug	   interactions	   with	  
immunosuppression.	  	  Since	  then,	  the	  exponential	  increase	  in	  the	  development	  of	  new	  
directly	  DAAs	  with	  and	  without	  PEG	  in	  the	  post-­‐transplant	  setting	  has	  raised	  hopes	  of	  
improving	   outcomes	   for	   this	   patient	   cohort.	   The	   new	   DAAs	   have	   undoubtedly	  





There	  has	  undoubtedly	  been	  a	  paradigm	  shift	   in	  the	  management	  of	  HCV	  recurrence	  
post	  liver	  transplantation.	  Rather	  than	  wait	  for	  evidence	  of	  histological	  recurrence	  post	  
transplantation	  to	  instigate	  anti-­‐viral	  therapy,	  treatment	  is	  now	  being	  considered	  pre-­‐
liver	   transplantation	   to	   help	   reduce	   re-­‐infection	   post	   transplantation.	   PEG	   can	  
precipitate	   hepatic	   decompensation	   in	   patients	   with	   cirrhosis	   leading	   to	   significant	  
morbidity	  and	  mortality.	  Treating	  patients	  active	  on	  the	  liver	  transplant	  waiting	  list	  has	  
therefore	  been	  a	  contentious	  issue.	  However,	  data	  using	  the	  new	  DAAs	  would	  suggest	  
that	   that	   we	   can	   certainly	   increase	   the	   number	   of	   patients	   entering	   liver	  
transplantation	  with	  an	  undetectable	  HCV	  viral	   load,	  thereby	  reducing	  the	  number	  of	  
patients	  developing	  HCV	   recurrence	  and	   rapid	   fibrosis	  progression	   (Curry	  MP,	  2013).	  
The	   new	   DAAs	   also	   heralds	   the	   dawn	   of	   potential	   salvage	   therapy	   and	   fibrosis	  
regression.	  This	  approach	  may	  mirror	   the	  experience	  and	   results	   in	   chronic	  HBV	  and	  
the	   use	   of	   the	   oral	   nucleos(t)ide	   agents.	   Recent	   data	   taken	   from	   a	   multi-­‐centre	  
European	  study	  demonstrated	  a	  cumulative	  incidence	  of	  inactivation	  and	  delisting	  for	  
liver	  transplantation	  was	  16%	  and	  0%	  at	  24	  weeks,	  27%	  and	  10%	  at	  48	  weeks	  and	  33%	  
and	  19%	  at	  60	  weeks	  following	  DAA	  treatment	  (Belli	  et	  al.,	  2016).	  34	  patients	  from	  a	  
total	  of	  103	  were	  successfully	  inactivated,	  all	  of	  whom	  demonstrated	  an	  improvement	  
in	  MELD	   and	   CPS.	   Baseline	  MELD,	   delta	  MELD	   and	   delta	   albumin	   (both	   assessed	   12	  
weeks	   post	   DAA	   therapy)	   were	   identified	   as	   predictors	   of	   inactivation	   from	   liver	  
transplantation.	   These	  data	  would	   suggest	   that	   the	   ‘Holy	  Grail’	   of	   fibrosis	   regression	  
and	   clinical	   improvement	  with	   the	  use	  of	  DAAs	   is	  not	  as	   impossible	  as	   first	   thought.	  
Longer	   term	   benefits	   of	   DAA	   therapy	   however	   is	   still	   required.	   	   It	   should	   also	   be	  
highlighted	  that	  DAA	  therapy	  comes	  with	  a	  financial	  burden,	  one	  which	  certain	  Nations	  





Numerous	   factors	   influencing	   HCV	   recurrence	   post	   liver	   transplantation	   have	   been	  
established.	  However,	  the	  group	  of	  patients	  that	  need	  to	  be	  identified	  early	  are	  those	  
with	  rapid	  fibrosis	  progression.	  The	  definition	  of	  rapid	  fibrosis	  progression	  I	  used	  in	  this	  
thesis,	  which	   is	  well	   validated,	   is	   the	   development	   of	   F≥2	   at	   12	  months	   (Firpi	   et	   al.,	  
2004).	   The	   development	   of	   F≥2	   has	   added	   importance	   as	   it	   also	   an	   indication	   for	  
consideration	   of	   anti-­‐viral	   therapy.	   In	   the	   three	   sets	   of	   experiments	   I	   performed,	  
patients	   were	   catergorised	   as	   having	   slow	   fibrosis	   progression	   (F<2)	   or	   fast	   fibrosis	  
progression	  (F≥2).	  	  	  
	  
Chapter	   IV	   addressed	   the	   role	   of	   donor	   and	   recipient	   rs12979860	   IL-­‐28B	  
polymorphisms	   in	   HCV	   recurrence	   post	   liver	   transplantation.	   My	   results	   were	   in	  
keeping	  with	  other	  published	  series	  from	  North	  America,	  Europe	  and	  Asia.	   	  Although	  
my	  data	  remains	  unpublished,	  it	  appears	  to	  be	  the	  only	  UK	  based	  study	  evaluating	  the	  
role	   of	   donor	   and	   recipient	   IL-­‐28B	   genotype	   in	   the	  post	   transplant	   period.	   Recipient	  
non-­‐CC	  rs12979860	  IL-­‐28B	  genotype	  were	  more	  likely	  to	  develop	  F≥2	  at	  12	  months	  and	  
progress	   to	   F≥4	   post	   transplantation.	   In	   addition,	   patients	   with	   donor/recipient	  
rs12979860	   IL-­‐28B	  CC	  combination	  were	   less	   likely	   to	  develop	  F≥2	  at	  12	  months	  and	  
F≥4.	   The	   donor/recipient	   rs129779860	   IL-­‐28B	  CC	   combination	  was	   associated	  with	   a	  
100%	  SVR	   rate	  but	  only	  6	  patients	  were	   included.	  The	   findings	   from	  this	  experiment	  
were	  not	  new	  or	  unique	  to	  the	  scientific	  world.	  However,	  it	  served	  a	  purpose	  both	  for	  
my	   Institution	   in	  defining	  the	   frequency	  of	   the	  rs12979860	   IL-­‐28B	  genotype	  amongst	  





When	   I	   started	   investigating	   the	   role	   of	   CXCL10	   in	   predicting	   HCV	   recurrence	   post	  
transplantation	   there	   was	   limited	   data	   available.	   Given	   that	   CXCL10	   is	   produced	   by	  
HSCs	  and	  is	  also	  a	  marker	  of	  ISG	  expression,	  it	  made	  it	  an	  extremely	  attractive	  serum	  
marker	   for	   fibrosis	   progression	   and	   a	   marker	   to	   help	   predict	   response	   to	   AVT	  
respectively.	   	  CXCL10	  has	  been	  investigated	   in	  patients	  with	  HCV	  mono-­‐infection	  and	  
in	   HIV/HCV	   co-­‐infected	   patients	   undergoing	   AVT	   pre-­‐transplantation.	   Three	   studies,	  
including	   my	   own	   have	   established	   that	   CXCL10	   is	   a	   robust	   predictor	   of	   fibrosis	  
progression	  post	   liver	   transplantation	   in	  patients	  with	  HCV	   recurrence	   (Berres	  et	   al.,	  
2011).	  	  The	  combination	  of	  recipient	  rs12979860	  IL-­‐28B	  non-­‐CC	  genotype	  and	  CXCL10	  
levels	   pre-­‐transplant	   was	   an	   interesting	   finding	   which	   helped	   improve	   the	  
identification	   of	   patients	   that	   were	   likely	   to	   respond	   to	   AVT.	   When	   submitting	   my	  
paper	   for	   publication	   some	   of	   the	   comments	   I	   received	   related	   to	   the	   relevance	   of	  
CXCL10	  in	  the	  era	  of	  potentially	  interferon-­‐free	  regimens.	  My	  rebuttal	  to	  the	  reviewers	  
and	  my	  stance	  is	  that	  although	  these	  new	  regimens	  are	  on	  the	  horizon,	  at	  the	  time	  of	  
performing	  my	  experiments,	  no	  such	  therapies	  were	  available	  outside	  the	  remits	  of	  a	  
clinical	   trial.	  The	  majority	  of	  patients	   I	  studied	  treated	  with	  AVT	  were	  treated	  due	  to	  
clinical	   necessity.	   Waiting	   for	   newer	   therapies	   was	   not	   an	   option	   and	   they	   were	  
certainly	   not	   suitable	   candidates	   for	   a	   clinical	   trial.	   	   A	   longitudinal	   assessment	   of	  
CXCL10	  expression	  pre	  and	  post	  transplant	  is	  an	  interesting	  future	  study.	  
	  
CXCL10	  clearly	  plays	  an	  integral	  role	  in	  host	  immune	  response	  to	  HCV	  infection.	  Its	  role	  
post	   liver	  transplant	  still	  requires	  further	  investigation.	  Proposed	  further	  experiments	  
should	   include	   the	   measurement	   of	   all	   forms	   of	   CXCL10	   (total,	   long	   and	   short)	   to	  




Correlation	   with	   DPP4	   levels	   is	   also	   required.	   Assessment	   of	   HCV	   specific	   IFN-­‐γ	  
producing	   T	   cells	   and	   CD56	   dim	   and	   bright	   NK	   cells	   would	   also	   help	   improve	   the	  
understanding	   of	   mechanisms	   for	   HCV	   persistence	   and	   accelerated	   frbrosis	  
progression	   post	   transplantation.	   The	   expression	   of	   CXCR3	   on	   NK	   and	   T	   cell	  
populations	   should	   also	   be	   undertaken.	   These	   proposed	   experiments	   will	   now	   of	  
course	  be	  conducted	  in	  the	  DAA	  era.	  Data	  in	  patients	  pre-­‐liver	  transplantation	  with	  the	  
combination	  of	  sofosbuvir	  and	  ribavirin	  has	  demonstrated	  DPP4	  and	  CXCL10	  were	  not	  
viable	  biomarkers	  in	  predicting	  treatment	  outcome(Meissner	  et	  al.,	  2015).	  	  	  
	  
My	  own	   study	   group	  has	   continued	   some	  of	   this	  work	   and	   studied	  32	  patients	  with	  
compensated	  Child	  Pugh	  B	  or	  C	  cirrhosis	  that	  underwent	  12	  weeks	  of	  treatment	  with	  
sofosbuvir	   with	   an	   NS5A	   inhibitor	   and	   ribavirin	   (Childs,	   2015).	   CXCL10	   levels	   were	  
higher	  at	  baseline	  and	  TW12	  in	  patients	  that	  did	  not	  achieve	  a	  SVR	  and	  declined	  during	  
therapy.	  In	  patients	  that	  achieved	  a	  SVR	  there	  was	  an	  initial	  rise	  in	  CXCL10	  levels	  from	  
baseline	  to	  TW4.	  A	  cut	  off	  CXCL10	  of	  <	  250	  pg/ml	  demonstrated	  a	  positive	  predictive	  
value	  of	  92%	  fro	  SVR.	  DPP4	  were	  significantly	  higher	  at	  TW12	  in	  patients	  that	  achieved	  
SVR	  with	   levels	   increasing	   from	  baseline	  to	  TW12.	  CXCL10	  and	  DPP4	   levels	  positively	  
correlated	   at	   baseline	   but	   an	   inverse	   correlation	  was	   evident	   at	   TW12.	   In	   the	   same	  
cohort,	   we	   also	   investigated	   NK	   cell	   activation	   (Nkp30	   expression)	   and	   NKG2D	  
expression	   on	   treatment	   outcomes	   ((Childs,	   2016).	   The	   data	   demonstrated	   higher	  
Nkp30	  expression	  at	  baseline,	  on	   treatment	  and	  at	   the	  end	  of	   treatment	   in	  patients	  
that	   did	   not	   achieve	   a	   SVR	   suggesting	   increased	   NK	   activation	   and	   upregulated	   ISG	  






The	  most	  exciting	  sets	  of	  experiments	  I	  performed	  were	  related	  to	  my	  miRNA	  work.	  	  It	  
is	   clear	   to	   see	   that	   miRNAs	   offer	   an	   attractive	   insight	   into	   disease	   mechanisms.	   In	  
addition,	   their	   stable	   cell-­‐free	   form	   within	   blood	   and	   other	   tissues	   offers	   the	  
opportunity	   to	   develop	   biomarkers.	   Finally,	   miRNAs	   provide	   the	   possibility	   of	  
therapeutic	  intervention,	  so	  called	  antagamirs.	  Recently	  published	  data	  on	  miravirsen,	  
a	   potent	   inhibitor	   of	   miRNA-­‐122	   function,	   demonstrated	   a	   reduction	   in	   HCV	   RNA	  
(Janssen	  et	  al.,	  2013).	  Our	  understanding	  the	  role	  and	  application	  of	  miRNAs	  continues	  
to	  grow	  and	  at	  present	  my	  study	  is	  only	  one	  of	  two	  studies	  performed	  using	  miRNAs	  to	  
help	  predict	  HCV	  recurrence	  post	  liver	  transplantation	  (Gehrau	  et	  al.,	  2013).	  Numerous	  
studies	  have	  now	  been	  performed	  using	  miRNAs	   to	  help	  predict	   disease	   recurrence,	  	  
and	  acute	  cellular	  rejection	  following	  liver	  transplantation	  (Morita	  et	  al.,	  2016,	  Liese	  et	  
al.,	  2016,	  Shaked	  et	  al.,	  2016)	  
	  
When	  designing	  the	  miRNA	  experiments,	  I	  wanted	  to	  delineate	  the	  integral	  pathways	  
involved	   in	   patients	   that	   develop	   rapid	   fibrosis	   progression	   by	   12	   months.	   These	  
patients	  were	  then	  compared	  to	  a	  group	  of	  patients	  with	  slow	  fibrosis	  progression	  (F<2	  
at	  12	  months)	  that	  were	  matched	  for	  known	  factors	  that	  influence	  HCV	  recurrence	  i.e.	  
CIT,	   donor	   age,	   HCV	   VL,	   recipient	   age	   etc.	   In	   essence,	   by	   removing	   these	   variables	  
which	   are	   known	   to	   influence	   fibrosis	   progression,	   only	   true	   mechanistic	   pathways	  
would	  be	  delineated.	  	  A	  control	  group	  of	  non-­‐HCV	  patients	  with	  no	  fibrosis	  biopsied	  in	  
the	  post-­‐transplant	  period	  (group	  D)	  was	  important	  to	  demonstrate	  that	  any	  findings	  
were	  unique	   to	  patients	  with	  HCV	  only.	   Finally,	   group	  C	  provided	   information	   into	  a	  




Differentiating	   between	   acute	   cellular	   rejection	   and	   recurrent	   HCV	   is	   an	   important	  
decision	  to	  make	  which	  if	  made	  incorrectly	  can	  affect	  the	  natural	  course	  of	  the	  patient	  
and	   graft.	   This	   is	   one	   of	   the	   key	   strengths	   of	   my	   miRNA	   experiments.	   The	   miRNA	  
identified	   were	   specific	   to	   the	   cohorts	   studied	   and	   not	   due	   to	   randomly	   elected	  
miRNAs.	  One	  of	  the	  criticisms	  of	  this	  paper	  when	  sent	  for	  peer	  review	  were	  the	  small	  
numbers	  included	  in	  the	  final	  analysis.	  The	  numbers	  were	  limited	  due	  to	  the	  extensive	  
matching	  of	  the	  known	  risk	  factors	  that	  are	  known	  to	   impact	  on	  HCV	  related	  fibrosis	  
progression	  post	  liver	  transplantation.	  	  
	  
My	  results	  demonstrated	  an	   integral	   role	  of	  miRNA-­‐146a	   in	   the	  pathogenesis	  of	  HCV	  
recurrence	  post	  transplantation	  and	  a	  potential	  role	  of	  miRNA-­‐19a	  and	  miRNA-­‐20a	  as	  
potential	   serum	   biomarkers	   that	   can	   delineate	   fibrosis	   rates	   in	   this	   patient	   cohort.	  
These	  data	  undoubtedly	  require	  further	  validation	  in	  prospective	  cohorts.	  We	  initially	  
collected	   plasma	   from	   all	   patients	   undergoing	   liver	   transplantation	   for	   HCV	   (2011	  
onwards)	   to	  have	  a	  prospective	  cohort	   to	  potentially	  validate	   the	   role	  of	  miRNA-­‐19a	  
and	   miRNA-­‐20a	   as	   fibrosis	   biomarkers.	   However,	   the	   advent	   of	   DAA	   changed	   our	  
approach	   to	   patients	   with	   more	   being	   successfully	   cured	   with	   pre-­‐transplant	   or	  
following	   transplantation.	   Certainly,	   the	   need	   for	   robust	   predictors	   of	   rapid	   fibrosis	  
progression	  in	  patients	  with	  HCV	  infection	  following	  liver	  transplantation	  has	  declined	  
significantly	  given	  the	  highly	  efficacious	  AVT	  now	  available.	  	  
	  
A	   cautious	   observation	   was	   made	   regarding	   differentiating	   between	   ACR	   and	   HCV	  
recurrence	   given	   the	   small	   patient	   sample	   numbers	   involved.	   Further	   validation	   is	  




formed	  the	  basis	  of	   further	  studies	  assessing	  fibrosis	  progression	   in	  other	  cohorts.	   In	  
particular,	  we	  have	  used	  miRNAs	  to	  help	  develop	  biomarkers	  for	  progressive	  fibrosis	  in	  
young	  adults	  following	  liver	  transplantation.	  	  
	  
This	  thesis	  and	  the	  experiments	  I	  have	  undertaken	  exposed	  me	  to	  variety	  of	  scientific	  
techniques	  ranging	  from	  PCR	  to	  microRNA	  gene	  expression.	   I	  believe	   it	  has	  therefore	  
given	  an	  excellent	  grounding	  and	  platform	  to	  continue	  my	  scientific	  career.	  Although,	  
my	   research	   interests	   are	   no	   longer	   based	   in	   HCV,	   a	   lot	   these	   techniques	   and	   in	  
particular	  my	  understanding	  of	  miRNAs	  and	  their	  applications	  as	  biomarkers	  are	  very	  
relevant	  to	  my	  new	  areas	  of	  interest.	  	  I	  am	  very	  grateful	  for	  all	  staff	  within	  the	  Institute	  
of	   Liver	   Studies	   and	   King’s	   College	   London	   who	   helped	   me	   with	   the	   design	   and	  
execution	  of	  my	  experiments.	  I	  am	  also	  indebted	  and	  grateful	  to	  my	  patients	  without	  
whom	  none	  of	  these	  experiments	  would	  ne	  possible.	  
	  
In	   conclusion,	   the	   results	   in	   this	   thesis	   have	   shown	   that	   donor	   and	   recipient	  
rs12979860	   IL-­‐28B	   polymorphisms	   (Chapter	   VI)	   and	   CXCL10	   levels	   (Chapter	   V)	   can	  
identify	   patients	  with	   rapid	  HCV	   recurrence	   post	   transplantation.	   CXCL10	   levels	   pre-­‐
AVT	  were	  also	  a	  sensitive	  predictor	  of	  treatment	  response.	  Additionally,	  this	  thesis	  has	  
also	   identified	   miRNAs	   of	   interest	   which	   are	   involved	   in	   the	   pathogenesis	   of	   HCV	  
recurrence	  and	  may	  act	  as	  possible	  biomarkers	  of	  disease	  progression	  or	  therapeutic	  
targets.	  The	  promise	  of	  the	  new	  DAAs	  appears	  to	  hold	  true	  and	  importantly,	  if	  	  made	  
available	   to	   those	   in	   greatest	   need,	   then	   potentially,	   in	   20	   years	   time	  HCV	   infection	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